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Glossary
ABC Advanced breast cancer
AC Doxorubicin cyclophosphamide
ALND Axillary lymph node dissection
BC Breast cancer
BRCA Breast cancer associated
CMF Cyclophosphamide, methotrexate and 5 fluouracil
CT Chemotherapy
DDCT Dose dense chemotherapy
DDFS Distant disease free survival
DFS Disease free survival
DMFS Distant metastasis free survival
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ER Estrogen receptor
EoL End of life
Her2 Epidermal growth factor receptor type 2
HR Hazard ratio
IDFS Invasive disease free survival
IGF Insulin growth factor
IGFR Insulin growth factor receptor
LHRH Luteinizing hormone releasing hormone
MBC Metastatic breast cancer
OS Overall survival
ORR Overall response rate
pCR Pathologic complete response
PFS Progression free survival
RR Response rate
SLN Sentinel lymph node
TN Triple negative
TNBC Triple negative breast cancer
TK Tirosine kinase
TKI Tirosine kinase inhibitor
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
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Synopsis
Introduction: Breast cancer care in the past
This work starts with an overview of the treatment of breast cancer (BC). From the first reports of patients ill 
with BC until 1950. From 1950 until 2000, there is a more detailed account on how BC patients were treated 
with emphasis on the different modalities, local, regional and systemic treatments and their evolution.
Part 1: Who to treat with adjuvant systemic therapy?
Chapter 1: TNM is not dead in breast cancer
It has been said that the current TNM staging system might not be suitable for predicting breast cancer (BC) 
outcomes and for making therapeutic decisions, especially for patients with screen detected BC which is 
smaller. The reason for this is also due to the non inclusion of tumor biology parameters in the current TNM 
system. We hypothesize that in a population where there is still a large abundance of non screen detected 
BC, with a low median age of incidence and abundance of high TNM staged lesions, biology is still second to 
classical staging in predicting prognosis.
We analyzed a population of consecutive BC patients from a single institution during ten years. We 
characterized current established prognostic factors, classical staging variables included in the current TNM 
staging system and biological variables, currently not included in the TNM system. We quantified the 
capacity of individual prognostic factors to predict survival. We analyzed a population of 1699 consecutive 
BC patients. We found that individually both the TNM system prognostic factors and the biological prognostic 
factors are differing among BC survivors and dead patients in a statistically significant distribution. Explicitly, 
patients with larger tumors, positive nodes, higher stage lesions, ER negative, HER2 positive, TN or lower 
differentiation tumors show decreased survival.
In the multivariate analysis we can conclude that in a population such as ours classical TNM staging 
variables, irrespective of tumor biological features, are still the most powerful outcome predictors.
Chapter 2: Defining breast cancer prognosis: The predictive power and mechanism of centrosome 
alterations in breast cancer
We performed a systematic analysis of the literature and compiled an extensive data set of gene expression 
data originated in primary tumours of BC patients with prognostic information. We analysed this data seeking 
for genes consistently up  or down regulated in poor prognosis BC, i.e. that relapsed after initial treatment. In 
the course this bioinformatics analysis our lab  identified 65 genes statistically significant across multiple 
datasets that can discriminate between relapsed and non-relapsed BC patients. Among the identified genes, 
we have detected genes such as MKI67, a marker of mitotic activity which is routinely used in the clinic. 
Unexpectedly, we also discovered several genes found to be involved in centrosome clustering, The most 
prominent of these is the kinesin KIFC1, also called HSET, and previously identified as regulator of 
centrosome clustering. Centrosome abnormalities (numerical, structural) have been observed in cancer. 
Indeed, compelling data has shown that cells from many cancers have multiple and abnormal centrosomes, 
that are either correlated with tumour malignancy or considered an early tumorigenesis event. However, 
extra centrosomes come at a cost and cells must be able to handle such abnormalities or otherwise die. 
Thus our results suggested a new mechanism of breast cancer progression with negative prognostic value. 
We aimed at quantifying the predictive power of centrosome clustering in BC clinical setting and at detecting 
this process in BC patient material. We validated the centrosome clustering genes KIFC1 and TACC3 in 
formalin fixed paraffin embedded (FFPE) BC patient material, using quantitative real-time PCR (RT-qPCR) 
technology. Our results indicate that the tested KIFC1 has a clear IHC signal (1) and that the protein 
expression patterns and levels correlate with prognosis, with relapsing patients having increased expression 
and nuclear localisation of this kinesin (2). Next we were able to show that centrosome clustering does occur 
in vivo. We identified centrosome amplification and clustering in breast cancer samples, and we established 
a fluorescence microscopy-based IHC approach by staining FFPE samples with centrosomal markers. Using 
this approach we have observed centrosome amplification and clustering in a small set of poor prognosis 
samples. By expanding the number of samples in which we have characterised the number of centrosomes, 
we were able to confirm our preliminary observation that centrosomes are clustered in relapsed BC. 
Part 2: How to treat breast cancer subtypes?
Chapter 3: How many diseases is triple negative breast cancer? (review)
Triple negative breast cancer is a subtype of breast cancer that does not express the estrogen receptor, the 
progesterone receptor and the epidermal growth factor receptor type 2 (Her2). These tumors are not yet 
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treated with targeted therapies probably because no positive markers have been described to reliably 
classify them - they are described for what they are not. Perhaps for this reason, they are among the most 
aggressive of breast carcinomas, albeit with very heterogenous clinical behavior. The clinical observation 
that these patients do not carry a uniformly dismal prognosis, coupled with data coming from pathology and 
epidemiology, suggests that this negative definition is not capturing a single clinical entity, but several. We 
critically evaluate this evidence in this paper, reviewing clinical and epidemiological data, as well as 
molecular data. There is evidence for heterogeneity, but it is not clear how many diseases are grouped into 
triple negative breast cancer. Answering this question, and identifying the molecular basis of heterogeneity 
will help define prognosis and, eventually, the identification of new targeted therapies.
Chapter 4: Systemic treatment for triple negative breast cancer (review)
Chemotherapy remains the backbone of treatment for triple negative breast cancer (TNBC). Despite the 
appearance of new targeted and biologic agents there has been no targeted therapy validated for TNBC, 
possibly because the biology of TNBC has not been conclusively elucidated. Many studies have shown that 
TNBC derive significant benefit of chemotherapy in the neoadjuvant, adjuvant and metastatic treatment, 
possibly more benefit than other BC subtypes. Neoadjuvant chemotherapy studies have repeatedly shown 
higher response rates in TNBC than non-TNBC. Pathologic complete response has been shown to predict 
improved long term outcomes in BC. Although specific adjuvant regimens for TNBC are under study, third 
generation chemotherapy regimens utilizing dose dense or metronomic polychemotherapy are among the 
most effective tools presently available. The role of specific chemotherapy agents, namely platinum salts, in 
the treatment of TNBC remains undefined. Taxanes and anthracyclines are active in TNBC and remain 
important agents, but have not shown specific benefit over non-TNBC. TNBC is itself a heterogeneous group 
in which subgroups like basal like BC defined by higher proliferation and including those TNBC arising in 
BRCA1 mutation carriers may be more sensitive to platinum agents and relatively less sensitive to taxanes. 
The molecular characterization of TNBC is lacking and therefore the search for targeted therapy is still 
ongoing.
Chapter 5: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal 
antibody  cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative 
breast cancer
Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers, an 
aggressive subtype of breast cancer. Our randomized phase II study investigated cisplatin with or without 
cetuximab in this setting. 
Patients who had received no more than one previous chemotherapy regimen were randomly assigned on a 
2:1 schedule to receive no more than six cycles of cisplatin plus cetuximab or cisplatin alone. Patients 
receiving cisplatin alone could switch to cisplatin plus cetuximab  or cetuximab  alone on disease progression. 
The primary end point was overall response rate (ORR). Secondary end points studied included progression-
free survival (PFS), overall survival (OS), and safety profiles. The full analysis set comprised 115 patients 
receiving cisplatin plus cetuximab  and 58 receiving cisplatin alone; 31 patients whose disease progressed on 
cisplatin alone switched to cetuximab-containing therapy. The ORR was 20% with cisplatin plus cetuximab 
and 10% with cisplatin alone (odds ratio, 2.13). Cisplatin plus cetuximab resulted in longer PFS compared 
with cisplatin alone (median, 3.7 v 1.5 months; hazard ratio, 0.67. Corresponding median OS was 12.9 
versus 9.4 months. While the primary study end point was not met, adding cetuximab  to cisplatin doubled the 
ORR and appeared to prolong PFS and OS, warranting further investigation in mTNBC. 
Chapter 6: Blocking angiogenesis to treat breast cancer (review)
Angiogenesis is a hallmark of cancer because tumors larger than 1mm need new vessels to sustain their 
growth. Since the discovery of the molecular players of this process and some inhibitors, that angiogenesis 
became a promising therapeutic target. Bevacizumab  was the first molecular-targeted antiangiogenic 
therapy approved by the FDA and is used as first-line therapy in metastatic breast cancer. A second class of 
approved inhibitors (sunitinib, sorafenib, pazopanib and axitinib) include oral small-molecule tyrosine kinase 
inhibitors that target vascular endothelial growth factor receptors, platelet-derived growth factor receptors, 
and other kinases including KIT, Ret, BRAF and Flt-3, but none of these have gained approval to treat breast 
cancer.
This review analyzes and summarizes data from clinical trials of anti-angiogenic agents in the treatment of 
BC. Phase III trials of bevacizumab  in advanced BC have demonstrated a reduction in disease progression 
(22–52%), increased response rates and improvements in progression-free survival of 1.2 to 5.5 months, but 
no improvements in OS. Bevacizumab  phase III trials in early BC have both been negative. Bevacizumab 
combined with chemotherapy is associated with more adverse events. Phase III trials of the tyrosine kinase 
inhibitor sunitinib  were negative, while randomized phase II trials of sorafenib  and pazopanib  have improved 
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some outcomes. Endostatin has been tested in neoadjuvant clinical trials in combination with anthracycline-
based chemotherapy in treatment-naive patients and has increased the clinical response rate, but more trials 
are needed to establish this drug. Most trials of anti-angiogenic agents in BC have reported improved RR 
and PFS but no increase in OS compared to chemotherapy alone, leading to skepticism towards blocking 
angiogenesis. Selected trials in selected BC populations with translational endpoints related to harvested 
tumor tissue and other biological material samples, preferentially at several timepoints, will be crucial if 
antiangiogenesis is to survive as a strategy to treat BC.
Chapter 7: Does hypoxic response mediate primary  resistance to sunitinib in untreated locally 
advanced breast cancer?
The antiangiogenic drug sunitinib  has never been evaluated as single agent in untreated BC patients. We 
aimed to characterize the activity of sunitinib, alone and with docetaxel, in untreated locally advanced or 
operable BC, and, to uncover the mechanisms of response. Twelve patients were treated with an upfront 
window of sunitinib  followed by four cycles of sunitinib  plus docetaxel. Response, resistance and toxicity 
were evaluated according to standard clinical parameters, magnetic resonance imaging, positron emission 
tomography, pathology characterization and gene expression profiling. We detected primary resistance to 
sunitinib  upfront window in untreated BC, as evidenced by four non-responding patients. At surgery, five 
patients had viable disease in the breast and axilla, four had viable tumor cells in the breast alone and three 
were taken off study due to unacceptable toxicity and thus not evaluated. Early functional imaging was useful 
in predicting response. There were no pathologic complete responses (pCR). Comparison of gene 
expression profiling tumor data between early responders and non-responders allowed us to identify up-
regulation of VEGF and angiogenic pathways in non responders. Specifically, in tumors resistant to the 
single-agent sunitinib  we detected a transcriptional response to hypoxia characterized by over-expression of 
several HIF1α target genes. In this report of single-agent sunitinib  treatment of untreated localized BC 
patients, we found molecular evidence of primary resistance to sunitinib  likely mediated by up-regulation of 
hypoxia responsive genes.
Part 3: When to stop systemic treatment of breast cancer patients?
Chapter 8: The aggressiveness of cancer care in the last three months of life: a retrospective single 
centre analysis.
All adult patients with solid tumors who died in our hospital in 2003 and received chemotherapy for advanced 
cancer, were included. Detailed data concerning chemotherapy and toxicity, in the last three months of life, 
were collected from patientsʼ clinical charts. A total of 319 patients were included. Median age was 61 years. 
Median time from diagnosis of metastatic disease to death was 11 months. The proportion of patients who 
received chemotherapy in the last three months of life was 66% (n=211), in the last month 37% and in the 
last two weeks 21%. Among patients who received chemotherapy in the last three months of life, 50% 
started a new chemotherapy regimen in this period and 14% in the last month. There was an increased 
probability of receiving chemotherapy in the last three months of life in younger patients and in patients with 
breast, ovarian and pancreatic carcinomas. There was a large proportion of patients who received 
chemotherapy in the last three months of life, including initiation of a new regimen within the last 30 days. 
Thus, further study is needed to evaluate if such aggressive attitude results in better palliation of symptoms 
at the end of life.
Chapter 9: Is breast cancer treatment in the end of life changing?
We aimed to characterize the shifting trends in use of anti-cancer chemotherapy and palliative care 
approaches in the end of life of BC patients in different institutions and times. For this, we selected women 
that died of BC during six years, from 2007 to 2012, and were treated in a central acute care general hospital 
and compared it with the BC patients that died in 2003 and were treated in a large cancer center. We 
analyzed a total of 232 patients: the more recent group  has 114 women and the older cohort has 118. We 
used descriptive statistics to characterize CT in the EoL and use of palliative care resources. Both 
populations were similar in terms of BC characteristics. We observed more palliative care resources, pain 
clinic, palliative care teams and palliative radiotherapy, involved in the care of MBC patients and a shift 
towards more deaths at hospices. Systemic anti cancer treatments continue to be prolonged until very late in 
patients’ lives, notwithstanding, we could show a decrease in the use of such treatments. Other indicators of 
aggressiveness, namely hospital admissions, also show a decrease. We confirmed our hypothesis that there 
is more integration of multidisciplinary palliative care and less aggressiveness in the treatment of metastatic 
cancer patients, specifically, use of palliative anti-cancer treatment and hospital admissions. Nonetheless, 
we use systemic therapy until too late with underutilization of palliative medicine. 
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Chapter 10: Why do our patients get chemotherapy until the end of life? (editorial)
The editorial starts with a clinical case of a 21 year old patient that lives three months after starting palliative 
chemotherapy for the first time, a case that illustrates therapeutic futility at the end of life. Why are we not 
ceasing chemotherapy when it is useless, toxic, logistically complex and expensive? Are we prescribing 
chemotherapy until too late in solid tumor patientsʼ lives? Medical oncologists have overly optimistic 
predictions and, excessive, treatment-prone attitude and they are criticized by other health care providers for 
this. Increasingly, patients, their families, advocacy groups, policy makers, journalists and society at large 
dwell on this topic, which is a perplexing conundrum, because sometimes they are the ones demanding not 
to stop  aggressive systemic anticancer treatments, when it comes to their loved ones. There is a growing 
culture of awareness toward preserving quality of life, palliative care, symptom-directed care, hospice referral 
and end of life issues regarding terminal cancer patients. Sadly, this issue is gaining momentum, not 
because oncologists are questioning their practice but because health care costs are soaring. Whatever the 
motive, the reasons for administering chemotherapy at the end of life should be known. There are few and 
conflicting scientific data to guide treatments in this delicate setting and we review this evidence in this 
paper. 
Conclusion: What is the future of breast cancer care?
This work ends with a view into the future of BC care. Looking into the different areas from prevention, 
screening, hereditary BC, local, regional and systemic treatments of adjuvant and metastatic patients. The 
last three paragraphs are a final comment where the story of a patient with Her2 positive locally advanced 
breast cancer is used as paradigm of evolution, heterogeneity and dynamism in the management of BC.
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Synopsis in Portuguese
Introdução: Tratamento do carcinoma da mama
Este trabalho inicia-se com a história do tratamento do carcinoma da mama, desde os primeiros 
documentos que descrevem doentes com carcinoma da mama até 1950. Desde 1950 até 2000 o 
diagnóstico, risco e as modalidades terapêuticas usadas no tratamento das doentes são mais detalhadas 
com ênfase nas terapêuticas locais, regionais e sistémicas.
Parte 1:Quem tratar com terapêutica sistémica adjuvante
Capítulo 1: A classificação TNM não está morta no carcinoma da mama
Tem sido dito que a classificação TNM não é adequada para usar como ferramenta de prognóstico e 
decisão terapêutica no carcinoma da mama, especialmente em doentes com carcinoma detectado através 
de rastreio, que tem geralmente menores dimensões. A razão desta classificação não ser adequada prende-
se com o facto de não estarem incluidos parâmetros biológicos na classificação TNM atual. Pusemos a 
hipótese de que numa população com alta percentagem de carcinoma da mama não detectado em exames 
de rastreio, com uma mediana de idade baixa e com alta percentagem de estadios II e III, o estadiamento 
clássico, pela classificação TNM, é mais descriminatório que as características biológicas na determinação 
do prognóstico.
Para isto analisámos uma população de doentes com carcinoma da mama tratados consecutivamente na 
mesma instituição, durante 10 anos. Caracterizámos os fatores de prognóstico do estadiamento clássico 
incluídos na classificação TNM e as variantes biológicas, presentemente não incluídas na classificação 
TNM. Quantificámos a capacidade de cada um dos factores de prognóstico para para prever a 
sobrevivência. A população é de 1699 doentes com carcinoma da mama que foram tratádos com 
terapêutica sistémica adjuvante. Individualmente, cada um dos fatores de prognostico, clássicos ou 
biológicos, diferem significativamente entre doentes que sobrevivem e que não sobrevivem. Explicitamente, 
como previsto, doentes com tumores maiores, envolvimento dos gânglios axilares, estadios TNM mais 
avançados, que não expressam recetor de esrogéneo, com amplificação do gene Her2, triplos negativos ou 
de menor diferenciação têm menor sobrevida. Na análise multivariada, só os fatores de prognostico da 
classificação TNM, o grau histológico e a amplificação do gene Her2, esta última com menos significância 
estatistica são preditores independentes de sobrevivência.
Capítulo 2: Em busca de novos factores de prognostico: Poder preditivo e mecanismo das 
alterações de centrossomas em carcinoma da mama
Compilámos inúmeros grupos de experiências de genómica feitas em tumores primários de doentes com 
carcinoma da mama para as quais existe informação prognóstica. Estas experiências são feitas com o 
objectivo de descobrir novos factores de prognóstico. Reanalisámos os dados, repetindo a mesma 
pergunta: Quais são os genes com expressão diferencial estatisticamente significativa entre doentes que 
recaíram e doentes que não recaíram. Identificámos 65 genes nestas condições e o MKI67, o gene que 
codifica a proteina Ki67, estava nesse grupo. Identificámos vários genes que se sabe estarem envolvidos no 
processo de agregação de centrossomas. O  gene que considerámos mais promissor foi a kinesina KiFC1, 
que já tinha sido identificada como regulador da agregação de centrossomas. Anomalias cetrossomais 
numéricas e estruturais têm sido observadas em neoplasias. Há dados correlacionando anolmalias 
centrossomais estruturais e e numéricas com o grau de malignidade e os eventos precoces da 
carcinogénese. Mas estas anomalias centrossomais têm um peso para a célula que deve adapatar-se ou 
entrará em apoptose. Os nossos resultados sugerem que existe um mecanismo adaptativo, a agregação de 
centrossomas, com impacto prognóstico negativo. O nosso objetivo foi quantificar o valor prognóstico das 
anomalias centrossomais no carcinoma da mama. Para isto usámos material de doentes dos quais 
sabemos a história natural. Avaliámos os genes de agregação de centrossomas, KIFC1 e TACC3, nas 
amostras tumorais arquivadas em parafina: primeiro com PCR (polymerase chain reaction) quantitativa e 
depois com imunohistoquímica (IHQ). Apenas a proteína KIFC1 foi discriminatória em IHQ, não se tendo 
conseguido otimizar o anticorpo da TACC3. Os níveis proteicos de KIFC1 correlacionam-se com mau 
prognóstico. Nas doentes que recaíram observámos, no tumor primário, maior abundância desta proteína 
com localização nuclear. Em seguida, demonstrámos que a agregação de centrossomas é um fenómeno 
que ocorre in vivo. Identificámos centrossomas agregados em amostras de tumores primários de doentes 
que recaíram. Tecnicamente usámos microscopia de fluorescência e IHQ contra proteínas centrossomais 
que avaliámos nos tumores primários arquivados em blocos de parafina. Observámos agregação de 
centrossomas num pequeno número de doentes que recaíram, não validámos, ainda, este fenótipo celular 
em larga escala.
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Parte 2: Como tratar com terapêutica sistémica os vários subtipos de carcinoma da mama
Capítulo 3: Quantas doenças estão englobadas na definição carcinoma da mama triplo negativo? 
(revisão)
O carcinoma da mama triplo negativo é um tumor que não expressa três proteínas: recetor de estrogénio, 
recetor de progesterona e o recetor do fator de crescimento epidermico tipo 2 (Her2). As doentes com estes 
tumores não são ainda tratadas com terapêutica dirigida, possivelmente porque esta definição negativa não 
tem ajudado. Sabemos apenas as alterações genéticas que estes tumores não têm, não as que eles têm. 
Talvez por esta razão, estes tumores são o subtipo mais agressivo de carcinoma da mama. No entanto, na 
prática clínica observamos que estas doentes não têm sempre mau prognóstico, além de que dados de 
histopatologia e epidemiologia sugerem que esta definição negativa não está a capturar um único subtipo 
de carcinoma da mama, mas vários. Avaliámos criticamente esta evidência, clínica, histopatológica, 
epidemiológica e molecular. Há evidência de heterogeneidade, mas não é claro quantos subtipos estão 
englobados nesta definição de carcinoma da mama triplo negativo. A resposta a esta pergunta, e a 
identificação do fundamento molecular desta heterogeneidade vai ajudar a melhor definir o prognóstico e 
eventualmente a definir novos alvos terapêuticos nesta população difícil.
Capítulo 4: Terapêuica sistémica em carcinoma da mama triplo negativo (revisão)
A quimioterapia é a única terapêutica sistémica disponível para as doentes com carcinoma da mama triplo 
negativo, ao contrário dos outros dois subtipo de carcinoma da mama que têm com a terapêutica 
antiestrogénica e anti Her2, importantes benefícios. Apesar de terem surgido várias opções terapêuticas 
para estes doentes nennhuma terapêutica dirigida foi validada pelos ensaios clínicos conduzidos, 
possivelmente porque a biologia deste carcinoma ainda não foi elucidada. Muitos ensaios demonstram que 
os tumores triplos negativos beneficiam com quimioterapia e que as mais altas taxas de resposta patológica 
completa à terapêutica neoadjuvante são observadas precisamente nestes tumors. A resposta patológica 
completa correlaciona-se com a sobrevivência. Estamos a estudar regimes adjuvantes específicos para 
doentes com estes tumors, mas, neste momento, regimes de terceira geração com taxanos e antraciclinas 
são os mais promissores. O papel de subgrupos de fármacos específicos, como os sais de platina, mantém-
se mal definido. Quanto às antraciclinas e taxanos, estes grupos não mostraram beneficio específico em 
carcinoma da mama triplo negativo quando comparado com os outros subtipos. Os próprios carcinomas da 
mama triplos negativos são heterogéneos e carcinomas da mama basais triplos negativos com elevada taxa 
de proliferação e carcinomas da mama triplos negativos surgidos em doentes com mutação germinal 
BRCA1 poderão ser mais sensíveis a sais de platino e menos sensíveis a taxanos. Como a definição 
molecular ainda não foi explicada a busca de terapêutica dirigida vai continuar.
Capítulo 5: Ensaio randomizado de fase II do anticorpo monoclonal contra o recetor do fator de 
crescimento epidérmico tipo 1 combinado com cisplatino versus cisplatino em monoterapia em 
doentes com carcinoma da mama triplo negativo metastizado
O recetor do fator de crescimento epidérmico tipo 1 está sobre expresso nos tumores das doentes com 
carcinoma da mama triplo negativo metastizado, um subtipo agressivo de carcinoma da mama. Este ensaio 
investigou a combinação de cetuximab e cisplatino versus cisplatino isolado em doentes deste tipo.
Doentes em primeira ou segunda linha de terapêutica para doença metastizada foram randomizadas, num 
sistema de 2 para 1, para receber até 6 ciclos da combinação de cisplatino e cetuximab  ou cisplatino 
isolado. Às doentes randomizadas para o braço de monoterapia podiamos, após progressão, acrescentar 
cetuximab  ou tratá-las com cetuximab  isolado. O  objetivo primário foi a taxa de resposta global. Os objetivos 
secundários foram a sobrevivência livre de doença, a sobrevivência global e o perfil de segurança dos 
fármacos.
A população em análise foram 115 doentes tratadas com a combinação e 58 doentes tratadas com 
cisplatino em monoterapia, 31 destas em quem se documentou progressão passaram a ser tratadas com 
um regime que incluía cetuximab, isolado ou em combinação. A taxa de resposta global foi de 20% no braço 
da combinaçao e de 10% no braço da monoterapia (odds ratio, 2.13). A sobrevivência livre de doença foi de 
3.7 meses no braço da combinação e de 1.5 meses no braço em monoterapia (hazard ratio, 0.67). A 
sobrevivência global foi de 12.9 meses no braço da combinação versus 9.4 meses no braço de cisplatino. 
Conclui-se que, apesar de não ter sido alcançado o objectivo primário, acrescentar cetuximab, duplica a 
resposta e prolonga tanto a sobrevivência livre de doença como a sobrevivência global.
Capítulo 6: Bloquear a angiogénese para tratar o carcinoma da mama (revisão)
A angiogénese é uma característica que define a neoplasia, porque tumores com mais de 1mm precisam de 
formar novos vasos para poderem crescer. Desde que se descobriram as moléculas que orquestram esta 
transformação, que se têm procurado desenvolver e testar fármacos que interfiram com este processo. No 
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carcinoma da mama o bevacizumab foi o primeiro fármaco aprovado pela FDA em primeira linha para tratar 
doença metastática. Depois foram estudados um grupo de inibidores de tirosina cinase associados aos 
recetores transmembranares envolvidos na angiogénese como o VEGFR, PDGFR, KIT, RET, BRAF e Flt3: 
sunitinib, sorafenib, pazopanib e axitinib
Neste capítulo, analisaram-se e resumiram-se os dados dos ensaios clínicos das drogas anti-angiogénicas 
no tratamaneto do carcinoma da mama. Os ensaios de fase III do bevacizumab em carcinoma da mama 
mostraram uma redução na progressão de doença de 22 a 52% e aumento da sobrevivência livre de 
doença de 1.2 a 5.5 meses mas nunca foi demonstrado prolongamento de sobrevivência. Os ensaios de 
fase III em carcinoma da mama adjuvante com bevacizumab são dois e foram ambos negativos.
O ensaio de fase III com o inibidor da tirosina cinase, sunitinib  foi negativo, enquanto que os ensaios de fase 
II com os inibidores da tirosina cinase sorafenib  e pazopanib  melhoraram alguns indicadores de resposta e 
sobrevivência. A endostatina foi testada no contexto neoadjuvante com antraciclinas e melhorou a taxa de 
resposta, mas, mais ensaios são necessários para estabelecer este fármaco. A maioria dos ensaios clínicos 
dos agentes antiangiogénicos em carcinoma da mama reportaram aumento da taxa de resposta e de 
sobrevivência livre de doença mas nunca aumento da sobrevivência global quando comparado com 
quimioterapia isolada o que levou ao cepticismo a que assistimos atualmente em relação ao bloqueio da 
angiogénese.
Ensaios clínicos selecionados em doentes específicas com objetivos translacionais relacionados com 
material biológico colhido, preferefencialmente em diferentes intervalos da terapêutica, serão cruciais para 
o bloqueio da angiogénese sobreviver como estratégia terapêutica em carcinoma da mama.
Capítulo 7: A resposta à hipoxia medeia a resistência primária ao sunitinib em carcinoma da mama 
localmente avançado
O sunitinib  é um fármaco antiangiogénico que nunca foi avaliado isolado em doentes com carcinoma da 
mama não tratadas. O  nosso objetivo foi caracaterizar a atividade do sunitinib  isolado e em combinação 
com o docetaxel em carcinoma da mama não tratado, localmente avançado ou operável, mas de dimensão 
superior a 2 cm, para compreender os mecanismos de resposta. Doze doentes foram tratadas com duas 
semanas iniciais de sunitinib  seguido de quatro ciclos de combinação de sunitinib  e docetaxel. A resposta, a 
reistência e a toxicidade foram avaliadas de acordo com parametros clínicos, ressonância magnética 
nuclear, tomografia de emissão de positrões, histopatologia e perfis de expressão genómica.
Detetámos resistência primária ao sunitinib  na janela inicial de duas semanas, evidenciada em quatro 
doentes que não responderam. À data da cirurgia, cinco doentes tinham tumor viável na mama e axila, 
quatro tinahm tumor viável na mama e três foram retiradas do ensaio. Não houve respostas patológicas 
completas.
A comparação dos perfis de expressão genómica entre os respondedores e os não respondedores, aos 
quinze dias iniciais, permitiu-nos identificar sobre expressão de VEGF e outras vias angiogénicas nos não 
respondedores. Especificamente, em tumores resistentes ao sunitinib isolado detectámos uma resposta 
transcricional à hipoxia caracterizada por sobre expressão de vários dos genes alvo do HIF1α. Neste ensaio 
de sunitinib  isolado em doentes não tratadas com carcinoma da mama localmente avançado, encontrámos 
evidência molecular de resistência primária ao sunitinib  possivelmente mediada por sobre expressão de 
genes que respondem à hipoxia.
Parte 3: Quando parar a terapêutica sistémica às doentes com carcinoma da mama
Capítulo 8: Agressividade terapêutica ns últimos três meses de vida num estudo retrospetivo dum 
centro único
Incluímos todos os adultos que morreram com tumores sólidos na instituição em 2003 e foram tratados com 
quimioterapia para tratar neoplaias metastizadas. Colhemos dados detalhados relacionados com 
quimioterapia e toxicidade nos últimos três meses de vida a partir do processo clínico. Trezentas e 
dezanove doentes foram incluídos, a mediana de idade foi 61 anos. A mediana de sobrevivência de doença 
metastática foi de 11 meses. 66% (211) dos doentes foram tratados com QT nos últimos 3 meses de vida, 
37% foram tratados com QT no úlimo mês de vida e 21% nas últimas duas semanas. Nos doentes que 
foram tratados com QT nos últimos três meses de vida, 50% começaram um novo regime terapêutico neste 
período e 14% começaram um novo regime no último mês. Identificámos como determinantes de 
tratamento com QT no fim de vida a idade jovem, o carcinoma da mama, do ovário e do pâncreas.
Concluímos que administrámos QT no fim de vida frequentemente e iniciámos novos regimes terapêuticos 
no último mês de vida em 14% dos casos. Precisamos de aprofundar este trabalho para compreender se 
esta atitude agressiva resulta em melhor paliação de sintomas e qualidade de vida no fim de vida dos 
doentes com neoplasias disseminadas.
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Capítulo 9: O tratamento do carcinoma da mama no fim de vida está a mudar?
Quisémos caracterizar a modificação da tendência no uso de QT e de estratégias paliativas no fim de vida 
das doentes com carcinoma da mama em diferentes instituições e em intervalos de tempo diferentes. Para 
isto selecionámos doentes que morreram de carcinoma da mama durante 6 anos, entre 2007 e 2012, num 
hospital geral e comparámos com as doentes que morreram de carcinoma da mama em 2003 num centro 
oncológico. Avaliámos um total de 232 doentes. O  grupo mais recente tem 114 doentes e o grupo anterior 
tem 118 doentes. Usámos estatística descritiva para caracterizar QT no fim de vida e o uso de estratégias 
paliativas. Ambas as coortes são comparáveis em termos das características do carcinoma da mama. 
Observámos aumento do uso de estatégias paliativas: consulta da dor, consulta de cuidados paliativos e 
radioterapia paliativa no cuidado das doentes com carcinoma da mama metastizado. Evidenciámos 
aumento do número de mortes em serviços de cuidados paliativos. No entanto, a QT paliativa continua a ser 
prolongada até aos últimos meses de vida, embora tenhamos mostrado uma diminuição desta prática. 
Outros indicadores de agressividade como a admissão hospitalar também mostraram diminuição. 
Confirmámos a nossa hipótese de que há maior integração da medicina paliativa multidisciplinar e menos 
agressividade na terapêutica sistémica das doentes com carcinoma da mama nos últimos meses de vida.
Chapter 10: Porque é que os nossos doentes são tratados com quimioterapia até ao fim da vida? 
(editorial)
Este capítulo começa por dar o exmeplo duma jovem de 22 anos que viveu três meses após começar QT 
paliatva. Este caso epitomiza a futilidade terapêutica e é usado como ponto de partida para explorar as 
razões pelas quais administramos QT no fim de vida aos doentes quando é inútil, tóxica, logisticamente 
complexa e cara. Será que estamos a prescrever QT até tarde demais? Os oncologistas fazem previsões 
excessivamente otimistas e têm uma atitude pró terapêutica excessiva e são criticados por outros 
intervenientes nas instituições de saúde por isto. Crescentemente doentes, familiares, associações de 
doentes, definidores de políticas de saúde, jornalistas e a sociedade em geral afloram este tema mas 
tornam-se inconsistentes quando se trata dum doente próximo em que se modifica o discurso para que se 
façam terapêuticas sitémicas agressivas. Há uma crescente cultura de preservação da qualidade de vida, 
paliação, abordagem sintomática, referenciação a unidades de cuidados paliativos e outros temas do fim de 
vida dos doentes oncológicos terminais. Infelizmente, este tema tem ganhado momentum não porque os 
oncologistas estejam a refletir criticamente sobre a sua prática, mas porque os custos dos cuidados de 
saúde são crescentes e incomportáveis. Seja qual fôr o motivo, as razões que levam os oncologistas a 
administrar QT no fim de vida devem ser criticamente elucidadas. Mas há poucos dados para nos guiar 
nesta fase delicada da vida dos doentes e os que existem são por vezes irreconciliáveis, é uma revisão 
destes dados que foi feita neste capítulo.
Conclusão: A abordagem do carcinoma da mama no futuro?
Na conclusão, tenta-se olhar para o futuro e prever como será a tomada a cargo dum doente com carcioma 
da mama amanhã. Faz-se uma avaliação das várias àreas desde prevenção, rastreio, suscetibilidade 
genética e comportamental e terapêutica. Na terapêutica separa-se a terapêutica locoregional, sistémica 
adjuvante e da doença metastizada. Nos três últimos parágrafos a história duma mulher com um carcinoma 
localmente avançado que sobre expressa o recetor Her2, serve como ilustração de como devemos estar 
preparados para incorporar evolução, heterogeneidade e dinamismo no cuidado de doentes com carcinoma 
da mama.
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Introduction: Breast cancer care in the past
Egypt, Mesopotamia, India, Greece, Rome and Medieval Europe
The Edwin Smith surgical papyrus, which dates from 3000–2500 BC, is believed to be the first report of 
breast cancer, it describes forty eight cases of tumors or ulcers of the breast for which there was no 
treatment. It collects the teachings of Imhotep  a great Egyptian physician, a “Rennaissance” man at the 
center of Egyptian “Rennaissance”, he knew medicine architecture and astronomy. The Greeks, centuries 
later, in Egypt, fused Imhotep into their medical god Asclepius. Imhotep  writes with surgical clarity about 
broken bones, collapsed vertebrae, shattered skulls and abscesses of the skin, that he describes to be cool, 
with no fever, granulations or fluid, they are large, spreading and hard. Imhotep advises no treatment, only 
ointments. Assyrian cuneiform tables from 2000 BC, also mention breast cancer and Indian reports mention 
surgery and cautery as treatment approaches. The Greek historian Herodotus (400 BC), describes a surgical 
cure when he reports the story of the queen of Persia who had a red swollen mass in her breast with axillary 
lymph node invasion. Hippocrates only mentions breast cancer twice, and advises no treatment. Hippocrates 
coined the word cancer from the Greek word karkinos, that he described as large, superficial tumors, visible 
to the eye, like breast, epidermal or head and neck cancers. Karkinos means, in fact, crab. A better word is 
onkos, also greek, but meaning burden, mass or load. This word has a less physical tone and denotes a 
burden carried by the body, more concordant with the systemic nature of cancer.
The early Romans performed extensive surgery with removal of the pectoralis major muscle, but Celsus (40 
AD), advised against surgery. Galen (200 AD), was very pessimistic and attributed breast cancer to a 
particular humor that prevails in the body, “an excess of black bile, without boiling”. Despite this systemic 
theory, he advocated surgical removal of early lesions. This black bile without boiling is reminiscent of 
chronic inflammation or a cortisol or catecholamine response to aggression, curiously in unison to modern 
thinking. In the Middle Ages, surgical approaches were discouraged by the church. It was in the Middle Ages 
that the high incidence of breast cancer in nuns was first described; today, we understand the higher 
incidence of breast cancer in nulliparous women. In the Middle Ages this phenomenon was called the 
convent plague and breast cancer in nuns was seen as a punishment.
Renaissance to XXth Century
Ambroise Paré (1510-90), excised small tumors and treated advanced lesions with ointments. He was the 
first to advocate removal of the axillary lymph nodes en bloc with the breast, recognizing they were part of 
the malignant process. In the nineteenth century, great advances were made in surgery: the introduction of 
general anesthesia, antisepsis and microscopic pathology. 
A memorable legacy of the nineteenth century was the discovery that breast cancer was a hormone 
dependent cancer. The growth of breast lesions, in certain premenopausal patients, was observed to 
increase in certain phases of the menstrual cycle, and, it was observed that the disease grew more slowly in 
postmenopausal women. Beatson, in 1896, showed that breast cancer was hormonally dependent in a very 
famous paper where he describes the regression of breast lesions in two premenopausal breast cancer 
patients after removal of the ovaries. Today, ovariectomy remains a very useful and cheap treatment for 
adjuvant and advanced breast cancer with the added benefit of lowering ovarian carcinoma risk.
The results of surgery for breast cancer at this time were still poor, partly because of a high operative 
mortality of 20%. The patients that survived, rarely lived longer than two years. Paget, the famous British 
surgeon, confessed to never having seen a cure. German pathologists, a very important school before the 
World Wars, with microscopists dedicated to pathology and cell biology like Virchow and Boveri, were 
instrumental in documenting involvement of the axillary nodes and the pectoralis fascia in mastectomy 
samples. One of Vichowʼs students, Muller, was the first to report that cancers were composed of living cells. 
More interestingly, he reported the similarity of cells in a breast lesion and its metastases in the ribs and 
noted that cancer cells had lost the proportions of normal cells. Theodor Boveriʼs prescient depth of 
understanding of cell biology of cancer led one of his colleagues to write ten years after his death that, 
ʻʻBoveri was the greatest cytologist of his generation, a man so keen, so careful and so cautious, that any 
least suggestion from him deserves most thorough consideration. Boveriʼs work should be the starting point 
for any studies of causes, inheritance or cure of cancerʼʼ. Remarkably, this is still true today.
Aware of the results reported by the Germans, in the United States, Halstead, advocated the removal en 
bloc of the breast, the axillary contents and the pectoralis major, a surgery called radical mastectomy. In his 
series of 50 patients the local recurrence was 6%, compared to other series with 80%. However, with longer 
follow-up, this number was closer to 20%. Nevertheless, it was a great achievement that changed the 
management of breast cancer. Today, there are still women in follow-up at our institutions that have no 
pectoral muscle, leading to an impressive loss of functionality of the arm. The worldwide popularity of radical 
mastectomy led to even more aggressive approaches with internal mammary, supraclavicular, mediastinal 
lymphadenectomies and even arm amputation. Fortunately, these were abandoned for high operative 
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mortality and morbidity, and similar results to Halsteadʼs radical mastectomy. Halstead wrote that radical 
mastectomy was performed in “old” patients: “their average age is 55 years, and, they are no longer very 
active members of society”. This is shocking today but, at the time, the average life expectancy was 47 
years.
In the end of the century, X-rays and radium were discovered. Marie Curie won the Nobel Prize in chemistry 
in 1911, for the discovery of radium and polonium and the characterization of their chemical properties. In 
1937, a british surgeon, implanted radium needles into inoperable tumors and reported on a series of 200 
patients. The five-year survival was 29%, a result as good as that of radical mastectomy, but, the limited 
availability of radium, handling problems and fibrosis, precluded its wide use. In 1932, a report was published 
of 1022 patients that were irradiated, either because of early disease, frailty or surgery refusal. The 5-year 
survival of 80%, was better than in historical surgical controls. With this in mind, researchers started adding 
radiotherapy to the supraclavicular, internal mammary and axillary nodes to patients that had simple 
mastectomy - adjuvant radiotherapy. The long term toxic effects of radiotherapy, that were less predictable 
than those of surgery, were the reason for less enthusiasm for radiotherapy, as well as the increased 
availability of surgery. It was successfully demonstrated that inoperable cancers could be eliminated by 70 
Gy of radiotherapy over 3 months. We still have patients alive and in follow up  that had inoperable breast 
cancers treated by radiation alone.
1950-2000
The pace of change of breast cancer treatment in these 50 years is only surpassed by the even greater pace 
of change in the years 2000 to 2014. The evolution witnessed is truly more like a revolution. In 1954, the 
International Union Against Cancer devised the TNM classification, an integral part of cancer care. But two 
other changes were even more relevant: First, the discovery of x-rays which provided the basis for diagnosis 
by mammography and for treatment by radiotherapy. Second, the discovery of hormones by Starling in 1905. 
The discovery of estrogen changed breast cancer. It changed the concepts of carcinogenesis, incidence, risk 
factors and, most fundamentally, it changed breast cancer treatment. Estrogen had been responsible for 
Beatsonʼs surgical success while performing oophorectomy, and surgeons entered into a growing belief in 
endocrine surgery for controlling metastatic breast cancer. However, the second half of the twentieth century 
brought the rise and fall of endocrine surgery for metastatic disease. The importance of the hormonal milieu 
was subsequently confirmed by the use of adrenalectomy in 1951 and hypophysectomy in 1953. In the one-
third of patients who benefited, the mechanism by which this occurred was thought to be oestrogen 
deprivation, and the scientific foundation for this, was confirmed by the discovery of the oestrogen receptor 
(ER) in breast tumours, by Jensen, in 1967. Ablative endocrine surgery has now largely been superseded by 
the development of medical endocrine therapies. Thus, the estrogen antagonist, tamoxifen, has mostly 
replaced surgical oophorectomy, the aromatase inhibitors (which block peripheral synthesis of estrogen) 
have replaced adrenalectomy, and the luteinizing hormone releasing hormone (LHRH) agonists have 
replaced hypophysectomy, in the management of patients with adjuvant and metastatic breast cancer.
Regarding surgery, Patey recommended preserving the pectoralis major muscle, unless it was directly 
involved by cancer, an operation called “conservative” radical mastectomy. This operation eventually 
prevailed, since 1979, as the “modified” radical mastectomy, and is still a surgical standard today. But the 
change from radical to modified mastectomy was not the only change. The intellectual leadership  of Bernard 
Fisher and Umberto Veronesi dominated the landscape of breast cancer since 1970. They convincingly 
showed that lymph nodes were not an effective barrier to the spread of cancer and the seed for breast 
conservation was planted. Fisher wrote that “either the original surgical principles have become 
anachronistic or, if they are still valid, they were conceived originally for the wrong reasons”. This was written 
only 70 years after the reign of Halsteadʼs radical mastectomy swept the world. Fisher asserted that breast 
cancer was a systemic disease and viable cancer cells always, or almost always, disseminated before 
diagnosis. If this was true (1) variations in local treatment will not influence cure, and (2) effective systemic 
treatment was necessary to improve cure rates. Beginning at Guyʼs Hospital, in London, controlled clinical 
trials of breast conservation, would change breast surgery. These were also started in Milan, in 1973, and by 
the NSABP, in 1976, in the USA. These trials established that “lumpectomy”, followed by whole breast 
irradiation was as effective as total mastectomy for both local and distant disease control of most patients 
with early-stage breast cancers, and this was an obvious cosmetic improvement. Based on these outcomes, 
since 1990, breast-conserving surgery is the preferred treatment of stage I and II breast cancer.
If breast cancer is a systemic disease, the axilla should not be subjected to extensive surgical dissection, if 
the sentinel lymph node was found to be negative. Since the 1990s, the innovation of sparing axillary 
dissection has been reliably established. Radiotherapy, in the current setting, of minimal surgery, has won a 
very relevant position, but, the rethinking of the role of surgery in breast cancer has not yet come into 
acceptance. It would be the shattering of a dogma, but as anal, laryngeal and rectal carcinomas are treading 
that unchartered territory, soon the question will be put to breast cancer physicians. Meanwhile radiotherapy 
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is indicated in every single breast conserving surgery as well as for DCIS and there are still mastectomy 
patients that must undergo radiotherapy.
What about chemotherapy? The first experiments with mustard gas to treat humans were done, in Yale, in 
1942, but wartime secrecy prevented itʼs dissemination until 1946. To most, the birth of chemotherapy was in 
December 1943, in Bari harbor, Italy, during the II World War, when there was an explosion of mustard gas. 
The sailors were later diagnosed with bone marrow aplasia showing that the gas interfered with 
hematopoietic cell proliferation. This was thought to be useful in the treatment of acute leukemia, and, it gave 
mustard gas the wide dissemination that was lacking in the experiments done in small labs. Continued 
research produced alkylating agents such as busulfan, cyclophosphamide and chlorambucil, all still used 
today. None proved toxic exclusively for cancer cells or free of undesirable side effects, and none cured 
clinical breast cancers, but their judicious use proved clinically useful. These drugs administered systemically 
often produced temporary regression and occasionally complete disappearance of advanced breast cancers. 
Initial trials of intravenous, perioperative triethlylene-thiophos-phoramide (Thio-TEPA) in the late 1950s, 
intended to destroy tumor cells released during mastectomy, were failures, but extended adjuvant treatment 
with L-phenylalanine mustard, directed against occult micrometastases, improved the survival of patients 
with early stage breast cancer. These studies were published in early sixties and established the rationale for 
adjuvant treatment. The 1970s brought the concept of combination chemotherapy for adjuvant treatment, 
joining several drugs with different mechanisms of action, cyclophosphamide, fluorouracil, and methotrexate 
in the acronym CMF, that we still use today. The end of the 1970s brought doxorubicin. Anthracyclines are 
still essential drugs in the adjuvant treatment of breast cancer today. Despite the long term toxicity 
profile ,that includes cardiac failure and secondary leukemias. After several clinical trials asking questions 
about anthracycline sparing regimens, this group  of drugs is still unavoidable. In the early 1960s, paclitaxel 
was discovered as part of the North American National Cancer Institute (NCI) program in which extracts of 
thousands of plants and natural products were screened. In vitro, the crude extract of the bark of the Pacific 
yew, Taxus brevifolia, a slow growing evergreen, was found to have broad antineoplastic activity. The active 
component was only isolated in 1969, and, the structure, essential for synthesizing the molecule, was 
elucidated in 1971. Clinical trials started in 1977, and, because of its broad but not impressive activity, it was 
not given high priority. To make matters worse, paclitaxel, as we know today, is poorly soluble in water, and, 
at the time, due to its origin, the molecule was scarce. This meant procurement and preparation of quantities 
sufficient for large-scale clinical development would be difficult. In the 1980s paclitaxel was shown to have a 
60% response rate in metastatic breast cancer and the race started. Academia, pharmaceutical companies, 
chemists, botanists and environmentalists discussed how to move forward with such an effective drug in 
breast cancer that was menacing Pacific northwest forests. In the initial trials, and, due to its scarcity, 
paclitaxel was purified from the urine and feces of one patient to give to the next, as had happened with 
antibiotics in the II World War. In Europe, Rohne Poulenc, a chemical company, screened Taxus baccata, 
and was able to produce by semi synthesis an analogue of paclitaxel prepared from a non cytotoxic 
precursor extracted from the needles of the yew. This drug, docetaxel, entered trials in the begining of the 
1990s. One of the major toxicities of docetaxel are several effusions, pleural, pericardial and peritoneal. This 
fact could have jeopardized an efficacious drug, because, in the Phase I studies, the effusions were at first 
thought to be disease progression, and, only after closer scrutiny, were they finally interpreted as toxicity. 
This story is important, because, in drug development, we should be aware of serendipitous, unexpected 
toxicity; it may jeopardize the development of promising drugs.
In the 1980s, in the lab  of a formidable cancer scientist named Robert Weinberg, researchers were changing 
the paradigm in the new direction of drug discovery: identify the oncogene then design the drug. They cloned 
oncogenes from cell lines and animal models. There, in 1982, an oncogene was isolated in a rat 
neuroblastoma and named neu after neuroblastoma. In 1983, in a paper in Science, Dennis Slamon 
demonstrated that Her2/neu amplification was a negative prognostic factor in breast cancer. Her2 is an 
enormous transmembrane receptor protein securely fastened to the cell membrane, not unpredictably motile 
in the cytoplasm, like the untargetable oncogene, myc. Soon after, it was shown that an antibody could bind 
and inactivate this molecule. This ignited the effort to synthesize antibodies against Her2 blocking its action. 
Genentech, synthesized trastuzumab, and, in the beginning of the 1990s, trials in metastatic trials performed 
with this monoclonal antibody showed unquestionable activity.
Regarding the old question of heritable breast cancer, the clustering of breast cancer cases in families had 
been observed for decades, but only in 1990 was early-onset breast cancer linked to chromosome 17q21. In 
the subsequent years, there was a race to identify the gene in that region that was responsible for the 
phenotype. Twenty two genes were cloned and sequenced, but, mutations in BRCA1, appeared to explain 
most of inherited cases of breast and ovarian cancer. In the initial series of familial breast cancer, close to 
16
70% of the affected individuals had mutations in BRCA1. Mutations in BRCA2 were later associated with 
inherited female and male breast cancer. But half of the families with aggregation of breast cancer cases 
remain without identifiable mutations. Since then, families with affected young patients and with multiple 
cases in the family, undergo genetic testing for BRCA1 and BRCA2, and, if a mutation is found, an intensive 
screening program, consisting of mammography, sonography and MRI is recommended, and, interventions 
such as chemoprevention with tamoxifen or prophylactic surgery with oophorectomy or mastectomy are 
discussed. In fact tamoxifen was validated as a preventive strategy in a trial with 14000 women who had 
increased risk of breast cancer. The eligibility criteria allowed the randomization of patients over 60 years of 
age, or aged 35 to 59 years but with increased risk based on the Gail model, or women diagnosed with 
lobular breast cancer. Despite the 50% reduction in incidence of invasive breast cancer, the widespread use 
of tamoxifen in every women aged 60 has not been implemented.
Another very attractive strategy is population-based screening given the frequency and mortality of BC. An 
early randomized trial of screening with mammography and physical examination, in New York, in 1963, 
demonstrated that 30% of cancers could be detected by mammography alone, and deaths from cancer 
among screened women were reduced by 30%. The Breast Cancer Detection Demonstration Project 
(BCDDP), begun in 1973, and sponsored by the NCI and the American Cancer Society (ACS), screened 
283,222 asymptomatic women. The BCDDP established the feasibility of mass population screening. 
Multiple randomized clinical trials of mammographic screening followed, showing that regular mammograms 
could detect 85 to 90% of asymptomatic breast cancers, with a reduction of breast cancer mortality. Periodic 
mammograms and physical examinations for detection of breast cancer in asymptomatic women aged 50 
years of age and older received endorsement by the NCI, ACS, and numerous professional groups, although 
the recommended age to start screening remains controversial.
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Summary
Background:
It has been said that the current TNM staging system might not be suitable for predicting breast cancer (BC) 
outcomes and for making therapeutic decisions, especially for patients with screen detected BC which is 
smaller. The main reason being the non inclusion of tumor biology parameters in the current TNM system. 
We hypothesize that in a population where there is still a large number of non screen detected BC, with a 
low median age of incidence and frequent high TNM stage lesions, biology is still second to classical staging 
in predicting prognosis.
Patients and methods:
We analyzed a population of consecutive BC patients from a single institution during ten years. The patients 
were treated according to institutional protocols, and followed indefinitely. We characterized current 
established prognostic factors, classical staging variables included in the current TNM staging system and 
biological variables, currently not included in the TNM system. We quantified the capacity of individual 
prognostic factors to predict survival.
Furthermore, we performed multivariate regression analysis to study the power to predict survival of each 
individual prognostic factor in a model where all other factors are taken into account.
Results:
We analyzed a population of 1699 consecutive patients diagnosed between January 1st 2000 and 31st 
December 2009. In the univariate analysis, increased tumor size, involved axillary nodes, higher stage 
lesions, estrogen receptor negativity, HER2 positivity, triple negative status or lower differentiation tumors are 
significant predictors of decreased survival. However, in the multivariate regression analysis, only axillary 
lymph node involvement, TNM stage and histological grade are independent predictors of survival.
Conclusion:
We have concluded that, in a population such as ours, classical TNM staging variables, irrespective of tumor 
biological features, are still the most powerful predictors of patient survival.
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Introduction
Breast cancer (BC) is a heterogenous disease {Polyak, 2011, The Journal of Clinical Investigation, 121, 
3786}. It is still an important public health problem since it is the most frequent cancer in women and the 
second cause of death by cancer in women {Igene, 2008, Breast J, 14, 428-34}. Screening mammography 
allows the diagnosis of earlier stage breast cancer with smaller lesions and less frequent axillary lymph node 
involvement, leading to lower mortality {Puliti and Zappa, 2012, BMC Med, 10, 106} {Bleyer and Welch, 
2012, The New England Journal of Medicine, 367, 1998-2005}. BC originates in the glandular tissue of the 
mammary gland, the primary tumor (T), then, usually disseminates, first to the axillary nodes (N), and then to 
distant organs, where it forms metastases (M). With this in mind, sixty years ago, a French surgeon 
proposed that these three characteristics should be stratified in categories, integrated into a staging system 
to predict prognosis and tailor therapy. During the second half of the last century the TNM system was 
validated as a predictor disease free and overall survival {Gospodarowicz et al., 1998, Cancer Prev Control, 
2, 262-8}. The utility of the TNM system for predicting survival has been more useful in patients treated with 
curative intent, i.e., stage I-III BC, because stage IV BC is generally fatal with an expected median survival of 
2 to 3 years {Chung and Carlson, 2003, Oncologist, 8, 514-20}.
For the last half century we have known there are active systemic therapies for metastatic and adjuvant BC 
{Fisher et al., 1968, Ann Surg, 168, 337-56}{Fisher et al., 1975, The New England Journal of Medicine, 292, 
117-22}. Since 1970, several discoveries changed BC and showed that it is a heterogenous disease in 
treatment and prognosis. These include the unequivocal demonstration of the prognostic and predictive 
power of the estrogen receptor (ER) {Jensen, 1962, Perspect Biol Med, 6, 47-59} and antiestrogenic therapy 
{Jordan, 1976, Eur J Cancer, 12, 419-24} and the unravelling of epidermal growth factor biology as 
oncogenic in BC, namely Her2 {Slamon et al., 1987, Science, 235, 177-82}. Endocrine therapy is extremely 
relevant because ER is the main therapeutic target in BC. Her2 amplification is prognostic and predictive to 
Her2-directed therapy and its strength is independent of ER {Piccart-Gebhart et al., 2005, N Engl J Med, 
353, 1659-72}. Since 2005, trastuzumab  is standard adjuvant treatment for Her2-amplified BC. About fifteen 
percent of BC that do not express ER and do not have Her2 amplification are identified as Triple negative 
(TN). Despite several years of effort, no targeted therapy for TNBC has emerged, and, possibly because of 
this, it is associated with worse prognosis. The evaluation of the proliferative rate of BC cells, through 
histological grade or Ki67 nuclear staining, has also been integrated into patient care. The relevance of all 
these determinants, collectively termed BC biology, have aroused criticism of TNM {Veronesi et al., 2006, 
Breast (Edinburgh, Scotland), 15, 3-8; Veronesi et al., 2009, The Breast Journal, 15, 291-5}{Yi et al., 2011, 
Journal of Clinical Oncology, 29, 4654}{Park et al., 2011, Ann Oncol, 22, 1554-60}. It has been proposed that 
TNM should be modified to include BC biology.
Others, however, recognize the utility of TNM in BC even without incorporating biologic features {Uehiro et 
al., 2013, Breast cancer (Tokyo, Japan)}. Work from Japan, looking at smaller tumors and the identification of 
micrometastatic axillary disease, as reflected in the 7th edition of the TNM {Greene FL., 2009, TNM 
classification of malignant tumours. 7th ed., p. 181–93.} concludes that the TNM classification is still useful in 
predicting prognosis. For the present work, different from the Japanese series, that focuses on small tumors, 
we have hypothesized that TNM is still the most important prognostic indicator when axillary involvement is 
present (stage II and III BC). 
To test this hypothesis, we analyzed a consecutive population of BC patients from a single institution, treated 
with curative intent, mainly constituted by stage II and III BC. In the comprehensive cancer center, patients 
are treated according to institutional protocols for local and systemic therapy, with all treatment modalities 
delivered in the institution where patients are followed indefinitely. In the analysis, with the included TNM 
stage variables as well as standard biologic prognostic variables, we performed univariate survival analysis 
followed by multivariate regression analysis where we studied the contribution of each factor for survival.
Patients and methods
We performed retrospective analysis of ten years of BC cases in Instituto Português de Oncologia, Lisboa, 
this study was submitted and approved by the institutional ethics committee, informed consent from patients 
was waived. Sequential BC cases from 1st January 2000 until 31st December 2009 that were treated in the 
institution and, followed indefinitely, were analyzed. We chose these years to allow a median follow up  time 
of over five years. We also wanted to evaluate the effect of adjuvant anti Her2-directed therapy, instituted in 
2005, although we do not include these data in the current report. Data was collected from patient clinical 
charts, pathological reports and electronic medical records. When necessary, surgical protocols, or specific 
pharmacy, day hospital or radiotherapy records were reviewed. Relapse information was obtained from 
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primary care physicians, in the rare cases where it was necessary. Vital status was confirmed in the national 
online database system of death certificates when there was no such information in the institution medical 
records. 
We collected demographic data on age at diagnosis and sex. The disease was classified as localized, locally 
advanced or metastatic at diagnosis. Data on clinical and pathological T and N staging were recorded. 
Tumor samples were classified according to standard pathology criteria for histological subtype, 
differentiation, hormonal receptor expression and Her2 expression and/or amplification. Primary antibodies 
used here were estrogen receptor (clone SPI; Ventana Roche cat. 790-4324), progesterone receptor (clone 
1E2; Ventana Roche cat. 790-2223) and Her2 expression or amplification was evaluated by fluorescence in 
situ hybridization (FISH) with pathway HER-2/neu, clone 4B5; Ventana Roche cat. 780-001, in Ventana 
BENCHAMRK ULTRA instrument. Ki67 was not systematically evaluated. ER end PgR were evaluated by 
immunohistochemistry and the cutoff for positivity is 10%. Her2 positivity is considered when the IHC score 
is 3 or, in case of IHC score 2, if there is amplification of the gene by FISH.
Patients were treated with systemic therapy, in the neoadjuvant or adjuvant setting, as recommended by the 
institutional multidisciplinary clinic, according to institutional, national, european and international guidelines. 
Endocrine therapy was administered to ER or PgR positive BC cases. Since 2005, Her2 positive BC patients 
were treated with the monoclonal antibody trastuzumab. The data on therapy for advanced disease were not 
collected because it was not part of the study objective which was to evaluate the ability of the TNM 
classification to predict survival of patients with early stage BC and also due to its individuality and variability.
We collected data on the systemic neoadjuvant or adjuvant treatment administered. But this is not included 
in this report. In general, all but T1N0M0 BC patients were routinely treated with adjuvant chemotherapy. 
Some high risk patients with T1b  or T1cN0 carcinomas were equally treated. Most patients were treated with 
6 cycles of FEC: 5 fluouracil 500 mg per square meter, epirubicin 100 mg per square meter and 
cyclophosphamide 500 mg per square meter every three weeks for 6 cycles, in the majority of neoadjuvant 
and adjuvant cases. For low risk patients, without involved axillary nodes, 4 cycles of AC: doxorubicin 60 mg 
per square meter and cyclophosphamide 600 mg per square meter every three weeks for four cycles. Since 
2005, with the demonstration of the value of adjuvant taxanes in node positive patients, we changed the 
systemic chemotherapy protocol for node positive patients, to incorporate taxanes. Several options were 
available: 80 mg of paclitaxel per square meter by intravenous infusion weekly for 12 doses or 3 cycles of 
docetaxel 100 mg per square meter, after 3FEC. Regarding outcome variables, we collected data regarding 
date on local relapse and distant recurrence, location of distant disease which we do not present in this 
report, death from BC or other causes and date of last follow-up.
Statistical analysis was performed with PASW statistics version 19 (SPSS Inc., Chicago, IL, USA). We used 
T-tests to compare continuous variables and the Chi-squared test to compare categorical variables. All tests 
were two-sided and the results were considred significant if the p value was lower than 0.05.
Patient survival analysis, was performed the Kaplan-Meier (KM) method. Comparison of survival curves was 
evaluated by the log rank test. We performed multivariate analysis with categorical and continuos variables 
with logistic regression model.
Results
One thousand nine hundred (N=1900) patients were treated between 1st of January 2000 and 31st of 
December 2009, of which 41 are men (2%). The median age of the population is 56 years with a range 
between 15 and 87 years, but 75% of the sample had between 40 and 70 years at diagnosis, with a similar 
distribution of patients between these three decades i.e. 25% of the subjects in each decade. In 49 patients 
(2.5%) the disease was disseminated ab  initio, these patients did not undergo BC surgery. Two hundred and 
twelve (212 - 11%) other patients did not undergo surgery for various reasons that included inoperability, 
refusal, comorbidities and old age. These patients were treated with several combinations of systemic 
treatments, mainly endocrine therapy in patients with comorbidities and old age and radiotherapy was used 
for local control in more aggressive local disease.
The analysis includes 1639 patients that underwent BC surgery and were treated with curative intent. 
Because of the recruitment profile of the institution this cohort has a large percentage of locally advanced 
disease, 30% of the patients were treated with neoadjuvant systemic therapy. Eighty five percent (1398) of 
the patients had axillary lymph node dissection (ALND), in 61% there was axillary involvement. The 
remaining 241 (15%) patients did not undergo ALND, were staged with a sentinel lymph node biopsy (SLNB) 
which was negative, therefore, no further axillary exploration was deemed necessary. 
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Histologically, invasive ductal carcinoma currently denominated carcinoma not otherwise specified, was the 
most frequent histological subtype, comprising 92% of the cases. We collected pTNM and biological profile 
data of 1639 patients who underwent BC surgery (Table 1). Regarding tumor size, the sample has the same 
amount of T1 and T2 lesions, it has 61% of axillary lymph node involvement. Survival analysis according to 
TNM variables is shown graphically with KM survival curves (Figures 1 to 4). The survival analysis according 
to biology variables is similarly depicted with KM curves (Figures 5 to 8). The p value of the Log Rank test 
performed to show that the survival curves are not superimposable is similarly shown. TNM staging variables 
and biology variables are predictive of survival.
Two thirds of the cases express ER, 9% were not evaluated. Nearly half of the cases had no PgR evaluation. 
Regarding HER2, in 16% of the cases had higher abundance of this oncogene, either at the protein or gene 
level, however, 30% of the cases were not evaluated. There were 13% of TN cases.
Regarding outcome variables, the median follow-up  is 67 months for the whole population and 73 months for 
living patients. Four hundred and twenty one patients died, 361 deaths (22%) from metastatic breast 
carcinoma, 3,6% from other causes. The causes of death, other than BC, are known, but, we did not collect 
the data.
The logistic regression analysis contains data from the three TNM variables and the four biological variables 
included in the model. We conducted logistic regression to determine which variables are independent 
predictors of survival. In the model, for each survival predictor, we have a statistic and associated 
probabilities. These provide an index of the significance of each predictor in the equation. For assessing 
each predictor, we take the significance values, and, if the value of p is lower than 0.5 we reject the null 
hypothesis. We conclude the variable contributes significantly for predicting survival. The third column of 
table 2 shows the change in odds. If the value exceeds 1 then the odds of dying increase, if the figure is less 
than 1 any increase in the predictor leads to a drop  in the odds of death, this is the case for Her2 negative 
status. The odds ratio (OR), estimates the change in the odds of survival if any given patient has BC with the 
characteristic in study. The OR is calculated by using the regression coefficient of the variable as exponent. 
In the case of TNM variables, the regression coefficient of stage is 2, thus the OR is exp², or 7.4. The odds of 
dying from BC are 7.4 times greater for a patient who has higher stage disease. In case of the other 
significant TNM variables in the model, the regression coefficient of involved axillary nodes is 1.42, therefore 
the odds of dying is 4 times greater for a patient with involved axillary nodes. Regarding the biological 
variables, in our model, built with the data from our population, we show that the odds of survival are doubled 
in patients with Her2 negative BC and that increasing histological grade increases the odds of death 4 times. 
We stress that adjuvant trastuzumab was administered since 2005.
Discussion
The cohort has a majority (61%) of stage II disease, i.e., with axillary lymph node involvement, this value is 
high {Turner and Leo, 2013, 2013 ASCO Educational Book, 3-8}. There are two possible reasons: First, the 
median age of the cohort is lower in the patients of this institution, when compared to the median age of 
incidence of breast cancer in the Western world {Leong et al., 2010, World J Surg, 34, 2308-24} {Turner and 
Leo, 2013, 2013 ASCO Educational Book, 3-8}. As has been said, this institution recruits younger patients 
with more advanced disease. Second, on a socioeconomic perspective, this institution serves mainly the 
region of southern portugal that has a less mature screening program than the north and center, and mainly 
serves patients without private insurance {Dourado et al., 2012, Eur J Public Health}. The high axillary lymph 
node involvement, and the low median age of the cohort, are the two most important findings of our work. 
These influence decisively of our results and conclusions.
Fifteen percent (241) patients that did not have axillary dissection because they were staged with a SLNB 
and ALND was deemed unnecessary. After the results of ACOSOG Z11 and other SLN trials, this figure is 
low, but, up  to 2008, the SLN procedure was undergoing institutional validation. The main questions in the 
population spared ALND are about outcome measures, which we have addressed, and quality of life, which 
we have not. The incidence of lymphedema is not reported because the retrospective nature of data 
collection might induce bias of underreporting. In the institution, all patients are systematically geared 
towards an experienced team of physiotherapists in the immediate post surgical period where they stay until 
arm health and mobility is established, generally for some months. Furthermore, patients are taught about 
the need of lymphedema prevention and warning signs throughout life. Others have shown that these 
measures reduce the incidence of lymphedema {Boccardo et al., 2009, Lymphology, 42, 1-9; Erickson et al., 
2001, J Natl Cancer Inst, 93, 96-111}.
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The 2% metastatic (M) BC cases ab  initio is lower than other series {Chung and Carlson, 2003, Oncologist, 
8, 514-20}. There are two reasons for this. First, stage III BC in 2009 were not routinely staged with CT 
scans and PET therefore the true MBC rate might be underestimated. Second, because the institution is a 
tertiary referral center it might not receive so many MBC cases. Referring physicians, once MBC is an 
incurable condition, prefer to treat patients nearer to their homes, in an effort to preserve quality of life.
Her2 was not evaluated routinely until 2005 because trastuzumab  was not approved for adjuvant therapy of 
Her2 positive cases. PgR was not evaluated routinely because its prognostic and predictive role has not 
been unequivocally established. The positivity of PgR in ER negative cases is the only situation where 
patient management might change, favoring the use of endocrine therapy. In such cases, PgR determination 
by IHC was done. Nine percent of non evaluated ER is similar to other reports and preferentially happens in 
locally advanced or inoperable cases that are diagnosed by cytology. The lack of comprehensive 
assessment of HER2 and ER might underestimate the true percentage of Her2 positive and triple negative 
cases which is lower than expected for this population. 
In this sample there are 41 men, this is twice the expected number of male BC cases in such a sample size. 
The reason for this is the recruitment profile of the institution as a tertiary center. The institution has an active 
familial BC clinic where more than 1000 families are followed, this may bias the case mix, towards younger 
median age and abundance of male BC. Regarding hereditary syndromes of breast and ovarian carcinomas, 
there is a founder mutation in BRCA2 in the Portuguese population and the family risk clinic has strong 
abundance of such families {Machado et al. 2007, JCO}. The phenotypic expression of this mutation 
includes male BC.
In this work, our findings support our hypothesis, that in a population with more than half of axillary lymph 
node involvement, the strength of classical TNM prognostic factors is greater than biology-based prognostic 
factors. We were able to show in univariate analysis that all prognostic factors are individually predictive of 
survival. It is graphically apparent, but we then asked the question if the several KM curves are different. We 
used the Log Rank statistical test to answer this question and the null hypothesis of the test, i.e. is that the 
curves are superimposable, was rejected. All KM survival curves are statistically significantly different, this is 
shown by significant Log Rank tests.
Histological grade is not evaluated in tumors that were treated with neoadjuvant chemotherapy that is why 
the KM curve with worse survival is the curve of non evaluable grade. This survival curve is that of locally 
advanced BC that naturally has worse survival.
In the multivariate model, the classical TNM variables are independent predictors of survival, except tumor 
size, and, of the biology-based variables, only HER2 positivity and histological grade remain independent 
predictors of survival. The adverse prognostic feature of Her2 positivity in this population, only partially 
treated with adjuvant trastuzumab, is apparent. Furthermore, Her2 positive metastatic BC patients did not, at 
the time, have the current availablity of Her2 blocking agents like trastuzumab, lapatinib, pertuzumab  or 
TDM1. It should be extremely interesting to perform the Her2-stratified survival analysis in more modern 
cohorts, comprehensively treated with adjuvant trastuzumab, and, upon relapse, further treated with anti 
Her2 agents.
The main message of this paper is that in populations with stage II and III BC, classic prognostic factors are 
still more important than biology in predicting survival, and, necessarily, that the TNM classification is not 
outdated in BC. Our data is in accordance to the EBCTCG overview data which included nearly 100.000 
early BC cases randomized in 123 trials. Our questions are not the same as the overview, where the focus is 
on treatment. In the overview, the proportional benefits of adjuvant chemotherapy, in the analyzed 
population, were independent of age, nodal status, ER status and histological grade. But the EBCTCG 
metaanalysis, like our population, has over 50% node positive patients, in all trials combined. In the overview 
data, for the questions of anthracyclines versus taxanes, there are nearly 90% of node positive patients. 
Furthermore, the EBCTCG, like our data, has suboptimal characterization of BC biology. Our data, has 
issues that limit the generalization of our findings to current BC clinical practice where we are taking care of 
patients with small, screen detected BC, in which we thoroughly assess tumour biology parameters {Turner 
and Leo, 2013, 2013 ASCO  Educational Book, 3-8}. In such populations, it may be that the TNM 
classification is obsolete.
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Figure 1 Guerra et al.
Overall survival stratified according to primary tumour size as categorized by the TNM classification. (P value 
4x10-¹³)
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Figure 2 Guerra et al.
Overall survival stratified according to number of involved axillary lymph nodes as categorized by the TNM 
classification. Patients with no involved axillary nodes have a higher probality of survival. (P value 2x10-²⁵).
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Figure 3 Guerra et al.
Overall survival stratified according to lymph node involvement. Patients with no involved axillary nodes have 
a higher probality of survival. (P value 1x10-¹³).
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FIgure 4 Guerra et al.
Overall survival stratified according to TNM stage. (P value 3x10-⁶⁶)
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Figure 5 Guerra et al.
Overall survival stratified according to ER status. ER positive cases have higher probality of survival ( p vaue 
6x10-⁹)
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Figure 6 Guerra et al.
Overall survival stratified according to HER2 status. The lighter curve corresponds to the patients with HER2 
positive tumours. Patients with HER2 positive tumours are more likely do die (P value 0.003)
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Figure 7 Guerra et al.
Overall survival stratified according to TN status. The lighter curve corresponds to the patients with TN 
tumours. Patients with TN tumours are more likely do die (P value 0.042)
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Figure 8 Guerra et al.
Overall survival according to histological grade. Well differentiated tumours had a higher probability of 
survival. (P value 2x10-¹²). Histological grade is not evaluable in tumors treated with neoadjuvant 
chemotherapy.
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   Yes
   No
205 (12,5)
1434 (87,5)
*Chi-squared test; **Binomial test Binomial
Table 1 Distribution of analyzed prognostic factors in the population
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Multivariable Cox proportional hazards regression model for overall survival
Variables Regression  
coefficient
p value 95% 
confidence 
interval
TNM Variables Tumour size (continuous) 1.14 0.25 0.91-1.43
Involved axillary nodes 1.42 0.0000001 1.19-1.69
TNM stage (continuous) 2.00 0.0000001 1.36-2.95
Biology-based variables ER positivity 1.22 0.41 0.76-1.96
HER2 positivity 0.68 0.05 0.46-0.99
“Triple Negative” status 0.68 0.18 0.38-1.20
Histological grade (continuous) 1.38 0.000 1.20-1.58
Table 2 Multivariable Cox proportional hazards regression model for overall survival including the eight 
variables that are shown in Figures 1 to 8
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Abstract
It has been known that breast cancers harbor centrosome changes, namely centrosome amplification, and, 
more precisely, increased centrosome numbers. It has also been shown that increased centrosomes are an 
initiator of chromosomal instability, through inadequate spindle formation. Multipolar mitoses, endanger cell 
viability, by generating aneuploidy. However, cells with multiple centrosomes have an adaptive mechanism to 
protect them from multipolar mitoses which is centrosome clustering. We hypothesized that centrosome 
clustering is a negative prognostic factor in breast cancer. With our work in silico we showed there were two 
genes involved in centrosome clustering and that these were also negative prognostic factors. In patient 
samples we were able to show that increased abundance of these gene and protein products correlate with 
relapse and with the centrosome clustering phenotype at cellular level.
Introduction
The centrosome is the major microtubule organizing center (MTOC) of the cell {Bettencourt-Dias et al., 2011, 
Trends Genet, 27, 307-15}. The MTOC is responsible for orchestrating mitosis in dividing cells and thus 
centrosome replication is tightly regulated, duplicating once and only once per cell cycle {Bettencourt-Dias et 
al., 2011, Trends Genet, 27, 307-15}. In quiescent cells, centrosomes are involved in maintaining cell shape 
and polarity {Bettencourt-Dias et al., 2011, Trends Genet, 27, 307-15}. As first observed by Theodore Boveri 
in 1902 {Theodore Boveri, 2008, J Cell Sci, 121, 1-84}, many cancers harbor numerical and structural 
centrosome abnormalities. More than a century has passed and no one has ever answered the question if 
such abnormalities are a cause or a consequence of carcinogenesis. This is the case of human breast 
cancers where 80% of breast carcinomas present centrosome amplification {Salisbury et al., 2004, Journal 
of mammary gland biology and neoplasia, 9, 275-83}. Characterization of centrosome abnormalities in breast 
cancer fine-needle aspiration biopsies was done by other groups and found to be present in only 10% of the 
cases. In these carcinomas, centrosome amplification correlated with genomic instability {Kronenwett et al., 
2005, Br J Cancer, 92, 389-95}. Centrosome amplification, morphologically, includes, increase in centrosome 
number and volume, increase in pericentriolar material, increased centrioles, and increased phosphorylation 
of centrosome proteins. Functional abnormalities include, inappropriate centrosome duplication and 
nucleation of larger microtubule arrays. This may be the cause of chromosomal instability through the 
development of multipolar mitotic spindles {Lingle et al., 2002, Proceedings of the National Academy of 
Sciences of the United States of America, 99, 1978-83}. In addition, centrosome amplification may affect cell 
polarity in interphase because cytoplasmic architecture and directional vesicular trafficking may be 
disorganized in a cell with multiple MTOCs {Lingle et al., 2002, Proceedings of the National Academy of 
Sciences of the United States of America, 99, 1978-83}.
Increased centrosomes are associated with changes in cell polarity, changes in cell and tissue differentiation, 
and chromosome missegregation through abnormal and multipolar mitoses. However, cancer cells cannot 
survive undergoing multipolar mitosis, and, when harboring multiple centrosomes, cells cluster them in order 
to undergo bipolar mitosis. It has been described that, in cancer cells, with centrosome amplification, 
centrosome clustering prevented cell multipolarity and it was shown that clustering centrosomes is a survival 
advantage for the breast cancer cell but these experiments have been carried out in cell line models 
{Quintyne et al., 2005, Science, 307, 127-9} {Kwon et al., 2008, Genes & Development, 22, 2189-203}
{Fielding et al., 2011, Oncogene, 30, 521-34}
We focused on centrosome clustering mechanisms, and hypothesized, that through the survival advantage 
this mechanism provides the cell, centrosome clustering may be an adverse prognostic feature in breast 
cancer patients. In our work, we first worked in silico, and we used public gene expression datasets of 
patient material and cell line data of centrosome clustering screens. For the individual marker work we 
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focused on three molecules: PLK4 which is a gene involved in centrosome amplification, and in two genes 
involved in centrosome clustering: TACC3 and KIFC1.
Materials and methods
Data collection, pre-processing and graphical display 
We mined Gene Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo) {Barrett T, 2009, 
Nucleic Acids Res., 37, D885-90}{R Development Core Team., 2009, R Foundation for Statistical Computing} 
according to the criteria: 1) Breast gland tissue, simple hyperplasia, atypical hyperplasia, ductal carcinoma in 
situ (DCIS), invasive ductal carcinoma and axillary node metastases tissue; 2) Primary breast cancers that 
had been operated and treated with curative intent according to international guidelines and had a median 
follow up of five years and 3) for both prior conditions, microarray experiments performed in the Affymetrix® 
Human Genome U133A microarray platform (HGU133a). (Table 1)
Data analysis was performed with R Statistical Computing software {R Development Core Team., 2009, R 
Foundation for Statistical Computing} complemented with Bioconductor packages {Gentleman RC, 2004, 
Genome Biol, 5, R80}. Heatmaps and Venn-diagrams were plotted using gplots (http://CRAN.R-project.org/
package=gplots) and VennDiagram (http://CRAN.R-project.org/package=VennDiagram) packages, 
respectively. Affy {Gautier L, 2004, Bioinformatics, 20, 307-15} and frma {McCall MN, 2010, Biostatistics, 11, 
242-5} packages were used for raw data uploading and normalization. The R script used is available upon 
request. 
Differential expression analysis 
We have used a Bayesian differential expression analysis approach implemented in the R package limma 
{Smyth GK, 2004, Stat Appl Genet Mol Biol, 3: Article 3} to define differentially expressed genes. Threshold 
for selection of differentially expressed probe sets was set to a B-statistic parameter Lods (already adjusted 
for multiple testing) 5 and a log2 ratio + 0.58 or - 0.58. The very conservative Lods>5 was based on 
differential expression analysis results between breast cancer samples from {Nagalla et al., 2013, Genome 
Biol, 14, R34) datasets, where several significant differentially expressed probe sets were found. For our 
experiment we used a conservative threshold, expecting less differentially expressed genes, to control for 
inter-dataset variability noise.
Assessment of Significance of Study Overlap
To determine if the level of overlap  among the studies was significant, we performed a Monte Carlo 
simulation that generates random numbers to model a process {Chan et al., 2008, Cancer Epidemiol 
Biomarkers Prev, 17, 543-52}. Python scripts were created to perform Monte Carlo simulations. In each of 
the 10,000 permutations, the appropriate number of Entrez Gene IDs from the total gene list of each study 
was randomly chosen and each ID was randomly labeled as ʻʻUPʼʼ for up-regulated or ʻʻDOWNʼʼ  for down-
regulated. We used an ʻʻall-or-noneʼʼ approach in which the level of overlap  for a particular gene was only 
considered if all the independent studies reporting its differential expression agreed on the direction. The 
level of overlap  among studies in each permutation was counted as in the real analysis. On completion of the 
permutations, a distribution of overlap  results from the simulations was determined and a p value was 
estimated by comparing the overlap from the simulations to the actual level of overlap  in the real data. 
Significance was defined at p < 0.05. We used hypergeometric testing to assess gene set enrichment when 
gene lists derived from BC analysis were intersected with lists of genes involved in centrosome clustering.
Samples and clinical data 
FFPE breast cancer samples from primary surgery of patients that were treated with curative intent and 
continued follow-up  indefinitely at Instituto Português de Oncologia Lisboa (IPOL) were used for validation 
(Table 2). For this initial validation we used 14 patient samples 8 had relapsed and 5 of these have died and 
6 were in follow up  without evidence of relapse. Hematoxylin-and eosin-stained sections were used by an 
experienced breast pathologist (SA) for histopathological characterization and area selection.
RNA extraction and cDNA synthesis 
Archived breast cancer surgical blocks in FFPE were cut into tissue sections of 5 µm. These were 
deparaffinized and counterstained with Mayerʼs hematoxylin and eosin. Cancer-enriched areas were needle 
microdissected under the breast pathologist (SA) guidance. Total RNA was extracted with the RNeasy FFPE 
kit (Qiagen), according to manufacturerʼs instructions with a slight modification: proteinase K cell-lysis at 
56°C was performed overnight. The RNase-Free DNase Set (Qiagen) “on column” DNA digestion procedure 
was included. Each extracted RNA was reverse-transcribed with the First-Strand cDNA Synthesis kit (GE 
Healthcare), using a 1:1 mixture of random primers (pd(N)6) and oligo-dT primers (NotI-d(T)18). cDNA from 
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control samples (high-quality RNA from HCT-116 and a primary skin fibroblasts cell lines) was synthesized 
from 3 µg of total RNA. 
RT-qPCR 
RNA concentration and integrity could not be assessed using standard methods due to known FFPE 
degradation issues and to the small amounts of extracted samples. Thus, to indirectly check the amount of 
each isolated total RNA FFPE sample and its RT-qPCR downstream performance, we prepared two 
standards dilution series using cDNA from the two control cell lines, corresponding to 100 ng, 10 ng, 1 ng, 
0.1 ng, 0.01 ng, 0.001 ng and 0.0001 ng of the original total RNA. These series were subsequently used to 
calculate a RT-qPCR standard curve for the non-differentially expressed gene MAPKAPK2 (Lods=-2.7). 
Primer sets were designed with the NCBI Primer-BLAST tool {Ye J, 2012, BMC Bioinformatics, 13, 134}, to 
work at 59 °C and with an amplicon length of 70–100bp. Duplicates of each breast cancer sample were 
analyzed by RT-qPCR using SsoFast™ EvaGreen® Supermix (Bio-Rad, Hercules CA, USA) reagent in 10 L 
of reaction mixture containing template (2 L, ~200pg/ L) and primers (0.5 M each). Samples were processed 
in a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules CA, USA) according to the 
cycling program: 95 °C for 60 s, 50 cycles of 95°C for 10s and 59°C for 15s. Fluorescence data collection 
occurred at 59°C. Relative differential expression analysis of target genes by RT-qPCR was based on the 2-
∆∆Ct methodology from {Livak KJ, 2001, Methods, 25, 402-8} using mean quantification cycle of duplicates 
as cycle threshold (Ct). 
Immunohistochemistry 
In breast cancer samples (3 µm thick tissue sections), IHC was performed according to standard protocols. 
Primary antibodies were diluted in Bond Primary Antibody Diluent (Leica Microsystems) plus background-
reducing components at the dilutions: KIFC1 (1:150, mouse monoclonal, Abnova, 53-152). Slides were 
incubate with Polymer Kit-Envision (HRP) DAKO  150 µl for 30 minutes. Washed and sequentially stained 
with diaminobenzidine, Mayerʼs hematoxilin and ethanol. Nuclei were counterstained with Mayerʼs 
hematoxylin. Images were acquired on a Leica DM5500 microscope. 
Fluorescence microscopy 
From each paraffin block, 3 !m-thick tissue sections were obtained using a conventional microtome and 
transferred to positively charged glass slides and oven dried (70º C) for a minimum of one hour. Sections 
were then deparaffinized in xylene and placed in 100% ethanol. Then, in order to block the endogenous 
peroxidase, the slides were treated with a 2% hydrogen peroxide in methanol solution for 10 minutes and 
washed in running water. Antigen retrieval was done in a pressure cooker in a 0.01M sodium citrate buffered 
solution (pH 6) for sixteen minutes, followed by incubation with a blocking buffer (triphosphate-buffered 
saline (TBS) with 5% bovine serum albumin) for 10 minutes at room temperature to avoid nonspecific 
binding by primary and secondary antibodies. The slides were then incubated with primary antibodies diluted 
in Bond Primary Antibody Diluent (Leica Microsystems) with background-reducing components for one hour 
at room temperature. Primary antibodies used were against polyglutamylated tubulin (GT335, 1:800, clone, 
Firm) and pericentrin (1:250, Abcam). The sections were then washed three times with TBS (5 minutes/
wash) before incubation with the fluorochrome-conjugated secondary antibodies fluorescein isothiocyanate 
(FITC)-conjugated donkey anti-rabbit IgG and rhodamine red-conjugated donkey anti-mouse IgG (1:50, 
Jackson ImmunoResearch) for thirty minutes at 37ºC. The sections were then washed extensively with TBS 
and dehydrated through gradient alcohols. Finally, the sections were counterstained and mounted with 4,6-
diamidino-2-phenylin-dole (DAPI) for nuclear DNA (Vectashield Vector with DAPI, Burlingame, CA, USA) and 
examined by fluorescence microscopy using a Ti-E inverted microscope (Nikon Eclipse), using an ORCA 
ER2 CCD camera (Hamamatsu) and Nikon software.
Mitotic and multipolar index
In at least two independent experiments, cells were screened and a minimum of 500 cells were counted for 
the mitotic index (mitoses per cells counted in %) and up  to 20 mitoses per tumor were analyzed for the 
mitotic profile (cells in prophase, prometaphase, metaphase, anaphase and telophases) and the occurrence 
of multipolar mitosis (multipolar mitosis per cells counted; range of total mitoses counted).
Statistical analysis 
Data analysis was performed with R language for Statistical Computing {R Development Core Team., 2009, 
R Foundation for Statistical Computing}. Expression differences between different conditions of breast 
cancer progression and relapsed and non relapsed BC patients microarray data were determined with a 
Bayesian T-test implemented in the R package limma {Wettenhall and Smyth, 2004, Bioinformatics, 20, 
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3705-6}. Statistical significance of RT-qPCR data was calculated with Wilcoxon Rank Sum test (confidence 
level=0.95). IHC categorical data was analyzed with Pearsonʼs Chi-squared test. 
Mitotic control
To find over-represented GO biological processes among specific sets of genes we used the GSEA tool from 
InnateDB (http://www.innatedb.ca/) using Entrez ID as gene identifier. There was high abundance of mitotic 
genes, therefore, we collected 16 datasets of cells that could serve as an internal control for mitotic genes. 
Two senescent cancer cell lines treated with chemotherapy. Two cell lines with replicative senescence. 
Normal breast tissue in parous and nulliparous women. Four datasets of mammosphere cells in different 
proliferative stages. We then used microarray signatures from patient cancer samples . Finally we used 
controls of proliferating Drosophila melanogaster cells and umbilical cord progenitors. The methodology is, 
for the studied centrosomal genes, to check if they are present in these signatures, if present, if ʻʻUPʼʼ  (red) 
for up-regulated or ʻʻDOWNʼʼ (blue) for down-regulated genes. The finding of MKI67 as prognosis predictor 
prompted us to specifically perform linear correlation of the expression vector of MKI67 with the KIFC1 
expression vector in each of the datasets (Fig 6).
Results
Centrosome abnormalities in breast cancer progression
Centrosome amplification has been detected in DCIS, suggesting that centrosome amplification is an early 
event in these lesions. Therefore we compiled datasets of breast carcinoma precursor lesions and their 
expression profile and assessed whether there was overlap between these genes and the genes in 
centrosome proteome and the genes involved in centrosome clustering. Breast cancer presents precursor 
lesions: simple hyperplasia, atypical hyperplasia and DCIS. There are publicly available expression datasets 
of normal mammary gland as well as precursor lesions and invasive carcinomas of the breast and metastatic 
sites, namely axillary lymph node metastasis. The Vogelstein coloretal carcinogenesis model {Goyette et al., 
1992, Mol Cell Biol, 12, 1387-95} is applicable in BC. There is continuum of genetic aberrations and cancer 
defining properties throughout these stages (Figure 1). The change in expression of the genes in the 
centrosome proteome across several states of breast cancer progression including normal breast, 
hyperplasia, DCIS and invasive cancer in the breast as well as metastatic lesions. There is a statistically 
significant change in expression across the continuum of breast cancer pre invasive, invasive and metastatic 
lesions for centrosome proteome genes and the centrosome clustering proteome genes (Figure 2). We were 
able to detect the stepwise increase in expression for three selected genes Plk4, TACC3 and KIFC1. Plk4 a 
gene involved in centrosome amplification. For centrosome clustering we have assessed TACC3 and KIFC1 
molecules involved in centrosome clustering. KIFC1 (also denominated HSET) is involved in clustering 
centrosomes in acentrosomal cells as well as in cells with centrosome amplification.
Quantifying the prognostic impact of centrosomal genes in expression datasets of breast cancer
We performed a systematic analysis of the literature and compiled an extensive data set of gene expression 
data for >4000 of Breast Cancer (BC) patients with prognostic information (relapsed versus non-relapsed), 
individual datasets are shown in Table 1 Eighteen datasets were retrieved but only 14 were used because 
some datasets had no informative genes at the statistical cutoffs. Setting stringent cutoffs enables reduction 
of interdataset variability and background noise. The expression arrays were from untreated primary breast 
cancers at the time of primary surgery. In this analysis there is no expression data of relapsed material, i.e. 
distant organ metastasis. We analysed this data seeking for genes consistently up  or down regulated in poor 
prognosis BC, i.e. that relapsed after initial treatment. In the course this bioinformatics analysis we identified 
65 genes statistically significant across multiple datasets (≥2) that can discriminate between relapsed and 
non-relapsed BC patients. We used the B  statistic with a false discovery rate of 0.05, lods score of 0 and an 
adjusted p-value of 0.05. To test whether 65 genes in common was more than should be expected by 
chance we did a Monte Carlo simulation where we were able to show that in a random simulation there 
would be less genes in common (Figure 3A). Working with whole genome expression arrays and comparing 
the discriminant genes for two conditions among two datasets by chance only one gene would be in common 
and we found 65. For the same simulation in three, four or five datasets in the Monte Carlo Simulation there 
are no common genes and we found 18, 2 and 2 common genes, respectively, in these intersection 
experiments. 
Among the identified genes, we have detected genes such as MKI67, a marker of mitotic activity and 
routinely used in the clinic. In the intersection of the 65 BC prognostic genes with the list of centrosome 
clustering genes found in the screens we have previously curated, there are 6 common genes in the 
intersection of the 65 and in the 158 centrosome clustering genes. These gens are KIFC1, TACC3, BUB1, 
PRC1, CENPA, and BIRC5. The gene intersection was not due to chance. We performed a statistical 
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hypergeometric test where we show a p-value of 8.5 e-7 for this intersection of 6 genes not being due to 
chance. In other words, 6 genes involved in BC prognosis and centrosome clustering are more than should 
be expected by chance (Figure 3B). We looked specifically the absolute difference in expression of KIFC1, 
TACC3 and PLK4 in the microarray data (Figure 3C). We were able to show that the differences in gene 
expression levels were statistically significant for the genes involved in centrosome clustering, KIFC1 and 
TACC3, but not for the gene involved in centrosome amplification. For this phenotype we tested only PLK4, 
largely responsible for this phenotype, it was not significantly changed between patients with different 
outcomes (Figure 3D).
The prognostic value of centrosomal genes in different breast cancer subtypes
Since the year 2000, we are increasingly viewing BC as three different diseases, possibly with even more 
subtypes. With clinical relevance and implications there are primarily ER positive tumors, Her2 positive 
tumors and triple negative tumors. In the clinic we assess proliferation markers and these have been 
specifically important in discriminating between ER positive disease. In the seminal publication {Perou et al., 
2000, Nature, 406, 747-52}, gene expression profiling separated BC into five subtypes: Tumors that 
expressed ER but had low proliferation rate (Luminal A) or high proliferative rate (Luminal B). Tumors that 
express Her2 and those that do not express any receptor (triple negative) and, finally, in the initial classifier, 
tumors that are normal or have no specific subtype. We assessed if centrosomal genes were more or less 
able to predict prognosis in the different BC subtypes. Because the initial PAM50 classifier is expression 
based it is possible to separate into subtypes all the datasets we used, even if data on ER, PgR, Her2, 
histological grade and Ki67 are not available comprehensively in all datasets. Our results show that the six 
chosen genes are not different throughout breast cancer subtypes in their capacity to predict prognosis. This 
result is shown for dataset GSE1456, on of the most informative datasets we worked with (Figure 4).
Validate the centrosome clustering genes by non high throughput method in patient samples
Our work was performed in silico up to this point. In this step we have sought to validate our findings in FFPE 
embedded patient samples. The methodology includes designing of primers for qPCR for the evaluated 
genes MKI67, KIFC1 and TACC3. We selected a consecutive breast cancer case series and tested in 
relapsed and in non relapsed primaries. We tested by qPCR using the methodology of extracting mRNA from 
the FFPE blocks (Figure 5). There is a statistically difference in mRNA abundance for the tested genes. For 
generalizability and clinical applicability it is best to validate the use of antibodies for IHC because qPCR is 
not routinely available in pathology departments. Therefore, we worked on the validation and optimization of 
antibodies against KIFC1 and TACC3. The TACC3 antibody was not discriminative and we could not validate 
the findings of the qPCR with IHC. On the other hand, the results for KIFC1 are coherent with the qPCR 
results and retain clinical significance.
Identify and quantify the phenotype of centrosome clustering in relapsed breast cancers
Despite higher levels of genes involved in centrosome clustering we tested if we have evidence of this 
phenotype in relapsed patient samples. For this, we used immnunoflourescence confocal microscopy 
detecting centrosome molecules. We stained gamma tubulin and pericentrin. We studied metaphase plates 
in the primary tumor FFPE from relapsed breast cancer patients. The objective is to find: 1) amplified 
centrosomes, 2) clustered centrosomes. The blue staining shows DNA stained with DAPI and the green and 
red markers show pericentrin that is abundant in pericentriolar material and gamma tubulin which is the main 
protein of centrosomes. In breast carcinomas mitosis are not abundant. Generally less than 10 mitotic 
figures per high power field, therefore this work is particularly painstaking. We were able to find two such 
mitotic figures in tumor samples with increased numbers of centrosomes, increased levels of KIFC1 and 
TACC3 and where we were able to find the centrosomes clustered in the metaphase plate.
Controlling for proliferation markers
Finally, we were struck by the enormous abundance of proliferation genes in our initial 65 gene group. In fact 
it is known that the BC prognosis signatures, derived from the datasets we used, were mainly proliferation 
driven. This begged the question if with our metaanalysis we were not discovering new biology but simply 
validating the fact that tumors that proliferate more have worse prognosis. This has been known to 
pathologists and clinicians since the XIXth century. To answer this, we compared our 65 gene group  with 
gene groups that were said to represent proliferation signatures. We used several proliferation signatures 
from senescent breast cancer cell lines, then from normal mammary gland cells from reduction 
mammoplasties and then from breast cancer datasets. We also used non human and non breast tissue 
controls fro proliferation signatures, where we saw that proliferation genes are highly conserved. There is 
some overlap  for the proliferation genes as can be seen (Figure 6A). The results in the figure show a subset 
of genes involved in centrosome amplification and clustering. After this, we focused on MKI67, as has been 
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said MKI67 is one of the genes that is assessed routinely in breast cancer samples as a proliferation marker. 
The question we asked is if the signal of bad prognosis being captured by high Ki67 is the same as the 
signal we are detecting assessing centrosome clustering. As is shown graphically there is no correlation 
between the two molecules and numerically the r² is 0.38.
Conclusion
In this study, we were able to show that a phenomenon that was known to occur in breast cancer, 
centrosome clustering, occurs, and is correlated with worse prognosis. We have shown this in two ways: 
First, using an unbiased method, with differential expression analysis, the differentially expressed genes that 
predicted for relapse had an enrichment of centrosome genes. We detected genes involved in centrosome 
amplification and genes involved in centrosome clustering. Then, using a different experimental approach, 
with patient samples, single markers and confocal microscopy. We these techniques, were able to show that 
in patients with worse prognosis there was increased amount of mRNA of KIFC1 and TACC3. We were able 
to validate the KIFC1 increase at the protein level, with IHC, showing increased staining for the protein. 
Finally in these tumors with higher abundance of proteins involved in centrosome clustering we detected 
multiple centrosomes, and, most importantly, we were able to detect mitotic figures where the 
supranumerary centrosomes appear clustered.
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GEO n pts Location Citation
GSE1456 159 Stockholm Pawitan et al., 2005, Breast Cancer Research : BCR {Pawitan et al., 2005, Breast Cancer Research : BCR, 7, R953-64}
GSE2109 812 Arizona Microarray Quality Control Consortium {Consortium et al., 2010, Nat Biotechnol}
GSE2429 8 Washington Poola et al., 2005, Nat Med {Poola et al., 2005, Nat Med, 11, 481-3}
GSE3744 47 Boston Richardson et al., 2006, Cancer Cell {Richardson et al., 2006, Cancer Cell, 9, 121-32}
GSE5460 129 Boston Lu et al., 2008, Breast Cancer Res Treat {Lu et al., 2008, Breast Cancer Res Treat, 108, 191-201}
GSE5764 30 Czech Republic Turashvili et al., 2007, BMC Cancer{Turashvili et al., 2007, BMC Cancer, 7, 55}
GSE7390 198 Brussels Desmedt et al., 2007, Clinical cancer research {Desmedt et al., 2007, Clinical cancer research : an official journal of the American Association for Cancer Research, 13, 3207-14}
GSE10780 185 Florida Chen et al., 2010, Breast Cancer Res Treat {Chen et al., 2010, Breast Cancer Res Treat, 119, 335-46}
GSE10810 58 Granada Pedraza et al., 2010, Cancer {Pedraza et al., 2010, Cancer, 116, 486-96}
GSE15852 86 Malaysia Pau Ni et al., 2010, Pathol Res Pract {Pau Ni et al., 2010, Pathol Res Pract, 206, 223-8}
GSE16873 40 Boston Emery et al., 2009, Am J Pathol {Emery et al., 2009, Am J Pathol, 175, 1292-302}
GSE17907 109 Marseille Sircoulomb et al., 2010, BMC Cancer {Sircoulomb et al., 2010, BMC Cancer, 10, 539}
GSE19615 115 Boston Li et al., 2010, Nat Med {Li et al., 2010, Nat Med, 16, 214-8}
GSE20194 278 Arizona Popovici et al., 2010, Breast Cancer Research {Popovici et al., 2010, Breast Cancer Research : BCR, 12, R5}
GSE21422 19 Berlin Kretschmer et al., 2011, Mol Cancer {Kretschmer et al., 2011, Mol Cancer, 10, 15}
GSE22544 20 Georgia (USA) Hawthorn et al., 2010, BMC Cancer {Hawthorn et al., 2010, BMC Cancer, 10, 460}
GSE23177 116 Leuven Smeets et al., 2011, Breast Cancer Res Treat {Smeets et al., 2011, Breast Cancer Res Treat, 129, 767-76}
GSE23593 50 Duke (NC) Barry et al., 2010, J Clin Oncol {Barry et al., 2010, J Clin Oncol, 28, 2198-206}
GSE29431 66 Barcelona Unpublished
GSE14017 29 Houston Zhang et al., 2009, Cancer Cell {Zhang et al., 2009, Cancer Cell, 16, 67-78}
GSE20565 172 Paris Meyniel et al., 2010, BMC Cancer {Meyniel et al., 2010, BMC Cancer, 10, 222}
GSE11078 23 Paris Landemaine et al., 2008, Cancer Research {Landemaine et al., 2008, Cancer Research, 68, 6092-9}
GSE14018 36 Houston Zhang et al., 2009, Cancer Cell {Zhang et al., 2009, Cancer Cell, 16, 67-78}
GSE12630 276 California Monzon et al., 2009, J Clin Oncol {Monzon et al., 2009, J Clin Oncol, 27, 2503-8}
GSE44408 44 Barcelona Unpublished
 GSE12093 136 Rotterdam Zhang et al., 2009, Breast Cancer Res Treat {Zhang et al., 2009, Breast Cancer Res Treat, 116, 303-9}
 GSE11121 200 Mainz Schmidt et al., 2008, Cancer Research {Schmidt et al., 2008, Cancer Research, 68, 5405-13}
 GSE9195 77 Brussels Loi et al., 2008, BMC Genomics {Loi et al., 2008, BMC Genomics, 9, 239}
 GSE7390 198 Brussels Desmedt et al., 2007, Clinical cancer research {Desmedt et al., 2007, Clinical cancer research : an official journal of the American Association for Cancer Research, 13, 3207-14}
 GSE6532 741 Brussels Loi et al., 2007, J Clin Oncol {Loi et al., 2007, J Clin Oncol, 25, 1239-46}
 GSE5327 58 Rotterdam Minn et al., 2007, PNAS {Minn et al., 2007, Proceedings of the National Academy of Sciences of the United States of America, 104, 6740-5}
 GSE4922 249 Stockholm Ivshina et al., 2006, Cancer Research {Ivshina et al., 2006, Cancer Research, 66, 10292-301}
 GSE3494 236 Stockholm Miller et al., 2005, PNAS {Miller et al., 2005, Proceedings of the National Academy of Sciences of the United States of America, 102, 13550-5}
 GSE2990 187 Brussels Sotiriou et al., 2006, J Natl Cancer Inst {Sotiriou et al., 2006, J Natl Cancer Inst, 98, 262-72}
 GSE2034 286 Rotterdam Wang et al., 2005, Lancet {Wang et al., 2005, Lancet, 365, 671-9}
 GSE1456 159 Rotterdam Pawitan et al., 2005, Breast Cancer Research
 GSE20194 278 Houston Popovici et al., 2010, Breast Cancer Research 
 GSE4779 102 EORTC Farmer et al., 2009, Nat Med
Table 1 Datasets available in public databases used for the in silico metaanalysis. GEO gene Expression 
Omnibus
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62 60 17 100 na 0 3 3 17m
57 27 20 100 na 0 3 3 11m
47 15 0 focal 0 3 2 5
76 35 4 100 na 0 2 4 24m
67 25 19 100 na na 2 2 24m
46 22 0 100 0 0 1 0
27 11 0 100 na 0 3 1 30m
31 23 0 100 na 0 3 6
35 5 0 100 na 0 2
75 40 12 100 na 0 2
63 15 0 100 na 0 2
66 28 1 100 na 0 2
93 22 0 100 na 0 2
71 25 1 100 na 0 2
Table 2. - Patient clinical data. The patient material used for experimental studies was of a sample of 
consecutive breast cancer cases. Shown are clinical and pathological data of the primary tumor. ER 
estrogen receptor, PGR progesterone receptor, HER2 epidermal growth factor receptor type 2, grade as 
assessed by Elston and Ellis.
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Fig.1 - Breast Cancer progression model
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IDC infiltrating ductal carcinoma. Grades according to Ellston and Ellis
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Fig.2 – Centrosome and centrosome clustering genes 
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Fig.3 - Discovery of centrosome clustering genes as 
prognostic markers of breast cancer relapse by in 
silico metaanalysis
 A.
65 genes are significant, by Monte Carlo simulation
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Fig.4 - Centrosome clustering genes are prognostic in 
breast cancer molecular computational subtypes 










Fig.5 – The two centrosome clustering genes KIFC1 
and TACC3 are significantly up-regulated in 
retrospective breast cancer samples associated with 
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Fig.6 – The value of centrosome clustering genes is not 
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Abstract
Triple negative breast cancer is a subtype of breast cancer that does not express the estrogen receptor, the 
progesterone receptor and the epidermal growth factor receptor type 2 (Her2). These tumors are not yet 
treated with targeted therapies, probably because no positive markers have been described to reliably 
classify them - they are described for what they are not. Perhaps for this reason, they are among the most 
aggressive of breast carcinomas. The clinical observation that these patients do not carry a uniformly dismal 
prognosis, coupled with data coming from pathology and epidemiology, suggests that this negative definition 
is not capturing a single clinical entity, but several. We critically evaluate this evidence in this paper, 
reviewing clinical and epidemiological data, as well as molecular data. There is evidence for heterogeneity, 
but it is not clear how many diseases are grouped into triple negative breast cancer. Answering this question, 
and identifying the molecular basis of heterogeneity will help  define prognosis and, eventually, the 
identification of new targeted therapies.
Preface
The sources of information used in this article are articles indexed to PubMed retrieved after a search with 
keywords: triple negative breast cancer, basal like breast cancer, african american, PARP inhibitors and 
chemotherapy resistance. Major conference proceedings were searched for unpublished reports. Clinical 
trials were searched for at http://clinicaltrials.gov.
Introduction
Breast cancer (BC) is the leading cause of death in women aged 35 to 55 years, in developed 
countries, and the most frequent cancer in women. The incidence of BC is increasing. Over the twenty five 
year period 1982-2006 the incidence rate increased by 51% (Cancer Statistics: Registrations of cancer 
diagnosed in 2006, England). There are several clinical types of BC, defined by amplification of specific 
markers. Steroid hormone receptor overexpression (estrogen and/or progesterone receptors: ER, PgR) 
define the most abundant type of BC. Roughly 70% of BC is ER and/or PgR positive {Ravdin et al., 2007, 
The New England Journal of Medicine, 356, 1670-4; Marques et al., 2009, Breast Cancer Res Treat, 114, 
223-32}. Her2 receptor amplification, defines a second type, with an incidence of roughly 20% {Slamon et al., 
1987, Science, 235, 177-82}. Her2+ BC can be either ER+ or ER-, but its dominant biological driver and 
clinical feature is traceable to Her2 gene amplification, a potent oncogene. The remaining cases are termed 
triple negative BC (TNBC), breast carcinomas that neither express the ER nor the PgR and do not have 
overexpression of Her2. TNBC can represent between 10 to 82% of the cases in published series, a 
variability due to sampling issues and population heterogeneity {Stark et al., 2010, Cancer; Dent et al., 2007, 
Clin Cancer Res, 13, 4429-34; Cleator et al., 2007, The Lancet Oncology, 8, 235-44; Huo et al., 2009, J Clin 
Oncol, 27, 4515-21}.
TNBC is the clinical subtype of breast cancer with the worse prognosis when compared to ER (and/
or PgR) positive disease and Her2 positive disease {Onitilo et al., 2009, Clinical Medicine & Research, 7, 4; 
Dent et al., 2007, Clin Cancer Res, 13, 4429-34}. This may be due in part to the fact that it is the only clinical 
subtype of BC for which there is no validated adjuvant targeted therapy. Patients with BC overexpressing ER 
and/or PgR benefit from antiestrogenic therapy and those overexpressing Her2 benefit from anti-HER2 
therapy. In fact, in the pre anti-Her2 therapy era, TNBC and Her2 positive BC had a similar dismal survival 
{Spitale et al., 2009, Ann Oncol, 20, 628-35}. Validated treatments for TNBC are surgery, radiotherapy and 
chemotherapy. However, not all TNBC respond to chemotherapy {Eralp  et al., 2008, Ann Oncol, 19, 669-74; 
Wysocki et al., 2008, Med Sci Monit, 14, SC7-10; Ivanov et al., 2008, Breast Cancer Res Treat, 111, 411-7}. 
This exemplifies that TNBC may be more than a single disease. Here we critically review the clinical, 
therapeutical, epidemiological and molecular evidence supporting this claim. Our objective is to 
systematically address the potential sources of heterogeneity and give the practicing clinician some clues to 
prognosis and prediction when faced with a TNBC patient. 
Clinical heterogeneity
 The aggressive behavior of TNBC, with presentation of de novo metastatic BC, large locally 
advanced breast lesion or metastatic disease developing shortly after adjuvant chemotherapy is a hallmark 
of breast oncology {Seewaldt and Scott, 2007, N Engl J Med, 356, e12; Collett et al., 2005, Cancer 
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Epidemiol Biomarkers Prev, 14, 1108-12; Vona-Davis et al., 2008, Cancer Epidemiol Biomarkers Prev, 17, 
3319-24}. TNBC frequently metastasizes to the viscera, liver, lung or brain {Dent et al., 2008, Breast Cancer 
Res Treat; Rodríguez-Pinilla et al., 2006, Clin Cancer Res, 12, 1533-9; Pinilla et al., 2006, Breast Cancer 
Res Treat, 99, 85-90; Gadiyaram et al., 2009, Cancer Research, 69, 6159; Tsang et al., 2009, Cancer 
Research, 69, 3072}. However, this is not always the case (Figure 1 and Table 1). TNBC can also present as 
a slow growing lesion, similar to the other ER+ BC {Yin et al., 2008, Breast Cancer Res Treat}. TNBC may 
also have an oligometastatic phenotype, similar to some ER+ BC, with lymph node and bone disease {Wei et 
al., 2008, Hum Pathol, 39, 1809-15}. 
 TNBC is also heterogeneous in terms of time of recurrence. Unlike ER+ BC whose recurrence curve 
is linear, TNBC has a high rate of recurrence in the first two years followed by a plateau {Lee et al., 2010, 
Breast Cancer Res Treat, 123, 177-87}. Despite frequent recurrences in the first two years, there appears to 
be a second delayed peak of TNBC recurrences {Park et al., 2009, Cancer Research, 69, 6032; Yin et al., 
2008, Breast Cancer Res Treat; Lee et al., 2009, Cancer Research, 69, 4044}. The pattern of late recurrence 
is generally associated with less aggressive disease, frequently with bone metastases {Dent et al., 2007, 
Clin Cancer Res, 13, 4429-34; Wei et al., 2008, Hum Pathol, 39, 1809-15}, whereas the one of early 
recurrence is associated with widely metastatic phenotype and dismal prognosis. 
 The data above, suggest the existence of at least two natural histories in TNBC (Figure 1 and Table 
1). However, we need to consider two potential confounding factors. First, that these differences are not just 
a proxy for age of incidence, i.e. that we are just seeing bad prognosis TNBC in younger women and good 
prognosis TNBC in older women {Tse et al., 2009, Histopathology, 55, 441-51}. Secondly, that the late 
recurrence, good prognosis group, may include the 20% of tumors that are false negatives for ER {Gong et 
al., 2007, The Lancet Oncology, 8, 203-11}. The false negativity rate for ER is getting lower as pathologists 
use reproducible techniques and are increasingly aware of international guidelines and present quantitative 
readouts of hormone receptors {Hammond et al., 2010, J Clin Oncol, 28, 2784-95}. The lower false negative 
rate for ER determination will naturally lower the incidence of TNBC.

Epidemiological heterogeneity
There is increasing evidence that TNBC may have a bimodal distribution, with the first incidence 
peak in pre-menopausal patients and a second peak after 70 years of age {Muguti, 1993, Journal of the 
Royal College of Surgeons of Edinburgh, 38, 75-8; Anderson et al., 2002, Breast Cancer Res Treat, 76, 
27-36; Lund et al., 2009, Breast Cancer Res Treat, 113, 357-370; Yin et al., 2008, Breast Cancer Res Treat}. 
Prognosis of stage-matched pre-menopausal TNBC is worse than older age TNBC. One can speculate on 
the underlying biology that explains this difference in outcome. Premenopausal TNBC would be a disease 
with a few very powerful molecular drivers, more akin to single hit neoplasms, whereas geriatric TNBC would 
be a disease of generalized chromossomal instability, a hallmark of aging tissues and of geriatric cancer 
{Curtin et al., 2005, The New England Journal of Medicine, 353, 2135-47}. In fact, such genomic 
heterogeneity has been observed in TNBC using deep  sequencing {Stephens et al., 2009, Nature, 462, 
1005-10} (Figure 2).
 Race is perhaps the most striking source of heterogeneity in TNBC, both in the natural history of the 
disease and its incidence. In the 1990s, before BC subtypes were part of our thought process, it was known 
that BC in women of African ancestry was more frequently ER negative, affected younger women and, when 
stage and age matched, had worse prognosis {Swanson and Lin, 1994, J Natl Cancer Inst Monographs, 
69-77; Crowe et al., 1986, Surgery, 100, 599-605; Natarajan et al., 1985, Cancer, 56, 1704-9}. Indeed, in the 
United States African American women have more frequently pre-menopausal aggressive TNBC {Huo et al., 
2009, J Clin Oncol, 27, 4515-21; Carey et al., 2006, JAMA, 295, 2492-502; Lund et al., 2009, Breast Cancer 
Res Treat, 113, 357-370; Zaky et al., 2009, Cancer Research, 69, 6045}. In contrast, Caucasian and Asian 
women tend to have TNBC with a later age of onset and less aggressive clinical course {Yin et al., 2008, 
Breast Cancer Res Treat; Kim et al., 2009, Cancer Research, 69, 4065; Kwong et al., 2009, Cancer 
Research, 69, 3071}, but still with higher recurrence rate in the first two years that subsequently decreases 
to the same hazard rate as ER, PgR positive and Her2 negative breast cancer {Nishimura and Arima, 2008, 
Breast Cancer, 15, 303-308; Lee et al., 2010, Breast Cancer Res Treat, 123, 177-87}. Women of African 
ancestry are less responsive to neoadjuvant chemotherapy and have worse prognosis when diagnosed with 
locally advanced TNBC {Frasci et al., 2009, Ann Oncol, 20, 1185-92}. Knowing that BRCA1 germline 
mutations are not frequent in black women one might suspect that TNBC arising in these women is not 
deficient in DNA repair and is, therefore, chemoresistant {Pegoraro et al., 2003, Int J Gynecol Cancer, 13, 
444-9} (figure 2). It is known that BC in BRCA deficient patients has better prognosis and is chemosensitive. 
The genome of the primary tumor and metastasis of a 44-year old, African American woman that presented 
with locally advanced chemorresistant disease that relapsed 8 months after primary treatment with 
widespread metastasis, was sequenced. The material analyzed was primary tumour, brain metastasis, a 
xenograft derived from the primary lesion and peripheral blood for control {Ding et al., 2010, Nature, 464, 
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999-1005}. It revealed that the mutational evolution is scarce, suggesting that the chemorresistance and 
metastatic phenotype is already present in a few cells in the primary lesion. In contrast, in lobular, ER+, 
breast cancer deep  sequencing revealed that new mutations are acquired in the metastasis, after 9 years of 
disease free interval, that were not present in the primary lesion {Shah et al., 2009, Nature, 461, 809-13} 
(figure 2). Both these studies remarkably reconcile the different behavior of these diseases in the clinic: On 
one hand, aggressive TNBC, that quickly relapses with chemorresistant disease, and, lobular breast cancer, 
that relapses generally after five years and is sensitive to tamoxifen.
Regarding incidence, TNBC has been defined as a rare disease in northern Europe and in some 
parts of USA {Linn and Van 't Veer, 2009, Eur J Cancer, 45 Suppl 1, 11-26}, accounting for less than 15% of 
BC cases, 10% in some series {Cleator et al., 2007, The Lancet Oncology, 8, 235-44}. In contrast, in states 
within the United States where more than 20% of the population is of African ancestry, the frequency of 
TNBC is substantially higher. Black, pre-menopausal, women were twice as likely to have TNBC than white 
women in North Carolina (39% vs. 14%) {Carey et al., 2006, JAMA, 295, 2492-502} and Atlanta (47% vs. 
22%) cohorts {Lund et al., 2009, Breast Cancer Res Treat, 113, 357-370}. Being of African ancestry 
increases three times the risk of a women developing TNBC, independent of other risk factors for breast 
cancer {Stead et al., 2009, Breast Cancer Res, 11, R18}. An epidemiological study from Nigeria reported that 
59% of BC are TNBC {Huo et al., 2009, J Clin Oncol, 27, 4515-21} and a study from Peru reported a 
frequency of 20% {Alarcon-Rozas et al., 2009, Cancer Research, 69, 2072}. A recent study that compared 
TNBC in the United States and in Ghana showed that TNBC appears in 82% of Ghanian women, 32% of 
African Americans and in 10% of white Americans {Stark et al., 2010, Cancer}. 
A possible explanatory factor for these ethnicity-based differences are intrinsic physiological 
differences. For example, breast density which is greater in black women {El-Bastawissi et al., 2001, Ann 
Epidemiol, 11, 257-63}. Since cancer in dense breasts is harder to diagnose by mammography {Boyd et al., 
2007, The New England Journal of Medicine, 356, 227; Barlow et al., 2006, JNCI Journal of the National 
Cancer Institute, 98, 1204}, this could mean that the worse prognosis of black women might be due to a 
delay in diagnosis. However, stage matching in epidemiological studies eliminates this hypothesis. 
Alternatively, denser mammary glands may have distinct growth factor profiles that predispose women to 
more aggressive cancer with estrogen independence. Indirect support for this scenario comes from the 
observation of different growth factor profiles, IGF-1 and HGF, and different incidence of non-cancer 
endpoints, like metabolic syndrome, in cohorts of black vs. white obese women {Baird and Travlos, 2007, 
Cancer Epidemiol Biomarkers Prev, 16, 1526 author reply 1526; Henderson et al., 2006, Cancer Epidemiol 
Biomarkers Prev, 15, 2298-302}. In fact, the metabolic syndrome is more prevalent in TNBC patients {Maiti et 
al., 2010, Breast Cancer Res Treat, 121, 479-83}. Obesity has long been recognized as a risk factor for BC 
{Vona-Davis et al., 2007, Obesity reviews : an official journal of the International Association for the Study of 
Obesity, 8, 395-408; Vona-Davis et al., 2008, Cancer Epidemiol Biomarkers Prev, 17, 3319-24; Montazeri et 
al., 2008, BMC Cancer, 8, 278}. Since women of black ethnicity are more frequently obese {Trivers et al., 
2009, Cancer Causes Control; Jones et al., 1997, American Journal of Epidemiology, 146, 394-404; Coates 
RJ, 1990, J Natl Cancer Inst.}, this could constitute a confounding factor. However, there is still no evidence 
that obesity alone is a specific risk factor for TNBC. 
Social and economic status have been claimed to have prognostic value. Women of low social and 
economic status have worse prognosis BC {Vona-Davis and Rose, 2009, Journal of women's health (2002), 
18, 883-93}. They are less educated, have less access to screening and health care. There is an association 
between being of black race and lower social and economic status (U.S. Bureau of the Census, Aug. 2008 
supplement to the Current Population Survey (CPS): www.census.gov.), which suggests that the race-based 
heterogeneity may be a surrogate for social rather than biological heterogeneity. An analysis of outcome of 
25,000 cancer patients enrolled in the Southwest Oncology Group  phase III clinical trials {Albain et al., 2009, 
JNCI Journal of the National Cancer Institute, 101, 984} showed that ethnicity does not affect outcome of 
carcinoma of the lung or colon nor for lymphoma, leukemia or multiple myeloma, but that it affects sex-
hormone responsive carcinomas of the breast, ovary and prostate. These unbiased observations, albeit not 
specifically addressing TNBC, support that, for breast cancer, there might be a true ethnicity-based 
heterogeneity. (see Table 1)
Molecular heterogeneity
Histologically, the majority of TNBC are grade 3 or poorly differentiated, infiltrating ductal carcinoma 
not otherwise specified (IDC NOS) (Figure 3A). These tumors have poor prognosis {Maehle et al., 1982, Br J 
Cancer, 46, 95-100; O'Reilly et al., 1990, Br J Cancer, 61, 671-4}. The few remaining cases are rare 
histological types like adenoid-cystic, medullary, apocrine, metaplastic or inflammatory BC. There is 
prognostic heterogeneity associated with these subtypes: the first three have good prognosis and the last 
two bad {Reis-Filho and Tutt, 2008, Histopathology, 52, 108-18; Hance et al., 2005, J Natl Cancer Inst, 97, 
966-75; Rizzo et al., 2009, Cancer, 115, 3009-15; Jung et al., 2010, Breast Cancer Res Treat}. 
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Five breast cancer subtypes have been identified based on gene expression termed Luminal A, 
Luminal B, Normal, Her2 and Basal {Perou et al., 2000, Nature, 406, 747-52}. There is some overlap 
between immunohistochemical (IHC) and the molecular subtypes. Basal BC, thus defined because of the 
expression of the basal cytokeratins 5/6, 14 and 17 {Pintens et al., 2009, Journal of Clinical Pathology, 62, 
624-8}, is similar to TNBC, but not totally overlapping. About twenty percent of TNBC are not basal-like and, 
similarly, about 20% of basal-like BC are not TNBC {Tan et al., 2008, Breast Cancer Res Treat, 111, 27-44}
(Figure 3B). Those TNBC that are not basal generally belong to the normal molecular subtype. The TNBC 
that are basal-like BC generally have bad prognosis, worse than TNBC per se, which suggests that the 
molecular classification might not be able to further subtype TNBCs and that it captures a group  of TNBC 
with bad prognosis. However, this group of tumours must be further classified.
The molecular classification of TNBC based on BRCA1 mutations is informative for a small number 
of TNBC cases (Figure 2, 3C). A proportion of the women with TNBC carry BRCA1 germline mutations, this 
proportion varies with age of diagnosis and family history but was as high as 40% in an unpublished series 
{Kandel et al., 2006, ASCO Meeting Abstracts, 24, 508}. The role of BRCA1 null TNBC arising in non-BRCA1 
germline mutation carriers is not yet clear, in part on methodological grounds, because in BRCA1 mutation 
carriers the BRCA1 protein, which is malfunctioning, is detected by IHC. The most frequent mechanism for 
somatic inactivation of the BRCA1 is promoter methylation, this happens in 10 to 15% of sporadic breast 
cancer but the immunohistochemical readout of the BRCA1 protein has not been established {Vaz et al., 
2007, Journal of Histochemistry and Cytochemistry, 55, 1105; Esteller et al., 2000, JNCI Journal of the 
National Cancer Institute, 92, 564}. Furthermore, 80% of the BC arising in BRCA1 germline mutation carriers 
are TNBC but with good prognosis {Rennert et al., 2007, The New England Journal of Medicine, 357, 
115-23}. Deep  sequencing of breast cancer genomes revealed that the BRCA1 null TNBC shows less 
genomic instability than the BRCA1 wild type TNBC {Stephens et al., 2009, Nature, 462, 1005-10}, 
suggesting a disease caused by less genomic alterations, the BRCA1 mutation being particularly relevant. 
BRCA1 status may thus be suggesting two distinct TNBCs. BRCA1 deficient TNBC, germline or somatic, is 
likely a different biological entity, deficient in DNA repair, and therefore responsive to therapy with PARP 
inhibitors and platinum salts that other TNBC, without BRCA1 deficiency, are not {J. O'Shaughnessy, 2009, J 
Clin Oncol 27:18s, 2009 (suppl abstr 3); A. Tutt, 2009, J Clin Oncol 27:18s, 2009 (suppl abstr CRA501); 
Venkitaraman, 2009, Cancer Cell, 16, 89-90; Koshy et al., 2010, Breast (Edinburgh, Scotland); Farmer et al., 
2005, Nature, 434, 917-21}. PARP1 is an enzyme involved in repair of double strand DNA breaks induced by 
platinum salts.
There have been attempts to establish a relationship  between normal mammary gland development 
and occurrence of BC, i.e. to map  different types of BC into different stages of the mammary gland 
development {Stingl and Caldas, 2007, Nature Reviews Cancer, 7, 791-9; Stratford et al., 2010, Expert Rev 
Mol Med, 12, e22}, as has been done for acute myeloid leukemia {Krivtsov and Armstrong, 2007, Nature 
Reviews Cancer, 7, 823-33}. TNBCs would correspond to a more primitive subtype of tumor, closer to the 
most undifferentiated BC progenitor cell (stem cell) {Pece et al., 2010, Cell, 140, 62-73}. This reasoning is 
supported by the observation that the putative BC stem cells in in vitro models are ER- and that, as they 
subsequently differentiate into mammary gland luminal cells, acquire ER {Liu et al., 2008, Proceedings of the 
National Academy of Sciences of the United States of America, 105, 1680–1685; Dontu et al., 2004, Trends 
Endocrinol Metab, 15, 193-7}. Thus some aggressive TNBC might be more similar to the BC stem cell 
phenotype, showing capacity to undergo epithelial to mesenchymal transition and reprogramming of 
embryonic genes whereas others would not {Ginestier et al., 2009, Cell Stem Cell, 5, 229-30; Ben-Porath et 
al., 2008, Nature genetics, 40, 499-507}. This hypothesis would be concordant with the data on 
chemoresistance of some TNBC. The link between breast development and tumorigenesis is conceptually 
appealing. However, there are still limited data to support it {Pece et al., 2010, Cell, 140, 62-73; Lim et al., 
2009, Nat Med, 15, 907-13}. 
Regarding individual markers that are assayed by immunohistochemistry or PCR (Table 2): p53 
protein expression is a predictor of shorter time to relapse in two independent european TNBC populations 
{Alberti et al., 2009, Cancer Research, 69, 2018}. Higher expression of EGFR protein appears to predict 
adverse prognosis in TNBC {Viale et al., 2009, Breast Cancer Res Treat, 116, 317-28}. This data is coherent 
with the expression of basal cytokeratins that separates TNBC in basal and non-basal, because EGFR 
seems to segregate with the basal-like breast cancers {Thike et al., 2010, Am J Surg Pathol, 34, 956-64; 
Dogu et al., 2009, Med Oncol}. It is still debatable whether EFGR is truly overexpressed in carcinomas 
versus their normal tissues of origin because the majority of reports do not measure EGFR expression in 
non-neoplastic control tissue, probably the erratic response to EFGR monoclonal antibodies and tyrosine 
kinase inhibitors is an illustration of this fact {Gusterson and Hunter, 2009, The Lancet Oncology, 10, 522-7}. 
Regarding anti-EGFR therapy and breast cancer, cetuximab  has been evaluated in TNBC {Baselga et al., 
2013, J Clin Oncol, 31, 2586-92}, and, in fact, EGFR positivity was not found to be predictive of response but 
one of itʼs downstream effectors, PTEN positivity, was {Khambata-Ford et al., 2010, ASCO Meeting 
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Abstracts, 28, 1056}. c-Kit protein expression was reported to be predictive of poor outcome {Park et al., 
2009, Cancer Research, 69, 6032} albeit being a targetable molecule with imatinib, the results in unselected 
breast cancer patients were disappointing {Cristofanilli et al., 2008, Ann Oncol, 19, 1713-9}. The loss of E-
cadherin, a well characterized phenomenon in breast and other carcinomas, because it correlates with 
loosing epithelial cohesiveness, is a marker of bad prognosis in TNBC {Kashiwagi et al., 2010, Br J Cancer, 
103, 249-55}. The presence of the androgen receptor has been reported to be frequent in TNBC, it is a 
hallmark of apocrine carcinoma, with good prognosis and possibly a targetable molecule albeit with a 
number of undesirable side effects {Farmer et al., 2005, Oncogene, 24, 4660-4671}.
There are some reports on the molecular heterogeneity of TNBC that assess pathways or groups of 
genes instead of single markers making use of genome-wide gene expression profiles. As we have seen the 
deficiency in DNA double strand break repair mechanisms also called the “BRACness of TNBC” has been 
tested and is being exploited in clinical trials. The observation that TNBC more frequently exhibit stem cell 
characteristics, i.e. the “stemness of TNBC”, can also be tested therapeutically because it should correlate 
with chemoresistance. Lastly, some authors have described the activation of immune response as a good 
prognostic marker in ER negative BC {Teschendorff et al., 2007, Genome Biol, 8, R157}. This can be called 
the “immunogenicity of TNBC”, a reasonable surrogate of another TNBC subgroup, this, coupled to a specific 
antigenic profile of TNBC cells is being exploited therapeutically with vaccination strategies {Curigliano et al., 
2010, Annals of Oncology}
Therapeutic heterogeneity
 There is a perplexing feature of TNBC, termed the “TN paradox”: chemoresponsiveness and 
chemoresistance {Carey et al., 2007, Clin Cancer Res, 13, 2329-34} (Fig 2). On one hand, TNBC are among 
the most chemoresponsive breast cancers: data from neoadjuvant studies show that the fraction of tumours 
experiencing pathologic complete response (pCR) is mostly comprised of TNBC, with a pCR rate generally 
over 50% {Carey et al., 2007, Clin Cancer Res, 13, 2329-34; Wang et al., 2009, Gan To Kagaku Ryoho, 36, 
255-8; von Minckwitz et al., 2008, J Natl Cancer Inst, 100, 552-62; von Minckwitz et al., 2008, J Natl Cancer 
Inst, 100, 542-51; Liedtke et al., 2008, J Clin Oncol, 26, 1275-81; Esserman et al., J Clin Oncol 27:18s, 2009 
(suppl abstr LBA515); Chang et al., 2010, Cancer; Colleoni et al., 2010, J Clin Oncol, 28, 2966-73}. On the 
other hand, TNBC are sometimes chemoresistant, as documented by the short survival of patients with 
metastatic disease in published series {Ding et al., 2010, Nature, 464, 999-1005; Lin et al., 2008, Cancer, 
113, 2638-45; Kassam et al., 2009, Clinical Breast Cancer, 9, 29-33}. One could argue that the apparent 
chemorresponsiveness found in neoadjuvant studies, evolves into a chemorresistant phenotype. However, 
this does not seem to be the case because in neoadjuvant trials with long follow up, those women that obtain 
a pathological complete response consistently maintain survival advantage over the years {Bear et al., 2006, 
J Clin Oncol, 24, 2019-27}, and the same observation has been done for TNBC that achieve pCR {Liedtke et 
al., 2008, J Clin Oncol, 26, 1275-81}. This suggests that chemosensitivity is a hard-wired feature of a 
particular tumor {Hüsemann et al., 2008, Cancer Cell, 13, 58-68; Ding et al., 2010, Nature, 464, 999-1005}. 

Since chemossensitive TNBC tends to be deficient in DNA repair, this suggests that reduced 
expression of genes involved in homologous recombination repair predict better response to antracyclines, 
that cause double strand breaks in DNA, than to taxanes which interfere with microtubule polimerization. 
This is indeed the case, as the DNA repair deficient TNBC had better response to anthracyclines than to 
taxanes {Rodriguez et al., 2010, Breast Cancer Res Treat, 123, 189-196}. 
Regarding apoptosis, two members of the p53 familly, p63/p73 and their network, have been shown 
to be upregulated in TNBC and predictive of response to cisplatin in vitro {Leong et al., 2007, The Journal of 
Clinical Investigation, 117, 1370-80}. This hypothesis was tested in a clinical trial and a surrogate of this 
network, a gene expression signature of E2F3 activation was found to predict response to cisplatin in TNBC 
{Silver et al., 2010, Journal of Clinical Oncology}. E2F3 is a transcription factor frequently upregulated and 
associated with bad prognosis in bladder and prostate carcinomas {Oeggerli et al., 2006, Oncogene, 25, 
6538-43; Foster et al., 2004, Oncogene, 23, 5871-9}. In this trial, those TNBC that had mutations in p53 also 
responded better to cisplatin {Silver et al., 2010, Journal of Clinical Oncology}. 
Besides these markers, what other marker could be more readily used in the clinic that captures the 
heterogeneity regarding pCR in TNBC? A study reported that, in TNBC, those that were basal-like had a 23% 
pCR rate and those that were non-basal-like had a 62% pCR rate. The chemotherapy regimen evaluated 
was standard fluorouracil, epirrubicin at 100mg/m² and cyclophosphamide (FEC100) and the definition of 
basal subtype was based on positivity for EGFR and basal cytokeratin 5/6 {Masuda et al., 2010, Cancer 
Chemotherapy and Pharmacology}. These assumptions are being tested in current randomized clinical trials 
in TNBC where PARP inhibitors, platinum salts, alquilating agents and anthracyclines are part of the 
investigational arms {Silver et al., 2010, Journal of Clinical Oncology; Petrelli et al., 2009, Expert opinion on 
investigational drugs, 18, 1467-77}.
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Future directions
There is no doubt that TNBC presents as a therapeutic problem. For therapy to be tackled, the 
underlying diagnostic challenge has to be met, and this is, in our opinion, the key unsolved issue, for we still 
do not know what TNBC is. We outlined the existing evidence pointing to different diseases present in this 
negatively defined entity. It is plausible that we face at least two distinct diseases or possibly several, but 
numerous questions remain unanswered.
Firstly, it is imperative that the epidemiological characterization of TNBCs arising in different 
populations is done. The hypotheses that there are different TNBCs in different racial, age, body mass index 
and genetic backgrounds must be tested. We need to quantify the specific prognostic value associated with 
each clinical and epidemiological variables to better choose therapy and inform patients. 
Secondly, we need to define the molecular drivers for each subtype of TNBC so that we can identify 
markers with definite prognostic value, that can be used by clinicians to decide with confidence whether the 
tumor is chemoresponsive, or whether other therapies must be tested. These markers may co-exist with 
existing ones, the same way that tumors may be simultaneously ER+ and HER2+. Currently, there are 
several promising leads, including immune response activation, p53 and EGFR protein expression, 
mesenchymal and stem cell features and androgen receptor expression {Lehmann et al., 2011, The Journal 
of Clinical Investigation, 121, 2750-67}. Determining the association of these potential markers with clinical 
parameters such as race, age of incidence and their predictive value for relapse and drug sensitivity, are also 
necessary steps to apply them in the clinic.
Finally, we need to identify targeted therapies for TNBC. This will happen if we are able to overcome 
the second challenge. Multiple targeted therapies that already explore potential differences in subtypes of 
TNBC are currently being tested in the clinic for TNBC with encouraging results. 
We have come a long way since the first sub-typing of breast cancer, and the development of the 
first targeted therapy, tamoxifen. TNBC is today ʻthe edge of our ignoranceʼ, those tumors that we still have 
not segmented into classes for which we know the underlying molecular basis. Soon we will be defining 
quadruple-negative, or quintuple negative breast cancers, as we identify new molecular drivers in breast 
cancer leading to new diagnostic markers and therapeutic targets.
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Figure legends & tables
Figure 1 - Heterogeneity in the natural history of triple negative breast cancer {Muguti, 1993, Journal of the 
Royal College of Surgeons of Edinburgh, 38, 75-8; Anderson et al., 2002, Breast Cancer Res Treat, 76, 
27-36; Lund et al., 2009, Breast Cancer Res Treat, 113, 357-370; Yin et al., 2008, Breast Cancer Res Treat; 
Seewaldt and Scott, 2007, N Engl J Med, 356, e12; Collett et al., 2005, Cancer Epidemiol Biomarkers Prev, 
14, 1108-12; Vona-Davis et al., 2008, Cancer Epidemiol Biomarkers Prev, 17, 3319-24; Dent et al., 2008, 
Breast Cancer Res Treat; Rodríguez-Pinilla et al., 2006, Clin Cancer Res, 12, 1533-9; Pinilla et al., 2006, 
Breast Cancer Res Treat, 99, 85-90; Gadiyaram et al., 2009, Cancer Research, 69, 6159; Tsang et al., 2009, 
Cancer Research, 69, 3072; Yin et al., 2008, Breast Cancer Res Treat; Lee et al., 2009, Cancer Research, 















Figure 2 - Hypothesis of genomic stability and TNBC heterogeneity {Stephens et al., 2009, Nature, 462, 
1005-10; Ding et al., 2010, Nature, 464, 999-1005; Curtin et al., 2005, The New England Journal of 


























Figure 3 - Histological and molecular heterogeneity of triple negative breast cancer and other subtypes of 























Table 1 - Clinical, epidemiological and therapeutic heterogeneity of triple negative breast cancer. 
Characteristics Worse outcome Better outcome
Age of presentation Young Old
Stage at presentation Advanced Early
Growth rate Fast Slow
First site metastasis Liver & brain Lymph nodes & bone
Chemotherapy response Resistant Exquisitely sensitive
Body mass index High Low
Race Black White
Social deprivation Yes No
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Table 2 - Molecular heterogeneity of triple negative breast cancer according to differences in expression and 
their correlation to outcome.







Androgen receptor - +
DSB repair deficiency + -
Stem cell markers + -
Immune response activation - +
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Systemic treatment for TNBC
Abstract
Chemotherapy remains the backbone of systemic therapy for triple negative breast cancer (TNBC). Despite 
the validation of targeted agents, there is no such therapy for TNBC, possibly because the biology of TNBC 
has not been conclusively elucidated, this tumor is still defined by what it is not. Data shows that these 
tumors benefit from chemotherapy in the neoadjuvant, adjuvant and metastatic setting, possibly even more 
than other BC subtypes. Neoadjuvant chemotherapy trials show higher response rates in TNBC than non-
TNBC. Pathologic complete response (pCR) has been shown to predict improved long term survival in BC. 
Specific adjuvant regimens for TNBC are under study, third generation chemotherapy regimens utilizing dose 
dense or metronomic polychemotherapy are some tools presently available. The role of specific 
chemotherapy agents, namely platinum salts, remains poorly defined. Taxanes and anthracyclines are active 
in TNBC and remain important agents, but have not shown specific benefit over non-TNBC. Targeted agents 
have been similarly difficult to study and approve for TNBC treatment. Trials with anti epithelial growth factor 
agents, antiangigenic agents and, more recently, PARP inhibitors have not met their primary endpoints. 
TNBC is itself a very heterogenous group  of tumors, in this paper we attempt to review data and point 
directions in the systemic treatment of TNBC.
Triple negative breast cancer subtypes
Since 2005, when the widespread use of anti Her2 therapy started to modify the natural history of Her2 
positive BC that TNBC became the subtype of BC for which there is no targeted therapy. Since then, several 
trials have been performed to try to understand what is targetable in TNBC and if so, if the clinical trials 
designed to test these hypothesis meet their endpoints. TNBC has a negative definition, it is defined by what 
it is not, therefore, we do not know what TNBC is. This is one of the important problems. We do not know 
what disease we are treating, with what alterations, in which genes.
TNBC is itself a heterogeneous group  in which subgroups like basal like BC, defined by higher proliferation, 
and, including those TNBC arising in BRCA1 mutation carriers, may be more sensitive to platinum agents 
and relatively less sensitive to taxanes. Lehmann et al, after several other experiments, have put forward a 
convincing classification of four subtypes with histological, genetic, epidemiological, therapeutic, and, 
therefore, practical implications {Lehmann et al., 2011, The Journal of Clinical Investigation, 121, 2750-67}. 
First, the basal-like 1 and 2 (BL1 and BL2): these are the TNBC that were in PAM50 classified as basal-like. 
They are the tumors that develop frequently in BRCA1 and BRCA2 mutation carriers. These tumors are 
susceptible to classical chemotherapy because they have mutations in DNA repair genes, these are the 
tumors that respond well to neoadjuvant chemotherapy. These tumors are genomically unstable and have a 
number of other alterations in proliferative genes which also concur for chemossensitivity. Histologically, they 
are invasive carcinomas NOS. They appear more frequently in young women.
Next, is the group  of TNBC that has genomic evidence of immune modulation. The activation of immune 
response has been another feature frequently present in TNBC, apparently exclusive from the typical 
proliferation driven basal-like TNBC. These tumors are frequently medullary histologically, they have good 
prognosis. These tumors were first identified in a large neoadjuvant trial that aimed to stratify the benefit of 
chemotherapy according to P53 mutation status {Farmer et al., 2009, Nat Med, 15, 68-74}{Teschendorff et 
al., 2007, Genome Biol, 8, R157}.
The third group  are TNBC associated with mesenchymal and stem cell features. These tumors are 
histologically anaplastic, displastic, metaplastic or sarcomatoid. These tumors have lost their epithelial 
features, they express non epithelial markers and stem cell markers like P-cadherin. These carcinomas are 
chemorresistant and account for the bad prognosis of TNBC. There do not seem to be preferential age 
groups for appearance of mesenchymal TNBC. These non epithelial features have been linked to a stem like 
phenotype and cancer stem cells have been postulated to be chemorresistant {Pece et al., 2010, Cell, 140, 
62-73}. These tumors might be susceptible to growth factor inhibition: EGFR, anti Src, anti angiogenesis, 
and anti IGF therapy.
Finally, the TNBC that expresses the androgen receptor. These tumors are histologically apocrine, have 
tendency towards local relapse and might be susceptible to anti androgens {Farmer et al., 2005, Oncogene, 
24, 4660-4671}.
This provoking classification has recently been put forward, but for the last decade we have been trying to 
retrospectively gather data and prospectively test specific agents in these breast tumors. This is a simplified 
classification that uses molecular and histological biomarkers to predict prognosis and response to specific 
systemic treatments. The Lehmann classification and other similar classifications, should start to be studied 
prospectively. Such studies will be particularly informative for this difficult subgroup of BC.
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In this paper, we have gone through trial data and retrospective series trying to understand how best to treat 




BC adjuvant clinical trials have generally been conducted in unselected BC cases, therefore, to study 
adjuvant outcomes of TNBC one must perform retrospective analysis of adjuvant trials. Regarding the most 
important body of data on adjuvant therapy, the ECBTCG published a study looking specifically at the benefit 
of anthracycline or alquilating agent based adjuvant chemotherapy versus not, in ER poor patients. There 
was a reduction in the risk of BC death from 32% to 24% (hazard ratio 0.73, p=0·0002) in women aged less 
than 50 years. In women in the fifth and sixth decades the reduction in the risk of dying of BC was 36% in 
those treated versus 42% in those not treated {EBCTCG, 2008, Lancet, 371, 29-40}. 
Very relevant in TNBC, is dose dense chemotherapy (DDCT) with peripheral blood stem cell rescue 
(PBSCR), because increased genomic instability and DNA repair pathway mutations are hallmarks of TNBC 
and these characteristics are thought to be harbingers of chemosensitivity. A West German Group trial of 
DDCT with PBSCR conducted in unselected patients, was reanalyzed and the benefit was greatest in 
patients with histological grade 3 TNBC, an interesting correlate of particular CT sensitivity {Gluz et al., 2008, 
Ann Oncol, 19, 861-70}. Similarly the NKI group led by Rodenhuis continues to explore a DNA repair 
deficiency signature as predictive of response to DDCT.
Neoadjuvant setting
Neoadjuvant chemotherapy (NACT) is administered before surgery, irrespective of the overall duration of 
treatment. It has been shown that clinical midcourse response predicts the achievement of pathological 
complete response (pCR) and long term outcome. Patients with tumors showing no response at midcourse 
might be considered as chemoresistant, patients without response at midcourse treatment have a pathologic 
response rate of less than 5%. Patients with indication for NACT represent 30% of all patients, and these 
patients have, due to high initial staging, higher risk of recurrence and death. 
NACT seems to be of particular interest in TNBC: There are several studies retrospectively showing that 
some TNBC patients respond better than other BC subtypes to NACT. This said, the survival advantage is 
only seen in those that attain pCR. The MDAnderson Cancer Center analyzed retrospectively their cohort of 
1118 patients treated with NACT and was able to show that the pCR rate in TNBC was twice the pCR rate of 
non-TNBC (22 vs. 11%). Regarding survival, TNBC vs non-TNBC have a 3 year OS of 74% vs 89%, but 
TNBC with pCR have a similar 3 year survival to non-TNBC with pCR (94 vs 98%) {Liedtke et al., 2008, J 
Clin Oncol, 26, 1275-81}. This is why NACT is of specific interest in these patients because if pCR is reached 
prognosis is similar to other BC subtypes. A retrospective series of 107 patients treated with anthracycline 
and alquilating agents showed TN tumors had a pCR rate of 35%. Curiously, the TNBC patients that 
achieved pCR did not recur, the TNBC that recurred had a distant metastasis free survival (DMFS) of 60% 
{Carey et al., 2007, Clin Cancer Res, 13, 2329-34}. This study similarly shows that if patients with TNBC are 
treated with NACT and obtain pCR they will have similar outcome than non-TNBC patients. Conversely, 
TNBC patients that do not, are a subgroup  of TNBC with worse survival. Due to CT resistance profile, these 
TNBC that do not respond to NACT might overlap with TNBC with mesenchymal features.
The National Adjuvant Breast and Bowel Project (NSABP) B27 trial randomized 2411 patients to an 
anthracycline vs. taxane question. The results show that ER negative tumors respond better to 
chemotherapy: pCR rate in the anthracycline arm (AC) was 14% in ER negative tumors, compared to 6% for 
ER positive tumors. With the addition of docetaxel the pCR increased in both subsets (23% vs. 14%). This 
trial did not detect differences in survival. It has been shown in adjuvant trials that sample sizes needed to 
detect a taxane survival benefit were over 3000, so this is possibly the reason for B27 never having showed 
survival advantage. There were two weaker points in B27. First, the definition of pCR did not consider lymph 
nodes and second, tamoxifen was given concurrently with CT. The non randomized, I-SPY1 Trial also 
studied the same drug regimen, TNBC had a 35% pCR rate {Esserman et al., 2012, J Clin Oncol, 30, 
3242-9}. 
Another single arm trial used taxanes followed by triple therapy with anthracycline, alquilating and anti folate 
(FEC). Here patients were studied by gene expression profiling according to the PAM50 classifier, the basal 
like subgroup  and the Her2 subgroup  had a pCR rate of 45%, whereas the luminal subgroups had a pCR 
rate of 6% and there was no pCR in the normal BC. In this trial, there is currently no data regarding outcome 
{Rouzier et al., 2005, Clin Cancer Res, 11, 5678-85}. There is a paradox in TNBC: The high pCR rate 
translates into a high DMFS, but as a group, including all women, those with pCR and those without, TNBC 
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has a DMFS of 60%, which is poor. This was similarly seen in two retrospective series of 145 and 107 BC, 
where the TNBC patients had 17% and 27% pCR rate, from the latter, none of the patients with pCR 
relapsed {Keam et al., 2007, BMC Cancer, 7, 203}{Carey et al., 2007, Clin Cancer Res, 13, 2329-34} 
The German Breast Group (GBG) has contributed extensively performing NACT trials, called Gepar trials. 
Gepar Duo asked three questions: 1) if we could spare alquilating agents 2) if DDCT has a role and 3) if 
sequential taxanes are better than the combination of anthracyclines and taxanes. It randomized 902 women 
to a dose dense two drug regimen (ADOC) verus a sequential two drug regimen followed by docetaxel (AC-
DOC). In the analysis relevant for TNBC, the pCR rate in ER negative disease was 23% versus 6% in ER 
positive. {von Minckwitz et al., 2005, J Clin Oncol, 23, 2676-85}.
Gepar Trio, the next trial from the German group, was designed for randomization after two cycles of TAC, 
and stratified patients according to response. Responders were randomized to four or six more cycles of 
TAC. Non responders were randomized to four more cycles of TAC or vinorelbine and capecitabine {von 
Minckwitz et al., 2008, J Natl Cancer Inst, 100, 552-62}{von Minckwitz et al., 2008, J Natl Cancer Inst, 100, 
542-51}. Differences in pCR were not significant in either comparison. This is an extremely provoking result: 
in patients that do not respond to anthracyclines, taxanes and alquilating agents, the use of fluoropyrimidines 
and vinca alkaloids seems futile. The expression of cytoplasmic poly(adenosine diphosphate-ribose) 
polymerase that has been correlated with TNBC and is a potential target of PARP inhibitors, was seen to be 
predictive of response to chemotherapy but also prognostic of survival {von Minckwitz et al., 2011, J Clin 
Oncol, 29, 2150-7}.
Gepar Quattro asks a question in Her2 positive locally advanced BC patients, if the addition of trastuzumab 
to chemotherapy, increases pCR {Untch et al., 2010, J Clin Oncol, 28, 2024-31}. Chemotherapy regimens 
include anthracyclines (EC), taxane (docetaxel) and fluoropirimidines (capecitabine). Patients with Her2 
positive tumors had 40% pCR, defined by no invasive breast cancer in the breast and lymph nodes, and a 
near 32% pCR rate considering disappearance also of ductal carcinoma in situ, while in the patients with 
Her2 negative tumors had a pCR rate of 15%. In a retrospective analysis of this and the previous trial, it was 
possible to find that thymosin beta 15A, a protein binds to and sequesters G actin monomers, and, therefore, 
inhibits actin polymerization, is a predictor of pCR, only in TNBC, but not in other biological subtypes. The 
evaluation of TMBS15A divided TNBC into a low and a high expression group (pCR rate 16.0% vs 47.2%) 
{Darb-Esfahani et al., 2012, Br J Cancer, 107, 1892-900}. This molecule was found in another study to be 
predictive of response to CT, in P53 mutated tumors {Bertheau et al., PLoS Med, 4}. The biologic rationale is 
thought to be the capacity of cells to repair damage induced by chemotherapy or not.
Gepar Quinto tested the addition of either bevacizumab  or everolimus to conventional anthracycline and 
taxane CT, in Her2 negative BC, and lapatinib  or trastuzumab  are added to a similar CT backbone in Her2 
positive BC patients. In the German trials pCR is defined as ypT0N0. The conclusion is that neither lapatinib 
nor everolimus can “rescue” non responding patients to CT plus bevacizumab  or CT plus trastuzumab. The 
addition of bevacizumab  did not increase pCR rate 15% vs. 17.5%. However in the subgroup  of 684 TNBC 
patients pCR rate was 27.8% vs. 36.4% (p  = 0.021) {von Minckwitz et al., 2012, The New England Journal of 
Medicine, 366, 299-309}.
Ten years ago the role of platinum salts specifically in TNBC started to be investigated. Gepar Sixto used 
carboplatin as neoadjuvant CT in addition to taxanes in Her2 positive and TNBC patients. Women were 
treated for 18 weeks with weekly paclitaxel and non-pegylated-liposomal doxorubicin. Her2 positive patients 
received concurrently trastuzumab  and lapatinib. TNBC patients received concurrently bevacizumab. All 
patients were randomized 1:1 to receive concurrently weekly carboplatin or not, stratified by subtype. Results 
show an increase in pCR from 37% without carboplatin to 44% with carboplatin. In TNBC patients the 
increase in pCR with the platinum addition was from 37% to 53%. In Her2 positive BC patients the addition 
of carboplatin decreased pCR from 37% to 33%. The authors concluded that adding platinum salts is 
beneficial only in TNBC patients and that bevacizumab  did not change pCR rate in these patients {von 
Minckwitz et al., 2014, Lancet Oncol}.
Specific drugs
Platinum salts
In 1988, Sledge et al reported a 47% response rate to cisplatin in first line metastatic (M)BC. This trial was 
conducted in 20 patients {Sledge et al., 1988, J Clin Oncol, 6, 1811-4}, the generalization to larger sample 
sizes that subsequently happened reduced response rate. The response rate in 2nd and 3rd line MBC, after 
anthracyclines and alquilating agents, has been shown to be close to 10% or less {Yap  et al., 1978, Cancer 
treatment reports, 62, 405-8}{Baselga et al., 2013, J Clin Oncol, 31, 2586-92}. This, and the development of 
taxanes, more efficacious and less toxic, was the reason platinum salts were not developed in BC. However, 
in ovarian cancer platinum salts were always the backbone of systemic therapy. With the Cancer Genome 
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Atlas dataset, TNBC has molecular similarities to ovarian caner, and, this, together with findings in BRCA 
deficient BC, has reignited the interest in platinum salts. TNBC and BRCA-deficient BC overlap, and there is 
cell line data showing that BRCA-/- cell lines are more sensitive to DNA-damaging agents, particularly those 
able to induce double strand breaks, such as cisplatin or carboplatin, when compared to doxorubicin or 
paclitaxel. This sensitivity is 3 fold higher than in the BRCA competent lines and is reversed with either 
BRCA1 upregulation or restoration {Tassone et al., 2003, Br J Cancer, 88, 1285-91} {Husain et al., 1998, 
Cancer Research, 58, 1120-3}. BRCA-null tumors are deficient in genes that encode for proteins critical in 
DNA integrity, genomic stability, and DNA repair, these tumors are basal-like in the PAM50 classification.
Researchers first characterized platinum salt activity in a retrospective analysis of 802 MBC patients, 67 had 
measurable disease and received a platinum and paclitaxel based regimen in the first or second line. The 
overall response rate (ORR) in these was 39%. In the TNBC patients, the ORR was 37.5%, and there was 
no difference compared to the hormone receptor positive subgroup {Uhm et al., 2009, Int J Cancer, 124, 
1457-62}.
The use of platinum salts in NA treatment of BRCA1 mutated TNBC was elegantly demonstrated by Byrski et 
al. (Table 1). The Polish group treated 10 women with BRCA1-associated breast cancer, 9 of which had 
TNBC, with 4 cycles of preoperative single-agent cisplatin (75 mg/m2) and 8 patients obtained pCR {Byrski 
et al., 2009, Breast Cancer Res Treat, 115, 359-63}. Silver et al administered NACT with cisplatin in TNBC, 
not necessarily BRCA deficient, the pCR rate was only 22% (6/28) with 36% of the tumors with a Miller-
Payne score of 4 or 5. Concordant with the Polish results, the two patients that were BRCA1 mutation 
carriers achieved pCR {Silver et al., 2010, Journal of Clinical Oncology}. The expression of p63/p73 as a 
readout of apoptosis in these tumor blocks, showed pCR in 3 of 9 (33%) positive patients but only 1 of 13 
(7%) negative patients. This group  studied the addition of the antiangiogenic agent bevacizumab to cisplatin 
in the NA treatment of 51 patients this resulted in a lower pCR rate of 16%, with 37% achieving a Miller-
Payne score of 4 or 5 {Ryan et al., 2009, J Clin Oncol, 27 suppl, abstr 551}
An Italian group, reported a very high pCR rate of 65% in 74 patients with TNBC treated with cisplatin 30mg/
m2, epirubicin 50mg/m2 and paclitaxel 120mg/m2 weekly for 8 weeks with GCSF support. Adjuvant 
alquilating therapy with 4 cycles of CMF was administered to all patients, and those with four or more 
positive nodes after preoperative therapy received an additional 4 cycles of CMF. Those patients who 
achieved a pCR had a 3- and 5- year disease-free survival (DFS) of 97% and 90%, respectively, compared 
with 3- and 5-year DFS rates of 61% and 56% in those with residual disease after preoperative therapy. 
Showing once more the correlation of pCR with survival {Frasci et al., 2009, Ann Oncol, 20, 1185-92}.
A similar italian trial of 30 TNBC patients treated with 4 preoperative cycles of epirubicin, cisplatin and 
fluorouracil (ECF) followed by weekly paclitaxel resulted in a pCR rate of 43% {Torrisi et al., 2008, Cancer 
Chemotherapy and Pharmacology, 62, 667-72}. An Italian retrospective analysis of NA, adjuvant and 
metastatic BC trials looking at the activity of any platinum-based chemotherapy in TNBC patients, showed 
pCR of 50%, 5 year survival of around 60% and ORR of 40% {Sirohi et al., 2008, Ann Oncol, 19, 1847-52}
A North American cooperative group, CALGB, is testing in 40603 trial carboplatin and bevacizumab  in TNBC. 
This a randomized Phase II NA study where patients are enrolled in one of 4 arms in a 2 by 2 factorial 
design. The CT backbone is 12 weekly administrations of paclitaxel followed by 4 cycles of dose dense 
doxorubicin and cyclophosphamide (AC). The factorial design either adds bevacizumab  or carboplatin or 
both. Von Mincwitz et al seem to have already conclusively answered this question in Gepar Sixto trial {von 
Minckwitz et al., 2014, Lancet Oncol}.
GEICAM, a Spanish cooperative group, conducted a NACT trial in TNBC positive for basal markers EGFR, 
CK5 and CK7 with the same regimen. The pCR rate only changed from 30 to 35% suggesting that 
carboplatin is not specifically useful in this setting, whereas in the BRCA1 null tumors platin salts seem to 
increase pCR rates {Alba et al., 2012, Breast Cancer Res Treat, 136, 487-93}. This results are concordant 
with the Polish by Byrski et al. and the New England results by SIlver et al.
Platinum salts have been extensively studied in MTNBC, BALI-1 is a multicentric trial that randomized 173 
patients to receive either cisplatin alone versus cisplatin in combination with cetuximab. Final analysis 
demonstrated a modest improvement in PFS among patients who received combination therapy, 1.5 versus 
3.7 months (HR 0.675 CI 0.470–0.969, P=0.032). Despite the doubling of ORR in the combination arm from 
10% to 20%, the study failed to meet its primary endpoint of greater than a 20% response {Baselga et al., 
2013, J Clin Oncol, 31, 2586-92}.
A North American trial asked the same question with a carboplatin combination, and had similar 20% ORR, 
additionally, the genomic patterns of response did not show consistent inhibition of EGFR signaling {Carey et 
al., 2012, J Clin Oncol, 30, 2615-23}. A follow up  to this trial, will use either cisplatin or carboplatin, asking 
which is more active in this context, and will ask prospectively the question whether p63 expression 
assessed by RT-PCR is predictive of response to platinum agents in TNBC patients {Isakoff SJ, 2007, J Clin 
Oncol, 25 , 10522}.
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The Polish group, due to the high prevalence of BRCA1 founder mutations in Poland, showed that the 
response rate in BRCA1-associated MBC is 80% with 45% complete response {Byrski et al., 2012, Breast 
Cancer Research : BCR, 14, R110}.
A large randomized phase III Triple Negative Breast Cancer Trial (TNT), with approximately 400 patients, in 
the UK, is underway, comparing carboplatin with docetaxel for MTNBC. Patients may receive up  to 6 cycles 
of treatment and will crossover to the other arm. The TNT study is designed to detect a 15% improvement in 
response to carboplatin compared to docetaxel. This trial will provide the answer to an important daily 
problem: What is the first line treatment, outside a clinical trial, to administer a MTNBC patient?
Anthracyclines
There is evidence that chromosomal instability correlates with anthracycline response in BC. In a 
retrospective study, fluorescent in situ hybridisation for chromossomes 1, 7, 11, 17 and 18, as a test for 
chromossomal instability, was used to identify patients with unstable tumors and study response to 
anthracyclines. In 322 patients recruited to BR9601 clinical trial, high tumor instability correlates with reduced 
DFS and overall survival. However, patients with unstable tumors, had better survival if treated with 
anthracyclines {Munro et al., 2012, Br J Cancer, 107, 71-4}. Instability seems to be predictive of response but 
simultaneously to indicate worse prognosis.
As a corollary, possibly anthracyclines might not be so useful in genomically stable subtypes of TNBC. There 
are only two suggestions that BRCA1 associated TNBC may be less sensitive to anthracycline-based 
therapy {Foulkes et al., 2003, J. Natl. Cancer Inst., 95, 1482-1485}. The first is that among 55 TNBC patients 
who received 6 cycles of fluorouracil, epirubicin 100mg/m2 and cyclophosphamide (FEC100), 12 BRCA1 
carriers were identified. The pCR rate for the 12 triple negative BRCA1 carriers was 17% compared with 
42% in the 55 sporadic TNBC patients non BRCA carriers {Petit T, 2007, J Clin Oncol, 25, 580}. The other, is 
a retrospective analysis of one of the Canadian adjuvant trials (MA5) comparing cyclcophosphamide, 
epirubicin, fluoruracil (CEF) to CMF, showed an improvement in 5-year overall survival from 51% to 71% for 
TNBC patients randomized to the CMF arm, while the anthracycline combination was superior in all other 
subgroups {Cheang M, 2009, J Clin Oncol, 27 }. The role of anthracyclines in TNBC is not clarified: On one 
hand, all trials have shown that TNBC patients benefit from anthracyclines and only two retrospective 
analyses do not confirm the findings but one of the studies defines TNBC differently, looking specifically at 
BRCA mutation carriers. A BRCA1 mutation, might affect anthracycline sensitivity like it has been shown for 
platinum salts, in this case negatively.
Taxanes
The data regarding taxanes in TNBC seems to be as unclear as the data for anthracyclines. It is perplexing 
how such conflicting data exist regarding the two most important therapeutic groups in the treatment of BC, 
concerning such a difficult BC subtype. A French retrospective analysis of NACT used to treat TNBC patients 
showed that FEC100 gave higher (58%) response rate than docetaxel (25%) {Petit T, 2007, J Clin Oncol, 25, 
580}.
The MD Anderson conducted a retrospective analysis of 1079 patients in NACT clinical trials with or without 
taxanes. In the ER negative subgroup, pCR was achieved in 15% without adding taxanes, and in 29% with 
taxanes {Mazouni et al., 2007, Ann Oncol, 18, 874-80}. A preoperative study of paclitaxel, followed by FAC, 
resulted in a 45% pCR rate among the basal-subgroup  of patients {Rouzier et al., 2005, Clin Cancer Res, 11, 
5678-85}
As with platinum and anthracycline agents, the BRCA1 population may demonstrate distinct patterns of 
response to taxanes compared to sporadic TNBC. In a Polish restrospective analysis, 44 BRCA1 carriers out 
of 3500 patients, only 6 of 15 who received docetaxel and doxorubicin had a complete or partial response, 
compared to 29 of 29 who received the non-taxane combination with DNA damaging drugs like 
anthracyclines or aquilating agents {Byrski et al., 2009, Breast Cancer Res Treat, 115, 359-63}.
The clinical trial CALGB 9344 was conducted more than 10 years ago but is still a very informative adjuvant 
trial. CALGB  9344 showed that the addition of paclitaxel to AC increased survival in circa 3000 patients. A 
retrospective analysis demonstrated that in Her2 negative patients, those that were ER negative, derived 
most benefit from taxanes {Hayes et al., 2007, The New England Journal of Medicine, 357, 1496-506}.
The BCIRG001 trial tested the benefit of TAC vs. FAC in 1500 patients {Martin et al., 2005, The New 
England Journal of Medicine, 352, 2302-13}. In the retrospective analysis of this trial, the benefits of 
docetaxel were independent of hormone receptor status {Hugh et al., 2009, J Clin Oncol, 27, 1168-76}. The 
NSABP B28 trial compared doxorubicin and cyclophosphamide with or without four cycles of paclitaxel, in 
3000 patients, and found no statistically significant difference in the relative risk of recurrence and overall 
survival, based on hormone receptor status {Mamounas et al., 2005, J Clin Oncol, 23, 3686-96}.
Another Polish retrospective analysis, evaluated 175 patients with MBC treated with docetaxel-based 
regimens and identified 19 with primary resistance to docetaxel {Wysocki et al., 2008, Med Sci Monit, 14, 
70
SC7-10}. Mutations in BRCA1, were found in 5 of the 19 (26%). The hypothesis that BRCA1 deficient BC do 
not respond well to taxanes needs to be prospectively tested, this will be done in the UK-based BRCA-trial, 
comparing carboplatin and docetaxel for first line treatment of MBC, like the TNT Trial but only in BRCA 
carriers.
Further data suggesting lack of benefit for taxanes for TNBC comes from a large trial in MBC using differing 
taxane regimens. The CALGB9342 trial, which evaluated three different doses of paclitaxel for metastatic 
breast cancer, showed no statistically significant difference in response rate or time to treatment failure, in 
general. CALGB9243 did not meet its primary endpoint and it did not show response differences between 
TNBC and hormone receptor positive tumors. However, as expected, in CALGB9243, the overall survival 
was significantly worse for the TNBC compared to hormone receptor positive group {Harris et al., 2006, 
Breast Cancer Research : BCR, 8, R66}. The inconclusive results of CALGB9342 were the main reason for 
the adjuvant trial ECOG trial 1199. This very important trial, that has definitely clarified the use of taxanes in 
the adjuvant treatment of BC, randomized nearly 5000 adjuvant BC patients to AC followed by docetaxel or 
paclitaxel given weekly or once every three weeks. This trial showed superiority of weekly paclitaxel in 
general and in a retrospective analysis on TNBC patients which showed better survival with weekly paclitaxel 
albeit bad survival when compared to other BC subgroups (Sparano NEJM 2008).
Another, later, ECOG study, the 2100 trial randomized 722 first line MBC patients to paclitaxel with or without 
bevacizumab {Miller et al., 2007, The New England Journal of Medicine, 357, 2666-76}. Because of 
trastuzumab efficacy, over 90% of the patients were Her2 negative, and more than a third were ER and PR 
negative. Therefore, it is possible that close to a third of ECOG 2100 patients had, in fact, MTNBC. The 
benefit of adding bevacizumab  was seen across the board. In fact the ECOG2100 results were the basis for 
the approval by the FDA and EMA of the first line MBC regimen of paclitaxel and bevacizumab  to treat BC. 
Interestingly, however, the progression free survival was only 4.6 months for the hormone receptor negative 
subset in the paclitaxel alone arm, compared to 8.0 months in the hormone receptor positive group. This 
data from the ECOG 2100 control arm shows that TNBC might not be so sensitive to single agent paclitaxel. 
But similarly to other trials, we cannot dissect the subtypes of TNBC in ECOG  2100. In fact, there is 
preclinical data demonstrating that functional BRCA1 might be required for anti-microtubule agent sensitivity 
{Quinn et al., 2003, Cancer Research, 63, 6221-8}. It is possible that a fraction of sporadic TNBC also has 
functional deficiency of BRCA1, therefore in this subgroup we might be able to demonstrate more resistance 
to taxanes, this is some of the data that will be available after the report of the TNT Trial. From this data we 
can once more appreciate the necessity of subtyping TNBC into a meaningful classification.
TNBC was shown to have more frequent expression of Caveolin-1 {Pinilla et al., 2006, Breast Cancer Res 
Treat, 99, 85-90}. One mechanism of cellular uptake of nanoparticle-albumin bound paclitaxel (nab-
paclitaxel) is via Caveolin-1 dependent receptor mediated transcytosis. Therefore, the use of nab-paclitaxel 
may warrant further testing for TNBC with high Caveolin-1 expression {Altundag et al., 2007, J Clin Oncol, 
25, 1294-5 author reply 1295-6}. EndoTAG®-1 (ET) is a novel combination of paclitaxel with neutral and 
positive lipids. It attacks activated negatively charged endothelial cells that are needed for the formation of 
new tumor blood vessels {Strieth et al., 2008, Clinical cancer research, 14, 4603-11}. ET is also being tested 
in TNBC for the same reason of nab-paclitaxel.
In fact, the amazing activity of taxanes in BC, possibly has to do with the activity of these agents in ER 
positive BC, which comprises 60 to 70% of the BC population. Neither in Her2 positive nor in TN have we got 
conclusive evidence that anthracyclines can be spared. As for platinum salts, as we have seen, there is 
renewed interest in TNBC, mostly fueled by their important activity in BRCA1 carriers, unfortunately, not 
undoubtedly seen in sporadic TNBC. In this analysis of classical chemotherapy for TNBC patients, there are 
several results showing that the replacement of alquilating agents by anthracyclines and taxanes that we 
have witnessed in the XXIst century, as well as the lack of development of platinum salts, might not have 
been beneficial for TNBC patients. Most importantly, taxanes are possibly less active in TNBC. This history 
of classical chemotherapy development in BC might have been deleterious specifically for TNBC patients.
Fluoropypirimidines
The activity of fluoropirimidines can only be inferred from retrospective subgroup analyses because they 
have not been studied prospectively. Several trials are underway to evaluate capecitabine in TNBC patients. 
CALGB49907, is a non inferiority adjuvant trial with either CMF or AC compared to capecitabine in women 
over age 65, after 600 patients were enrolled, the trial found capecitabine was inferior to standard 
chemotherapy with a hazard ratio (HR) higher than 2 {Muss et al., 2009, The New England Journal of 
Medicine, 360, 2055-65}. A planned subgroup  analysis, showed the benefit of standard chemotherapy was 
higher in hormone receptor negative patients (HR 3.04 for relapse-free survival, 2.62 for overall survival).
In the metastatic setting, two randomized phase III trials compared capecitabine plus ixabepilone to 
capecitabine monotherapy, in 1712 patients treated with prior anthracycline and taxane therapy {Rugo et al., 
2009, Cancer Research, 69, 3057-0}. Nearly 860 patients received capecitabine, 208 of these had TNBC, 
71
the ORR was 25% and the progression free survival (PFS) 4.2 months whereas it dropped to 15% and 1.7 
months in TNBC. A single arm phase 2 study of capecitabine with bevacizumab in MBC found nearly double 
the ORR, time to progression and overall survival in patients with ER positive tumors compared to patients 
with TNBC {Sledge et al., 2007, J Clin Oncol, 25, 1013}. Similarly to the taxanes, these data suggest that 
fluoropirimidines might be most efficacious in ER positive BC. The most evident benefit of classic 
combination chemotherapy in TNBC is in the neoadjuvant and adjuvant setting. In the metastatic context, 
when TN tumors have been shown to be more unstable (Ding et al, Nature 2010), and undergo new 
mutations at increased rate, it may be that single agent chemotherapy might not be suitable in TNBC.
Targeted agents
PARP inhibitors
BRCA gene products are non functional in a subset of sporadic TNBCs, generally through promoter 
hypermethylation or by other means. Additionally, these tumors might have DNA repair defects in homology-
directed repair pathways, not BRCA dependent. This is the reason PARP inhibitors were investigated in 
TNBC in general. Poly ADP ribose polymerase is an enzyme involved in base excision repair of DNA. If this 
enzyme is blocked, there will be double strand breaks that will not be repaired in case of homologous 
recombination deficiency, which is the case in BRCA null tumors. This phenomenon is called synthetic 
lethality, that two alterations concur to produce a phenotype {Farmer et al., 2005, Nature, 434, 917-21}
{Bryant et al., 2005, Nature, 434, 913-7}. Possibly as a compensatory feature, PARP1 is over expressed in 
TNBC {Fong et al., 2009, The New England Journal of Medicine, 361, 123}
Olparib, an oral PARP inhibitor, was shown to be active in BRCA null breast cancer. In a phase II trial where 
54 patients with germline mutations of BRCA1 or BRCA2 had locally advanced or metastatic BC, the 
response rate was 41%, and, 57% of these patients had TNBC {Tutt et al., 2010, Lancet, 376, 235-44}. The 
activity of olaparib  in wild type BRCA TNBC, was shown in another trial. Here, olaparib  was used in 23 
patients with MBC, where only 8 were BRCA mutation carriers, in this trial, there were no objective 
responses {Gelmon et al., 2011, Lancet Oncol, 12, 852-61}. These results suggest that isolated iPARP is not 
active in WT BRCA TNBC. There is another trial with veliparib, in combination with temozolomide where 
responses were observed only on BRCA carriers {Isakoff et al., 2010, J Clin Oncol, 28, 1019}. Olaparib  is 
now being planned to be studied in a very challenging adjuvant trial in BRCA mutation carriers (Table 4).
A phase II trial randomized 123 patients with metastatic TNBC to carboplatin and gemcitabine, alone or in 
combination with iniparib. Response rate increased from 16 to 48%, clinical benefit increased from 21 to 
62%, progression free survival increased from 3,6 to 6 months and survival increased from 7,7 to 12,3 
months. The results of this trial were better than expected. This trial was conducted in unselected TNBC and 
had an overall survival benefit, uncommon in randomized phase II studies, generally not designed with 
power to demonstrate survival benefits {O'Shaughnessy et al., 2011, The New England Journal of Medicine, 
364, 205-14}. These results were not confirmed by the ensuing phase III trial, where 519 patients with 
metastatic TNBC, in first to third line, were randomized to the same therapeutic regimen. In this trial, neither 
response nor survival were increased {OʼShaughnessy J, J Clin Oncol 29:81s, 2011 (suppl abstr 1007)}. In a 
retrospective analysis, it was seen that due to the heterogeneity of TNBC, only 25% of these patients had 
basal like TNBC and their BRCA status was unknown. Additionally the capacity of iniparib to inhibit PARP 
was put in question {Maegley et al., 2011, J Clin Oncol, 29, e13576}{Mateo et al., 2013, Nature reviews 
Clinical oncology, 10, 688} and today iniparib is a defunct drug {Sinha, 2014, J Natl Cancer Inst, 106}.
Anti Src
There is increased activity of the src tyrosine kinase in TNBC, and, promising results were reported in cell 
lines {Finn et al., 2009, Cancer Research, 69 }. A Phase I was conducted in non selected MBC patients, the 
cohort had 60% of ER positive disease. Dasatinib  combined with capecitabine were associated with clinical 
benefit in 56% of patients. Biomarker changes were consistent with what has been observed with 
bevacizumab, with significant decreases in plasma VEGF-A and increases in VEGFR-2 and collagen-IV, 
suggesting dasatinib might have an antiangiogenic effect {Somlo et al., 2013, Clinical cancer research, 19, 
1884-93}. Despite enthusiasm, the phase II trial as single agent in pretreated metastatic TNBC had a 5% 
response rate and a PFS of 2 months which are not encouraging results {Finn et al., 2011, Clinical cancer 
research, 17, 6905-13}.
Antiandrogenic therapy 
Two independent research groups have found that about 12% of TNBC expresses the androgen receptor 
(AR). The phase II trial with bicalutamide in metastatic, unselected, TNBC had a clinical benefit rate of 19% 
{Gucalp A, ASCO Meet Abstr 2012  30: 1006}.The same concept is being tested in a similar phase II trial, 
with abiraterone, but if tumors are not included based on AR expression, these trials might be futile efforts. 
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It has been said that highly proliferative lesions need increased angiogenesis {Schneider and Miller, 2005, J 
Clin Oncol, 23, 1782-90}, the aggressiveness of TNBC has been correlated to the levels of VEGF. There are 
increased levels of intratumoral VEGF in TNBC {Linderholm et al., 2009, Ann Oncol} and there are frequent 
gains in the VEGF gene in TNBC genome {Andre et al., 2009, Clin Cancer Res, 15, 441-51}.
The phase III clinical trials in MBC with bevacizumab in combination with taxanes or capecitabine did not 
prolong survival and approval of this drug in MBC has been withdrawn. The retrospective analysis aiming to 
test an increased efficacy in TNBC patients randomized in the investigational arm of E2100 trial suggested 
the addition of bevacizumab to paclitaxel reduced the risk of progression in first-line by 51% and doubled the 
PFS {OShaughnessy et al., 2009, Cancer Research, 69, 207-207}. A similar reduction in the risk of 
progression in TNBC patients, was reported in the AVADO trial, combining bevacizumab with docetaxel, 
although in RiBBOn-1 trial, which added bevacizumab to a chemotherapy regimen of choice, there was no 
benefit. A meta-analysis of the 621 TNBC patients from the three trials, revealed a reduction in 35% of the 
risk of progression and a PFS increase of 2.7 months, when bevacizumab  was added to chemotherapy 
regimens {O'shaughnessy et al., 2010, Cancer Research, 70, P6-12-03-P6-12-03}. Similar improvements 
were observed in the second-line setting: The 159 TNBC patients in RiBBOn-2 trial {Brufsky et al., 2012, 
Breast Cancer Res Treat}, demonstrated a 51% reduced risk of progression and a doubling of median 
progression free survival, among patients treated with the bevacizumab combination, compared with 
chemotherapy alone (2.7 versus 6.0 months), along with a trend towards improved survival (median, 17.9 
versus 12.6 months). With these encouraging results as backbone, numerous trials in neoadjuvant and 
adjuvant setting aimed to test the efficacy of bevacizumab specifically in TNBC patients.
The German Breast Group that has contributed heavily in NACT trials, designed Gepar Quinto. In the United 
States, the NSABP also designed a very similar trial. Both trials specifically tested the addition of 
bevacizumab to a third generation neoadjuvant chemotherapy backbone. GeparQuinto and NSAPB  B40, 
combined bevacizumab with anthracycline–taxane chemotherapy in Her2 negative patients, and 
demonstrated overall improvements in pCR rates for patients receiving bevacizumab compared with CT 
alone (GeparQuinto, 18.4% versus 14.9%, P = 0.04; B40, 34.5% versus 28.4%, P = 0.027) {von Minckwitz et 
al., 2012, The New England Journal of Medicine, 366, 299-309}{Bear et al., 2011, J Clin Oncol, 29, 
LBA1005}. A prespecified analysis of the 663 TNBC patients, in the German trial, revealed an improvement 
in pCR rates (39% versus 28%, P = 0.003) for patients receiving bevacizumab  compared with chemotherapy. 
The B40 study showed that adding bevacizumab  to chemotherapy did not improve pCR rates in the 479 
TNBC patients (51% versus 47%, P =0.44). The conflicting results of the metastatic trials (E2100, AVADO 
and RIBBON) and of the neoadjuvant trials (GEPAR Quinto and B40) could have been an indication that the 
tumors classified as TNBC might be very different diseases, nevertheless, the adjuvant trial was launched in 
2008, at initiation, not all the current data were available. Due to the inconsistency of previous trials, the 
results of the adjuvant trial in TNBC questioning the addition of bevacizumab  to standard chemotherapy 
regimens which were published recently were eagerly awaited.
In the Beatrice trial 2591 patients with TN operable primary invasive BC were randomly assigned to receive 
a minimum of four cycles of adjuvant CT alone or with 5mg/kg weekly bevacizumab  for 1 year. Similar 
proportions of patients received anthracycline and taxane therapy (59% and 58%), nontaxane anthracycline-
containing therapy (36% and 37%), nonanthracycline taxane-containing therapy (5% of both), and radiation 
therapy (74% and 73%). The study showed that the addition of bevacizumab did not improve invasive 
disease–free survival (IDFS), which was the primary endpoint, specifically excluding all in situ cancer events. 
An exploratory biomarker analysis suggested benefit of bevacizumab  in patients with high pretreatment 
vascular endothelial growth factor receptor 2 (VEGFR-2) levels. The HR for IDFS for bevacizuma-treated 
versus chemotherapy-alone patients were 0.61 among patients with VEGFR-2 levels above the median 
value and 1.24 for those with levels below median. Adjuvant bevacizumab was completed as planned in only 
68% of patients, suggesting a compliance issue. In fact toxicity data show, grade 3 or 4 adverse events in 
72% of patients in the bevacizumab  group and 57% of the CT group, with increased frequency of grade 3 or 
4 hypertension (12% vs 1%), severe cardiac events (1% vs < 0.5%), and treatment discontinuation (20% vs 
2%). The 3-year IDFS was 84% with bevacizumab  and 83% with CT alone. After 200 deaths, there was no 
difference in overall survival. Sites of recurrence were similar in the two treatment groups, with the most 
common being distant recurrence. The most common sites of distant recurrence were lung (28% and 27%), 
liver (20% and 15%), and bone (17% and 20%). The pattern of recurrence in TNBC patients is very different 
from hormone receptor positive disease with decreased bone events. Central nervous system disease was 
seen in 7% of patients in the bevacizumab group and in 12% in the chemotherapy group.
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Despite the fact that bevacizumab  did not meet its endpoint, the final survival analysis was not reported and 
will occur after a median follow-up of 5 years. This was a considerable effort, to randomize 2500 TNBC 
patients, that failed in this important group of patients. Several explanations have been put forward. It has 
been known that tumors need new vessels to grow larger than 2 mm, however, after tumors have been 
completely removed, the size of undetectable disease should be smaller than the 2 mm threshold. The 
longest administration of bevacizumab in this trial is mainly without CT, during adjuvant treatment, while we 
have observed that bevacizumab  is active combined with CT and not isolated. These might be two reasons 
for this negative trial. There is a reassuring point, the accelerated metastatic disease after cessation of anti 
angiogenesis observed in mouse models was not observed here {Cameron et al., 2013, Lancet Oncol, 14, 
933-42}.
Tirosine kinase inhibitors
Cell surface receptor tyrosine kinases (TK), including those linked to VEGF receptors, are relevant to 
angiogenesis stimulation, the effects of two TK inhibitors on endothelial cell proliferation have been 
evaluated in TNBC. Neoadjuvant and metastatic phase II and III trials have shown limited activity of sunitinib 
{Burstein et al., 2008, J Clin Oncol, 26, 1810-6}{Wildiers et al., 2010, Breast Cancer Res Treat, 123, 463-9}
{Curigliano G, 2010, Cancer Res, 70, Abstr P6-12-02}, significant toxicity and increased deaths {Mayer et al., 
2010, Ann Oncol, 21, 2370-6}{Crown J, 2010, J Clin Oncol, 28, LBA1011}{Bergh et al., 2012, Journal of 
Clinical Oncology}. Sorafenib  has equally modest single-agent activity {Moreno-Aspitia et al., 2009, J Clin 
Oncol, 27, 11-5}{Bianchi et al., 2009, Anticancer Drugs, 20, 616-24}; however, three randomized phase IIb 
trials have demonstrated improved overall outcomes for sorafenib–CT combinations in first- and second- line 
MBC {Gomez P, 2010, Cancer Res, 70, Abstr P2-16-01}{Hudis C, 2011, J Clin Oncol, 29, Abstr 1009}
{Bondarde S, 2010, Cancer Res, 70, Abstr P2-16-03}. A prespecified subgroup  analysis of TNBC patients in 
the SOLTI-0701 (N = 53) trial showed an improvement of almost two months in median PFS with the addition 
of sorafenib  to capecitabine (2.5 versus 4.3 months) {Gomez P, 2010, Cancer Res, 70, Abstr P2-16-01}. 
Similarly, in a North Amrican trial in the same setting a trend towards improved PFS was detected {Hudis C, 
2011, J Clin Oncol, 29, Abstr 1009}. The unconvincing results of sunitinib, and the conflicting results of 
sorafenib, will possibly jeopardize the further development of VEGF bound TK inhibitors in TNBC patients.
EFGR inhibitors: 
Monoclonal antibody
EGFR has been implicated as a molecular target for treatment of TNBC based on its frequent IHC 
expression (27%–57%) {Kreike et al., 2007, Breast Cancer Res, 9, R65}{Tan et al., 2008, Breast Cancer Res 
Treat, 111, 27-44}{Viale et al., 2009, Breast Cancer Res Treat, 116, 317-28}{Rakha et al., 2007, Cancer, 109, 
25-32}. Cetuximab  has demonstrated efficacy in two prospective studies and one retrospective analysis of 
randomized phase II trials in advanced TNBC. The largest EGFR trial, the international BALI-1, prospectively 
evaluated the addition of cetuximab to cisplatin to the first or second-line treatment of 173 MTNBC patients 
{Baselga et al., 2013, J Clin Oncol, 31, 2586-92}. The trial did not meet its primary endpoint of PFS 
prolongation. The addition of cetuximab  to irinotecan and carboplatin in first- and second-line treatment of 
MTNBC patients in the USOR-04-070 trial, a North American endevour {OʼShaughnessy J, 2007, Breast 
Cancer Res Treat, 106, S32}, that randomomized 72 patients, resulted in improved response rates in TNBC 
patients (30% versus 49%) with no improvements in PFS or OS. A third cetuximab trial, conducted in North 
America, added carboplatin to cetuximab  in 102 heavily pretreated MTNBC patients and resulted in a 
response rate of 17%. Prolonged PFS (2 versus 8 months) was seen in responders compared with the 
overall trial population {Carey LA, 2008, J Clin Oncol, 26, Abstr 1009}. None of these trials have proceeded 
to phase III and the development of cetuximab to treat TNBC patients has been abandoned.
Tirosine kinase inhibitors
A randomised phase II trial assessed the combination of erlotinib  with carboplatin and docetaxel in the 
neoadjuvant treatment of 30 TNBC patients and demonstrated promising activity with pCR of 40%. 
Retrospective data from two randomized phase II trials, demonstrated modest activity for gefitinib  (N = 82) in 
combination with standard neoadjuvant chemotherapy, and a lack of activity for lapatinib  (N = 131) in 
combination with paclitaxel in advanced TNBC patients {Finn et al., 2009, J Clin Oncol, 27, 3908-15}. 
Similarly the development of either TKI inhibitors linked to EGFR or to HER2 have both been abandoned.
Anti HSP90: Ganetespib
Heat Shock protein 90 (Hsp90), is a molecular chaperone protein essential for the stability and function of 
multiple cellular client proteins, a number of which have been implicated in the pathogenesis of BC. These 
are kinases and transcription factors {Friedland et al., 2013, Invest New Drugs}. The ENCHANT-1 trial 
(NCT01677455) was an open label, multicenter phase II proof of concept study evaluating first-line 
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ganetespib monotherapy in women with metastatic Her2-positive or TNBC but there are no efficacy results 
available yet. It is possible that smaller molecules like these with different mechanisms of action might 
produce interesting results.
Apoptosis inducers
Frequently the hardest property to attack in cancer cells is their capacity to evade apoptosis, because highly 
proliferative cells are susceptible to chemotherapy. One apoptosis inducer is LCL161 is a small molecule 
mimetic of the Smac mitochondrial protein. Like Smac, it binds to inhibitor of apoptosis proteins and prevents 
their interaction with active caspases. In a phase 1b  in BC combined with paclitaxel, 61% of the responses 
were seen in TNBC patients and therefore this molecule is considered promising in this particular subgroup 
{Dienstmann et al., 2012, Cancer Research, 72, P6-11-06}. Given this observation LCL161 will be studied 
with paclitaxel in the neoadjuvant setting, which has been shown to be a particularly favorable experimental 
set up for TNBC patients.
Conclusion
The attempt to show which of the most frequently employed therapeutic classes of conventional CT is most 
useful in TNBC has not yet been solved. It seems clearer today that alquilating agents and anthracyclines 
should not be replaced by taxanes, in neoadjuvant and adjuvant regimens. It is established that TNBC has 
consistently high pCR rates with modern combination CT in the neoadjuvant setting. Today it is 
unquestionable that those patients achieving pCR have better survival, approaching that of ER positive BC 
patients. A lot of data with platinum salts has shown that BRCA null TNBC patients might be the main 
subgroup  to benefit from these drugs, whereas wild type BRCA TNBC patients might not benefit with such 
magnitude. If we could daily adopt the Lehmann classification, which has not been reliably translated to the 
clinic, genomically unstable MTNBC and mesenchymal TNBC are possibly driving chemorresistance. The 
search for targeted systemic therapy for TNBC has met with three big setbacks in the last half a decade: 
PARP inhibition, epidermal growth factor and angiogenesis targeting. The way forward with iPARP is BRCA 
null TNBC, this will be tested in the upcoming adjuvant trial with olaparib. The way forward with anti 
angiogenesis and epidermal growth factor inhibition will be a clinically useful readout of mesenchymal TNBC. 
Genomically unstable TNBC, should be treated with aggressive combination chemotherapy, possibly even 
dose dense or high dose regimens. This story of failures in the systemic treatment of TNBC represents a 
failure of scientists, pharma, clinical researchers and society at large. It is time for a paradigm shift in BC 
drug development. BC oncologists will have to think 300 times smaller. The 9000 patient trials we developed, 
as in no other cancer, will now give rise to 30 patient trials. Efficacy has been shown in BCR-ABL mutated 
CML, BRAF mutated melanoma, C-KIT mutated GIST and ALK-mutated lung adenocarcinoma, with few 
patients. We will now prepare for trials in BC patients with a specific mutation, specifically susceptible to a 
given drug. The deception of TNBC treatment has paved the way forward.
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Table 1 Neoadjuvant trials with platinum salts in TNBC
Question and design of trialTrial Phase Rand n Endpoints and/or results
Cisplatin 75mg/m2 x4 q3w {Silver et al., 2010, 
Journal of Clinical Oncology}
II No 28 22% pCR (6/28). Both 
BRCA1 mutation carriers 
had pCR
Combination of cisplatin and bevacizumab {Ryan et 
al., 2009, J Clin Oncol, 27 suppl, abstr 551}
II No 51 26% pCR
Cisplatin 75mg/m2 x4 q3w {Byrski et al., 2009, 
Breast Cancer Res Treat, 115, 359-63}.
II No 25 72% pCR
Paclitaxel weekly +/- carboplatin followed by AC +/- 
bevacizumab
II Yes 362 NA
Metronomic CT: Weekly doxorubicin 24 mg/m2 x12 
and daily oral cyclophosphamide 60mg/m2 followed 
by weekly paclitaxel (80mg/m2) and carboplatin 
(AUC=2) x 12
II No 28 NA
Cisplatin 25 mg/m2 IV weekly + everolimus 5 mg 
PO daily for 1 week followed by Cisplatin 25 mg/m2 
IV + Paclitaxel 80 mg/m2 IV weekly + everolimus for 
11 weeks
II Yes 96 Inhibition of P53 family of 
proteins (P63 and P73)
Six cycles of TAC or TC in TN or HER2 positive BC II Yes 70 NA
Weekly paclitaxel with or without everolimus 
followed by FEC
II Yes 50 Inhibition of PI3K/PTEN/
AKT Pathway
Four cycles EC followed by four cycles of docetaxel 
vs. the combination of docetaxel and carboplatin 
{Alba et al., 2012, Breast Cancer Res Treat, 136, 
487-493}





Four cycles of carboplatin and paclitaxel followed by 
four cycles of cyclophosphamide
II No 60 NA
Weekly cisplatin, epirubicin and paclitaxel eight 
cycles and 4 adjuvant cycles of CMF to pts w/ less 
than 4 positive nodes or 8 to those w/ more (Frasci 
et al)
II No 74 65% pCR DFS at 3 and 5y: 
97% and 90% for those w/ 
pCR, 61% and 56% for 
those w/o pCR
Four cycles of ECF followed by three cycles of 
weekly paclitaxel
II No 30 43% pCR
Neoadjuvant Sunitinib (S) Administered with Weekly 
Paclitaxel (P)/Carboplatin(C) in Patients (Pts) with 
Locally Advanced Triple-Negative Breast Cancer 
(TNBC)
II No 22 9% pCR. Only 4 pts 
completed neoadjuvant CT, 
there was 68% grade 3/4 
hematological 
toxicity{Yardley et al., 2012, 
Cancer Research, 72, 
Supplement 3}
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Question and design of trialTrial Phase Rand n Endpoints and/or results
Predictors of Response to Neoadjuvant Docetaxel-
Carboplatin Chemotherapy for Patients With Stage 
II and III disease
II No 75 Predictors of pCR and of 
chemoresistance, response 
by MRI, pCR in BRCA 
carriers
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Table 3: Clinical trials testing the efficacy of platins and/or targeted agents, excluding PARP inhibitors, in the 
management of metastatic/locally advanced TNBC. These trials were all initiated between November 2006 
and September 2007. Source: http://clinicaltrials.gov/
PI, ID Trial Pha
se








II No 1 39 Cisplatin and 
Evaluation of p63/
p73 as a Biomarker 
of Response

















II Yes 1 180 Cetuximab and 
cisplatin or cisplatin 
alone









II Yes 3 or 
mor
e
100 Cetuximab alone or 
in combination with 
carboplatin












































II Yes 2 37 Abraxane, 
bevacizumab
PFS OS, toxicity Waiting report
NCT
00246571
II Yes 2 200 Sunitinib vs. 
standard of care 
chemotherapy




Trial was closed 
w/o patients
ORR, overall response rate; PFS, progression-free survival; OS, overall survival; RECIST, Response 
Evaluation Criteria in Solid Tumours; EGFR epidermal growth factor receptor
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Table 4: Clinical trials testing PARP inhibitors in TNBC or in BRCA-mutated BC. Source: http://
clinicaltrials.gov/. NCT numbers are provided for the trials registered in clinicaltrials.gov.












































II No Neoadjuvant iniparib, 
gemcitabine and 
carboplatin, q3w
pCR 36 NS May 2012
NCT
01045304
Metastatic II Yes Iniparib, gemcitabine 
and carboplatin qw or 
q2w







II No Intravenous iniparib 
and irinotecan








III Yes Adjuvant 
chemotherapy with or 
without olaparib








III Yes Chemotherapy for 
MBC with or without 
olaparib
OS 200 OS Jan 2020
 q3w, every 3 weeks; CBR, clinical benefit rate; ORR, overall response rate; PFS, progression free survival; 
OS, overall  survival; qw, weekly; q2w, every 2 weeks; RR, response rate; pCR, pathological  complete 
response; NS, not specified; TTP, time to progression
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Table 5 Adjuvant trials in TNBC 









III Yes Standard adjuvant 
chemotherapy concurrent with 
bevacizumab followed by 

















III Yes Standard adjuvant 
chemotherapy followed by 1 
year of capecitabine vs. 
standard adjuvant 
chemotherapy alone




II Yes Ixabepilone (I) Vs. Ixabepilone 
Plus Cetuximab 








III Yes 3 cycles FEC100 followed by 3 
cycles of docetaxel or followed 
by 3 cycles of ixabepilone 
5 year 
DFS










III Yes 4 cycles AC followed by 12 
cycles of paclitaxel qw or 
followed by 4 cycles of 
ixabepilone. Very similar 
question to PACS08. 






III Yes 4 cycles epirubicin plus 
cyclophosphamide followed by 4 
cycles docetaxel vs 6 cycles 
docetaxel plus carboplatin*





II/III No In HRD: Testing dose dense AC 
vs. PBPC harvest, intensified 
alquilating agents with PBPC 
reinfusion. 
In nonHRD: Testing, after 3 
cycles of ddAC, 3 cycles of 
ddAC vs. 3 cycles of docetaxel 
and capecitabine, according to 
response 
pCR 270 RFS, OS Ongoing
NCT 
00472693










III Yes Adjuvant olaparib vs. 
observation after a backbone of 
adjuvant CT at physicians 
choice





FEC100, fluorouracil, epirrubicin at 100mg/m2 and cyclophosphamide; DMFS, distant metastasis free 
survival; EFS, event free survival; * the dose of epirrubicin and docetaxel are 75mg/m2, which are lower than 
standard and the investigational arm has two cycles less than the comparator arm
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António Pêgo, Instituto Português de
Oncologia de Coimbra Francisco Gentil
E.P.E., Coimbra, Portugal; Andrew M.
Wardley, The Christie NHS Foundation
Trust, Manchester, United Kingdom; Bella
Kaufman, Sheba Medical Center, Tel
Hashomer; Salomon M. Stemmer, David-
off Center, Petach Tiqva, Israel; Arlene
Chan, Mount Hospital Perth, Perth, Austra-
lia; Jean-Charles Goeminne, Clinique et
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A B S T R A C T
Purpose
Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers
(mTNBCs), an aggressive subtype of breast cancer. Our randomized phase II study investigated
cisplatin with or without cetuximab in this setting.
Patients and Methods
Patients who had received no more than one previous chemotherapy regimen were randomly
assigned on a 2:1 schedule to receive no more than six cycles of cisplatin plus cetuximab or
cisplatin alone. Patients receiving cisplatin alone could switch to cisplatin plus cetuximab or
cetuximab alone on disease progression. The primary end point was overall response rate
(ORR). Secondary end points studied included progression-free survival (PFS), overall survival
(OS), and safety profiles. Analyses included a significance level of ! ! .10 with no adjustments
for multiplicity.
Results
The full analysis set comprised 115 patients receiving cisplatin plus cetuximab and 58 receiving
cisplatin alone; 31 patients whose disease progressed on cisplatin alone switched to cetuximab-
containing therapy. The ORR was 20% (95% CI, 13 to 29) with cisplatin plus cetuximab and 10%
(95% CI, 4 to 21) with cisplatin alone (odds ratio, 2.13; 95% CI, 0.81 to 5.59; P ! .11). Cisplatin
plus cetuximab resulted in longer PFS compared with cisplatin alone (median, 3.7 v 1.5 months;
hazard ratio [HR], 0.67; 95% CI, 0.47 to 0.97; P ! .032). Corresponding median OS was 12.9
versus 9.4 months (HR, 0.82; 95% CI, 0.56 to 1.20; P ! .31). Common grade 3/4 adverse events
included acne-like rash, neutropenia, and fatigue.
Conclusion
While the primary study end point was not met, adding cetuximab to cisplatin doubled the ORR
and appeared to prolong PFS and OS, warranting further investigation in mTNBC.
J Clin Oncol 31:2586-2592. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Triple-negative breast cancer (TNBC), which is de-
fined as estrogen receptor (ER),progesterone recep-
tor (PgR), and human epidermal growth factor
receptor 2 (HER2) –negative disease, accounts for
11% to 17%of allbreast cancers.1,2 The incidenceof
this type of breast cancer is greater among young
patients andAfricanAmerican patients.2 TNBC has
amore aggressive clinical course than other types of
breast cancer, with a much shorter median time
from recurrence todeath.3 In addition, these tumors
lack expression of hormone receptors and HER2
and they are not responsive to hormonal or anti-
HER2 therapy. The only available therapy for ad-
vanced TNBC is cytotoxic chemotherapy4 and
bevacizumab in combinationwith chemotherapy in
European countries, but prognosis generally re-
mains poor,5 especially formetastatic disease. Thus,
investigationofnovelways to treat patientswith this
subtype of breast cancer is of particular importance.
Epidermal growth factor receptor (EGFR) has
been shown to be highly expressed in TNBC cell
lines,6 andTNBCcell linesoverexpressing the recep-
toraregrowth inhibitedby theanti-EGFRmonoclo-
nal antibody cetuximab.7 In addition, a majority of
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may be particularly sensitive to DNA damaging agents such as cispla-
tin.4,8 Clinical studies have shown that the use of platinum-based
chemotherapy is associated with tumor response in both nonmeta-
static9 andmetastatic TNBC (mTNBC).10,11
In vitro studies have demonstrated that the EGFR-targeting
monoclonal antibody cetuximab potentiates the effects of oxalipla-
tin12 and radiation13 by impairing DNA repair. Cetuximab has also
been shown to enhance thedemonstratedantitumor activityof cispla-
tin and carboplatin.14-16 The safety and efficacy of the combination of
cetuximab with platinum-based regimens has been demonstrated
clinically in other tumor types.17-19
Although at the molecular level, patients with TNBC
comprise a heterogeneous subgroup, in the absence of predictive
biomarkers to identify patients who would benefit from cetux-
imab treatment we investigated all patients with mTNBC.4,20
Based on the high EGFR expression levels in TNBC, the sensitivity
of these tumors to DNA-damaging agents, the observed impair-
ment of DNA repair by cetuximab, and the strong preclinical
evidence for a synergistic effect of cetuximab and cisplatin, we
performed this randomized phase II study evaluating the efficacy




Eligible patients were ages 18 years or older with a histologically con-
firmed diagnosis of metastatic (stage IV) TNBC. ER-negative, PgR-negative,
andHER2-negative status were determined locally, and tumor receptor status
of the primary lesion was permitted for inclusion. Other main inclusion
criteria were: no more than one previous chemotherapeutic regimen for the
treatment of metastatic breast cancer, at least one measurable lesion by mag-
netic resonance imaging or computed tomography according to Response
Evaluation Criteria in Solid Tumors (RECIST, version 1.0),21 Eastern Coop-
erativeOncologyGroup (ECOG) performance status 0 to 2, and tumor tissue
available for EGFR expression assessment.Main exclusion criteria were: prior
therapy with a platinum agent ormitomycin; previous exposure to monoclo-
nal antibody therapy, signal transduction inhibitors, or EGFR-targeting ther-
apy; known history of brainmetastases; andother cancers except forbasal-cell
skin carcinoma or preinvasive cervical carcinoma.
The protocol was approved by independent ethics committees of the
participating centers and the study was carried out in accordance with the
Declaration ofHelsinki. All patients providedwritten informed consent.
Study Design
This open-label, randomized phase II study was conducted in Europe,
Australia, and Israel. Eligible patients were randomly assigned in a 2:1 ratio to
receive cisplatin with or without cetuximab. Randomization was performed
centrally using an Interactive Voice Response System with stratification ac-





Allocated to cisplatin alone (n = 61)
  Received allocated intervention (n = 60)
  Excluded from efficacy and safety (n = 3)
    analyses (significant deviations from 
    Good Clinical Practice guidelines)
  Did not receive allocated intervention (n = 1)
    (did not meet inclusion criteria)
Allocated to cisplatin plus cetuximab (n = 120)
  Received allocated intervention (n = 119)
  Excluded from efficacy and safety (n = 5)
    analyses (significant deviations from  
    Good Clinical Practice guidelines)
  Did not receive allocated intervention (n = 1)
    (did not meet inclusion criteria)
)0 = n( pu-wollof ot tsoL
Discontinued intervention (n = 54)
  Progressive disease imaging based (n = 42)
)2 = n( tneve esrevdA  
  Consent withdrawal (n = 2)
)3 = n( deiD  
  Symptomatic deterioration (n = 3)
  Protocol noncompliance (n = 1)
)1 = n( rehtO  
)1 = n( pu-wollof ot tsoL
Discontinued intervention (n = 108)
  Progressive disease imaging based (n = 86)
)6 = n( tneve esrevdA  
  Consent withdrawal (n = 6)
)4 = n( deiD  
  Symptomatic deterioration (n = 2)
)4 = n( rehtO  
)85 = n( desylanA
  Excluded from efficacy analysis (n = 0)
  Excluded from safety analysis (did (n = 1)
    not receive allocated intervention)
)511 = n( desylanA
  Excluded from efficacy analysis (n = 0)
  Excluded from safety analysis (did (n = 1)
    not receive allocated intervention)
)02 = n( dedulcxE
  Did not meet inclusion criteria (n = 12)
  Declined to participate (n = 4)
  )4 = n( snosaer rehtO
Fig 1. CONSORT diagram.
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Theprimary endpointwas thebestoverall response rate (ORR),defined
as the proportion of patients with a confirmed complete response or partial
response according to RECIST version 1. Secondary end points included
progression-free survival (PFS), overall survival, time to response, and safety.
The rate of disease control, defined as the proportion of patients with a
complete response,partial response,or stabledisease forat least6weeks asbest
response, was assessed in a post hoc analysis. Planned exploratory subgroup
analyses were used to investigate the association between bestORR and base-
line patient and disease characteristics and any association between first-cycle
acne-like rash and response inpatients receiving cisplatinplus cetuximabwho
were undergoing treatment at day 21.
Treatment and Assessments
In the cisplatin plus cetuximab group, patients were to receive an initial
dose of cetuximab (Merck KGaA,Darmstadt, Germany) 400mg/m2 by intra-
venous infusion followed by 250 mg/m2 once weekly. Patients were also to
receive intravenous cisplatin 75mg/m2 on day 1, every 3 weeks, for six cycles.
Patients benefiting from treatment could continue to receive weekly cetux-
imab 250 mg/m2 alone following the six cycles of cisplatin until first relapse,
unacceptable toxicity, orwithdrawal of consent.
Patients in the cisplatin-alone groupwere to receive cisplatin 75mg/m2
on day 1 every 3 weeks for six cycles.On disease progression, patients had the
option to switch to cisplatin plus cetuximab as above or cetuximab alone,
depending on whether the patient’s disease progression was reported during
or after the six cisplatin cycles, respectively.
Tumor response was assessed by local investigators every 6 weeks until
disease progression according to RECIST version, 1.0. After disease progres-
sion,dataon survival status and further anticancer treatmentusewas collected
systematically every 3months after the end of study visit. Adverse events were
recorded at treatment visits, the final tumor assessment, and the end of study
visit andwere gradedusing theNationalCancer InstituteCommonTerminol-
ogy Criteria forAdverse Events, version 3.0.
ER, PgR, and HER2 expression status was determined by immuno-
histochemistry of patient tumor sections. The IHC cutoff for ER-negative
and PgR-negative status was ! 10% of staining in the nuclei. HER2-
negative status was less than 3! by immunohistochemistry (based on
staining intensity).22 HER2-negative status was confirmed in 1! or 2!
expressing cells by fluorescence in situ hybridization analysis (confirming
the absence of gene amplification).23
Statistical Analysis
The statistical analysis was based on the objective of showing superiority
of cisplatin plus cetuximab over cisplatin alone in terms of overall response
together with showing that the overall response for cisplatin plus cetuximab
was above a prespecified clinically relevant threshold of 0.2. Two null hypoth-
eses were tested simultaneously, that is, to test whether theORR was equal in
both treatment groups and to test if theORRwas less than or equal to 20% in
the cisplatin plus cetuximab group. The simultaneous null hypothesis would
be rejected if both single null hypotheses were rejected. A planned sample size
of 180 was based on the following assumptions: an increase of at least 18% in
ORRwith cisplatin plus cetuximab comparedwith cisplatin alone (from 14%
to 32%); anORR ofmore than 20% in the cisplatin plus cetuximab group; 2:1
randomization ratio for cisplatin plus cetuximab versus cisplatin alone; a
two-sided" of .10; an 80% power for the rejection of both single null hypoth-
eses; and a 5% dropout rate. A randomization ratio of 2:1 was applied to
increasebothexposure in theexperimental groupandthepower for testing the
ORR in this group against 20%.
Efficacy analyses were performed on the full analysis set. Because of the
exploratory nature of the study, all statistical tests used a significance level of
" " .10, and no adjustments were made for multiplicity. The ORR in the
cisplatinplus cetuximab groupwas tested against .20using aone-sided z test at
a significance level of "/2 " .05.
BestORRswere comparedusing a two-sidedCochran-Mantel-Haenszel
test stratified by line of treatment. The odds ratio (cisplatin plus cetuximab v
cisplatin alone) between treatment groups andORR per group are presented
with the corresponding 95%CI.
Time-to-event variables were compared using a two-sided log-rank test
stratified by line of treatment. Kaplan-Meier curves (except for time to re-
sponse) and median values with corresponding two-sided 95% CIs are pre-
sented. Hazard ratios (cisplatin plus cetuximab v cisplatin alone) were
calculated by Cox’s proportional hazardsmodel stratified by line of treatment
and presentedwith 95%CI.
Data cutoff times for analyses were 6 months after the last patient had
been randomly assigned for best overall response, PFS, and time to response;
times for analyses for overall survival were after two thirds of the randomly
assigned patients had died.
The safety population included all patients to whom any dose of study
treatment was administered. Analysis of safety end points was performed
according to the actual treatment received. Adverse events were categorized
according to the Medical Dictionary for Regulatory Activities (version 12.0)
system organ classes and preferred terms, as well as predefined special adverse
event categories inwhich the preferred terms were pooled.
RESULTS
From June 2007 to February 2009, 181 patients were randomly as-
signed from 47 sites (Fig 1). Significant deviations from the Good






Characteristic No. of Patients % No. of Patients %
Age, years
Median 53.0 52
Standard deviation 12.5 10.7
# 65 93 81 51 88
# 65 22 19 7 12
ECOG performance status
0 72 63 39 67
1 37 32 17 29
2 6 5 2 3
Line of treatment!
First line 84 73 42 72
Second line 31 27 16 28
Time to metastasis, months†
Median 15.7 15.4
No. of patients 108 55
Interquartile range, Q1-Q3 5.0-26.4 1.8-29.7
Site of metastasis‡
Liver 36 31 17 29
Lung 64 56 26 45
Bone 37 32 20 34
Lymph nodes 49 43 22 38
Skin 20 17 8 14
Other 15 13 9 16
Previous anticancer therapy§ 101 88 53 91
Neoadjuvant 46 40 12 21
Adjuvant 75 65 41 71
Local therapy 53 46 26 45
No previous chemotherapy 19 17 10 17
Naturally postmenopausal 64 56 36 62
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
!According to Interactive Voice Response System.
†Duration from initial diagnosis to date of metastasis, Q1-Q3 interquartile
range (25% quartile to 75% quartile).
‡Patients could have metastases at more than one site.
§Patients could have received more than one type of therapy.
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ClinicalPractice guidelineswere identified atone site that resulted in a
lack of credibility of the data and a subsequent mandate from the
national health authority to exclude all their eight patients from the
analysis. This gave a full analysis set of 173 patients.One hundred and
fifteenpatientswere randomly assigned to receive cisplatinplus cetux-
imab and 58 were assigned to receive cisplatin alone. Thirty-one
(53%) of 57 patients in the cisplatin-alone group switched to cetux-
imab on disease progression: 21 patients switched to cisplatin plus
cetuximab and10 switched to cetuximab alone. Twopatientswhodid
not receive study treatmentwere excluded from the safetypopulation.
In the safety population, the cisplatin plus cetuximab group had
amedian duration of 13.1 weeks and 13.6 weeks of cetuximab and of
cisplatin treatments, respectively. A relative dose intensity of at least
90% for cetuximab and cisplatin was attained in 81 (71%) of 114
patients and 90 (80%) of 113 patients, respectively. The cisplatin-
alone group had a median treatment duration of cisplatin of 12.7
weeks.Patients switching tocetuximabafterprogressionhadamedian
treatment duration of cetuximab of 5.9 weeks.
The study groupswerewellbalanced forperformance status, line
of treatment, and median time to metastasis (Table 1). Overall, the
majority of patients had infiltrating ductal carcinoma (150 of 173;
86%), had received study treatment as first-line therapy (126 of 173;
73%), and had an ECOG performance status of 0 (111 of 173; 64%).
The patients’ median age was 52.0 years. Altogether, 82 (71%) of 115
patients in the cisplatin plus cetuximab group and 35 (60%) of 58
patients in the cisplatin-alone group received anticancer therapypost-
study treatment.
The best ORR was 20% (95% CI, 13 to 29; 23 of 115) and 10%
(95% CI, 4 to 21; six of 58) in the cisplatin plus cetuximab and
cisplatin-alone groups, respectively (odds ratio, 2.13; 95%CI, 0.81 to
5.59; P ! .11). Thus, the primary end pointwas notmet (Table 2).
Median PFS was significantly longer in the cisplatin plus cetux-
imab group than in the cisplatin-alone group (3.7 months v 1.5
months; hazard ratio [HR], 0.67; 95% CI, 0.47 to 0.97; P ! .032; Fig
2A). Median overall survival was 12.9 months in the cisplatin plus
cetuximab group and 9.4 months in the cisplatin-alone group (HR,
0.82; 95%CI, 0.56 to 1.20; P ! .31; Fig 2B).Median time to response
was 1.4 months and 1.3 months in the cisplatin plus cetuximab and
cisplatin-alone groups, respectively (HR, 0.75; 95% CI, 0.26 to 2.17;
P ! .60).
In the exploratory subgroup analyses regardingORR,odds ratios
in favor of cisplatin plus cetuximab over cisplatin alone seemed high-
est in postmenopausal patients and in patients receiving study treat-
ment as second-line therapy (Fig 3). Among patients undergoing
treatment at day 21 in the cisplatin plus cetuximab group with (n !
64) andwithout (n! 43)first-cycle acne-like rash, there seemed tobe
no difference in theORR (with acne-like rash, 20%; 13 of 64; without
acne-like rash, 23%; 10 of 43).
All 171 patients experienced at least one adverse event. Alto-
gether, 69 (61%) of 114patients in the cisplatin plus cetuximab group
and 24 (42%) of 57 patients in the cisplatin-alone group experienced






Response No. of Patients % No. of Patients %
Complete response 2 2 1 2
Partial response 21 18 5 9
Stable disease 48 42 18 31
Progressive disease 34 30 31 53
Not evaluable 10 9 3 5
Best overall response rate 23 20 6 10
95% CI 13 to 29 4 to 21
Odds ratio! 2.13
95% CI 0.81 to 5.59
NOTE. Complete responses, partial responses, and stable disease were
defined according to Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0.




 + cisplatin alone
 (n = 115) (n = 58)
No. of Events 92 47
Median PFS, mos 3.7 1.5
95% CI 2.8 to 4.3 1.4 to 2.8
HR (95% CI): 0.67 (0.47 to 0.97)



























Cetuximab 115 53 18 6 0 0
   + cisplatin
Cisplatin alone 58 16 5 1 1 0
BA




 + cisplatin alone
 (n = 115) (n = 58)
No. of Events 82 42
Median OS, mos 12.9 9.4
95% CI 9.6 to 15.6 6.7 to 14.2
HR (95% CI): 0.82 (0.56 to 1.20)






















Cetuximab 115 103 84 65 54 40 23 13 8 1 0
   + cisplatin
Cisplatin alone  58 48 38 29 19 12 5 3 2 1 0
0 126 18 24 3093 15 21 27
Fig 2. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). (A) Median PFS was significantly longer in patients who received cisplatin
plus cetuximab compared with patients who received cisplatin alone (3.7 months [mos] v 1.5 months; hazard ratio [HR], 0.67; 95% CI, 0.47 to 0.97; P ! .032). (B)
Median OS was 12.9 months in the cisplatin plus cetuximab group and 9.4 months in the cisplatin-alone group (HR, 0.82; 95% CI, 0.56 to 1.20; P ! .31).
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at least one grade 3 or 4 adverse event. Grade 3 or 4 adverse events
occurring in at least 5% of patients in the cisplatin plus cetuximab or
cisplatin-alone groups are listed in Table 3 and included neutropenia
(11 [10%] of 114 v three [5%] of 57), fatigue (10 [9%] of 114 v four
[7%] of 57), dyspnea (seven [6%] of 114 v one [2%] of 57), and
acne-like rash (17 [15%] of 114 v 0%). In the cisplatin plus cetuximab
group, grade 3 or 4 dyspnea was associatedwith clinical deterioration
and disease progression in all patients.Other grade 3/4 adverse events
with cisplatin plus cetuximab and cisplatin alone were sepsis (two
[2%] of 114 v 0%), hypertension (four [4%] of 114 v 0%), and
hypomagnesemia (four [4%] of 114 v one [2%] of 57). Any grade and
grade 3 infusion-related reactions occurred in 15 (13%) of 114
and three (3%) of 114 patients in the cisplatin plus cetuximab group,
respectively, and in no patients in the cisplatin-alone group. There
were no treatment-related adverse events leading to death.
DISCUSSION
This randomized phase II study demonstrated that cisplatin plus ce-
tuximabdoubled theORRachievedwith cisplatin alone (from10% to
20%) in patients with mTNBC. The primary end point of the study
wasnotmetandthis is thereforeanegative trial.However, it ispossible
that thismay not accurately represent the true activity of this combi-
nation regimen as, unlike other randomized phase II studies, the
primaryendpointwasbasedon twonullhypotheses;on theonehand,
superiorityof the cetuximab arm and,on theother, anORRof greater
than 20%. Therefore, the observed doubling of the ORR with the
addition of cetuximab to cisplatin should not be ignored when con-
sidering the potential of anti-EGFR agents in mTNBC.
The addition of cetuximab significantly prolonged median PFS
from1.5monthswith cisplatin alone to3.7monthswith cisplatinplus
cetuximab. There was a nonsignificant improvement in median sur-
vival of 3.5months observedwith cisplatin plus cetuximab, although
the sample size was small and 31 (53%) of 57 patients in the cisplatin-
alone group switched to a cetuximab-containing therapy on disease
progression. It is not possible to accurately assess the impact of this
cross-over on outcome, as response was not protocol-specified in
these patients.
The tolerability profile of cisplatin plus cetuximab was as ex-
pected, with no new safety concerns. Themore frequent grade 3 or 4
adverse events in the cisplatin plus cetuximab compared with the
cisplatin alone group are mainly owing to grade 3 acne-like rash
associatedwith cetuximab, whichwas generallymanageable. In addi-
tion, patients in the cisplatin plus cetuximab group had a slightly
higher incidence of grade 3 or 4 neutropenia than patients in the
cisplatin-alone group as well as some grade 3/4 infusion-related
reactions. Infusion-related reactions are a known adverse effect of
0.1 0.5 1 2 10 50
oitar sddO  setar esnopseR  
Subgroup n Cisplatin + cetuximab v )IC %59( enola nitalpsic 
Full analysis set 173 20% v )95.5 ot 18.0( 31.2 %01 
Age, years
  < 65 144 22% v )05.5 ot 77.0( 50.2 %21 
  ! 65 29 14% v )16.85 ot 21.0( 96.2 %0 
ECOG PS
  0-1 165 20% v )45.5 ot 08.0( 11.2 %11 
  2 8 17% v )56.64 ot 40.0( 63.1 %0 
Menopausal
  Postmenopausal 100 19% v )36.81 ot 38.0( 29.3 %6 
  Premenopausal 73 22% v )24.4 ot 53.0( 42.1 %81 
Treatment
  First-line 126 20% v )05.5 ot 46.0( 88.1 %21 
  Second-line 47 19% v )78.23 ot 93.0( 06.3 %6 
Benefit cisplatin + cetuximabBenefit cisplatin alone
Fig 3. Odds ratios for best overall re-
sponse rate in subgroup analyses. ECOG
PS, Eastern Cooperative Oncology Group
performance status.












Any grade 3 or 4 event 69 61 24 42
Any grade 4 event 12 11 4 7
Grade 3 or 4 adverse events in ! 5%
patients in either treatment arm
Neutropeni a 11 10 3 5
Fatigue 10 9 4 7
Dyspnea 7 6 1 2
Nausea 5 4 3 5
Vomiting 5 4 3 5
Asthenia 3 3 3 5
General physical health deterioration 0 3 5
Special adverse events!
Acne-like rash 17 15 0
Infusion-related reaction 3 3 0
Cardiac event (arrhythmia) 0 1 2
!Special adverse events are of composite categories of preferred terms that
were prospectively defined in the study protocol according to Medical
Dictionary for Regulatory Activities (MedDRA; version 12); all were grade 3.
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cetuximab treatment and severe neutropenia or neutropenic compli-
cations, such as sepsis, have been noted to occur more frequently in
patients receiving cetuximab plus platinum-based therapy compared
with platinum-based therapy alone in phase III trials in other tu-
mor types.18,24,25
Other phase II studies have reported clinical activity for
cetuximab in mTNBC, supporting the concept that this may be a
worthwhile approach for the treatment of this disease. In a ran-
domized phase II trial conducted by the Translational Breast Can-
cer Research Consortium (TBCRC 001), in which 54% of patients
had received prior chemotherapy for mTNBC, though cetuximab
alone (n ! 31) demonstrated low activity with a response rate of
6%, the combination of cetuximab and carboplatin (n ! 71) led to
a response rate of 17% and a clinical benefit rate of 31%.26 In a
second study of patients with metastatic breast cancer who were
randomly assigned to receive irinotecan followed by carboplatin
with or without cetuximab as first- or second-line treatment,
among a subgroup of 78 patients with mTNBC, a higher response
rate was reported in the group receiving cetuximab (49% v 30%).27
These data suggest that the addition of cetuximab to platinum-
based chemotherapy may offer clinical benefit for patients with
mTNBC. The data also highlight the importance of an appropriate
control group in cetuximab studies. For example, the 18% re-
sponse rate reported for the combination of cetuximab and carbo-
platin in TBCRC 001may appear disappointingly low, particularly
when compared with historical data of response rates with plati-
num salts in mTNBC.10,11 However, the response rate with the
combination is similar to the response rate thatwasobserved in our
cetuximab-containing arm and superior to the one observed with
cisplatin alone in our study.
A limitation of our study is the unavailability of data from the
analysis for predictive biomarkers of cetuximab activity. The identifi-
cation of patients with tumorsmost likely to respond to cetuximab is
clearly an areadeserving intense investigation. A retrospective analysis
of data from patients who received subsequent-line cetuximab for
colorectal cancer reported that high gene expression levels of the
EGFR ligands epiregulin and amphiregulin were found to be associ-
ated with improved disease control compared with lower levels.28 In
addition, disease control following treatment with cetuximab was
significantly higher among patients without tumor mutations in the
KRAS gene,28 an observation subsequently confirmed by analyses of
other studies of cetuximab in combination with standard first-line
therapy.19,29 In breast cancer, however, the KRAS gene is not fre-
quentlymutated30 and so is unlikely to be a useful predictivemarker.
In conclusion, the primary end point of the study was not met.
However, the addition of cetuximab to cisplatinwas associatedwith a
numerical doubling of the response rate and an increase in PFS when
compared with cisplatin alone in patients with mTNBC who had
received no more than one line of palliative chemotherapy. These
results suggest that EGFRmay be a suitable target in the treatment of
TNBC and that cetuximabmight be a potentially important addition
to treatment strategies for the management of patients with TNBC.
These findings warrant further investigation. Future approaches
might include the identification of predictive markers for the
treatment with cetuximab and the development of a more active
chemotherapy-cetuximab combination regimen in mTNBC.
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HelenaMelezínková,Merck KGaA (C) Consultant or Advisory Role:
Richard Greil,Merck KGaA (C) Stock Ownership: None Honoraria:
Richard Greil,Merck KGaA Research Funding: None Expert
Testimony: None Other Remuneration: None
AUTHOR CONTRIBUTIONS
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António Pêgo, Jean-Charles Goeminne,Marie-Pascale Graas, EvaMaria
Ciruelos Gil, Andreas Schneeweiss, Angela Zubel, Ahmad Awada
Data analysis and interpretation: José Baselga, Richard Greil, Salomon
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Blocking angiogenesis to treat breast cancer
Abstract
Angiogenesis is a hallmark of cancer because tumors larger than 1mm need new vessels to sustain their 
growth. Since the discovery of molecular players of this process and its inhibitors, that angiogenesis became 
a promising therapeutic target. This review will summarize and analyze data from clinical trials of anti-
angiogenic agents in the treatment of breast cancer (BC).
Before the bevacizumab era, matrix metaloproteinase inhibitors, thalidomide and endostatin were tested, as 
well as classic chemotherapy, administered metronomically. Bevacizumab was the first molecularly-targeted 
antiangiogenic therapy approved and extensively studied. Phase III trials of bevacizumab in advanced BC 
have demonstrated a reduction in disease progression (22–52%), increased response rates (RR) and 
improvements in progression-free survival (PFS) of 1 to 5 months, but no improvements in overall survival 
(OS). Bevacizumab  phase III trials in early BC have been closed or negative. Bevacizumab  combined with 
CT is associated with more adverse events.
A second class of approved inhibitors (sunitinib, sorafenib, pazopanib and axitinib) include oral small-
molecule tyrosine kinase inhibitors (TKI) that target vascular endothelial growth factor receptors (VEGFR), 
platelet-derived growth factor receptors, and other kinases including KIT, Ret, BRAF and Flt-3 but none of 
these have gained approval to treat BC. Phase III trials of the TKI, sunitinib, were negative, while 
randomized phase II trials of sorafenib  and pazopanib  have improved some outcomes. Toxicity is less 
predictable with these agents, first, the expected vascular class effects, but the “off-target” side effects, 
common to small molecule inhibitors, are of concern.
Most trials of anti-angiogenic agents in BC have reported improved RR and PFS but no increase in OS 
compared to CT alone, leading to skepticism towards blocking angiogenesis. Selected trials in selected BC 
populations with translational endpoints related to harvested tumor tissue and other biological material 
samples, preferentially at several timepoints, will be crucial if antiangiogenesis is to survive as a strategy to 
treat breast cancer.
Basic and translational research
Angiogenesis, the development of vessels from pre existant vessels is an indispensable process for tumor 
development, it is a hallmark of cancer [1]. In BC, this was shown in preclinical in vivo and in vitro models 
and in tumor samples. MCF7 cell lines transfected with VEGF gene or fibroblast growth factor (FGF) gene, 
develop more aggressive tumors in mice than the non modified cell line [2, 3]. On the other hand, an 
antiangiogenic treatment in the same model, can prevent the development of such tumors [4-6]. A similar 
experiment showed that cell lines that could not develop  cancer in mice could do so after acquiring an 
antiangiogenic phenotype characterized among others by VEGF and overexpression [7]. 
An experiment where the T47D cell line was transfected with a conditional expression vector with VEGF 
gene, showed, that, at implantation or shortly after, turning off VEFG expression had significant impact on 
tumor growth, whereas in a more advanced stage such reduction was not impactful. This model shows that 
the timing in cancer natural history when antiangiogenic therapy is administered is relevant [8]. 
There is crosstalk between antiangiogenic proteins and breast cancer carcinogenic proteins, namely, steroid 
hormones and their receptors and epithelial growth factors and their receptors. Intracytoplasmatic signaling 
via Her2 induces expression of HIF1α (Hypoxia inducing factor) and VEGF. Blocking Her2 with trastuzumab 
reduces VEGF expression [9, 10]. VEGF is an ERα target gene, while ERβ  decreases VEGF transcription 
[11, 12]. In cell lines, P53 inhibits VEGF expression by forming a complex with the transcriptional factor SP1 
[13]. This might be one of the reasons P53 mutated tumors have worse prognosis [14].
Data from patient samples has shown the relevance of angiogenesis in BC. One of the first studies 
searching angiogenic molecules in patient material was done precisely in BC. This study showed correlation 
between increased vascular density and worse prognosis in 49 patients, this was one of the first 
confirmations of the theory Judah Folkman put forward in 1971 [15, 16]. Judah Folkman was a pioneer, he 
postulated the existence of the proangiogenic molecules, years before they were known or detectable. 
Confirmatory studies ensued as well as the demonstration of this prognostic value in lymph node negative 
BC and ductal carcinoma in situ (DCIS) [17-19]. The correlations between increased angiogenesis in the 
primary tumor and worse prognosis have mainly been done with VEGF levels measured by trasnscript, 
immunohistochemistry or western blot in the primary tumor [20, 21]. Tumor VEGF levels have been 
established as an independant predictor of survival [22]. Furthermore, tumor VEGF level has also been 
shown to be a negative predictor of response to first line metastatic endocrine therapy and CT [23]. 
Regarding tumor VEGF2, there is a study showing that, in early breast cancer, high expression of VEGFR2 
in the primary tumor correlates with no efficacy of 2 year tamoxifen [24]. Other authors have looked at the 
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crosstalk between the downstream molecules of VEGF in BC development namely HIF1α [25]. 
Polymorphisms of germline VEGF have been correlated with BC risk and prognosis [26, 27].
Circulating VEGF studies have been difficult to interpret, because platelet VEFG is released into the 
circulation upon coagulation and the levels are very different if evaluation is done in plasma or serum and IT 
also depends on the anticoagulant used. Possibly because of this, studies have not shown correlation 
between increased circulating VEGF in MBC patients and survival [28-30]. Which was unexpected, due to 
the results in the primary tumors. Serum VEGF levels, do not have a standard measurement and have not 
been efficiently exploited for assessing response. But, in other tumor types, circulating VEGF level, predicts 
worse prognosis and correlates with the findings of primaries [22, 31]. Several hypothesis have been put 
forward for this inconsistency [32]: Could it be that VEGF is crucial in the primary tumor and looses its 
prognostic value in MBC due to numerous redundant pathways. Could this be the reason for the inefficacy of 
bevacizumab in MBC. In fact, angiogenesis is a differential of proangiogenic and anti angiogenic molecules 
in an equilibrium. Neovessels are the result of more proangiogenic molecules and there are antiangiogenic 
molecules detected in BC, namely endostatin [33]. Surprisingly, circulating endostatin is increased in more 
aggressive and in MBC patients [34, 35]. These paradoxical results have also been shown in other tumor 
types, and might be linked to the fact that the expression of collagen XVIII, the precursor of endostatin is 
increased in aggressive cancer [36, 37]. This can be the result of a negative feedback loop or of a basal 
antiangiogenic activity of angiostatin that was shown in initial trials. Despite effort, this equilibrium between 
pro and anti angiogenic factors has not been conclusively elucidated in BC [38]. The procurement of high 
quality samples of metastatic lesions as well as serum samples during treatment and the necessity of using 
reliable and generalizable laboratory techniques has thwarted this research.
Clinical research
Sixty molecules with angiogenic activity are being evaluated clinically in BC with very different mechanisms 
of action. A large part of these molecules are VEGF antagonists, because VEGF is possibly the most 
important angiogenic molecule in cancer and undoubtedly the best studied. There are monoclonal antibodies 
anti-VEGF or anti-VEGF receptors, soluble receptors, inhibitors of the VEGF coupled tyrosine kinase or 
antisense oligonucleotides [39]. The other class of molecules are inhibitors of matrix metalloproteinases. 
Finally, are the molecules that are directly antiangiogenic like thalidomide, whose mechanism of action is not 
well characterized and endostatin or angiostatin [40]. The antiangiogenic action of classic chemotherapy is 
also of interest, such as the metronomic administration of low dose cyclophosphamide or weekly paclitaxel. 
This is thought to be due to their cytostatic effect on endothelial cells, precursors of new premetastatic 
niches, in tumors resistant to cytotoxic approaches because of few mitotic cells [41]. 
Matrix metaloproteinase inhibitors
The initial clinical trials, started in the late 1990ʻs, prompted phase III trials that were negative [42, 43]. A 
randomized placebo-controlled phase III trial in first line MBC of maintenance marimastat after induction 
chemoptherapy, in 181 patients, did not prolong survival and was associated with grade 2-3 musculoskeletal 
toxicity, in 63% of the patients. Surprisingly, increased toxicity correlated with worse survival [44]. Two 
adjuvant studies with this drug were done. One phase II, where the objective was to obtain therapeutic 
plasma levels of marimastat. In this trial, 35% of the patients stopped the drug due to musuloskeletal toxicity 
while the maximum tolerated dose was only 25% of the dose predicted to be efficacious. These results did 
not give confidence to proceed to phase III [45]. The other, was a randomized double blind phase II trial with 
BMS275291, the objectives were toxicity and feasibility, it was stopped after the enrollment of 72 patients 
due to arthralgia and the development of the drug stopped [46]. The development of MMPi was stopped in 
cancer after these results.
Thalidomide 
This drug was tested after arguably interesting preclinical data, in numerous solid tumors [47]. A phase II trial 
with three doses was performed in 28 MBC patients with no objective responses and only two stabilizations. 
These two patients, one had stable disease for 16 weeks and the other for 11 weeks, but this patient had to 
stop the drug due to neurologic toxicity [48]. Serum from thalidomide-treated patients did not show decrease 
in VEGF levels. Another study confirmed these results, and drug development was abandoned for this 
indication [49].
Natural inhibitors of angiogenesis: endostatin
Until recently, there were no clinical trials specifically testing the natural inhibitors of angiogenesis in BC. In 
the two phase I clinical trials reported there were 7 patients with MBC but there was no response. 
Translational research studies, done as components of these trials, with biopsies of the lesions before and 
after treatment, evaluating VEGF levels and tumor perfusion studies, did not show a strong antiangiogenic 
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effect compared to the same essays done on bevacizumab-treated lesions [50, 51]. Endostatin has been 
further tested in neoadjuvant clinical trials in combination with anthracycline-based chemotherapy in 
treatment-naive patients and has increased the clinical response rate, but more trials are needed to establish 
this drug. The third generation of angiogenesis inhibitors is represented by recombinant human endostatin 
that is being tested in phase III clinical trials, there are interesting results available in the neoadjuvant setting.
Metronomic chemotherapy
Metronomic chemotherapy in BC was evaluated in a phase II trial with 64 patients where metotrexate was 
given weekly and cyclophosphamide was given continuously. In 52 of these patients it was used as third line. 
There were 2 complete responses and 12 partial responses with a 22% RR, PFS was 3 months. Serum 
VEGF decreased but without correlation with response [52]. A randomized follow-up of this trial used the 
same regimen with or without thalidomide, in 175 patients. RR was 20%, the same as the previous study, 
and the addition of thalidomide did not increase RR, while it increased toxicity, similarly, the serum VEGF 
decreased after 2 months of therapy, but without correlation with response [53].
It is not clear from these trials if there is true antiangiogenic effect of metronomic chemotherapy, nor is it 
clear which are the cells affected, the microenvironment or the epithelial BC cells [54]. There are other 
empirical observations of the metronomic effect of protratcted 5FU, capecitabine and weekly paclitaxel.
Bevacizumab
Metastatic setting
Bevacizumab was developed on the rational basis of VEGF biology and has activity in numerous tumors with 
bearable toxicity, it was shown that using the drug, in part, blocks angiogenesis [55, 56]. Bevacizumab 
created great excitement at the time, in fact it validated that blocking angiogenesis was a therapeutic 
modality in human cancer, although results were not as promising as initially expected [57]. In Phase II trials 
with monotherapy in pretreated MBC patients a 9% response rate was observed and less than 20% stable 
disease at 6 months [58]. In combination therapy, the addition of bevacizumab  to docetaxel or vinorelbine did 
not result in the expected increased RR [59]. Bevacizumab  was combined with trastuzumab  in patients 
progressing on the latter, there were responses and no additive toxicity [60]. This strategy of combination of 
bevacizumab and trastuzumab  has intermittently been tested in MBC trials and some small neoadjuvant 
trials. The definitive phase III adjuvant trial named BETH, has recently reported results. Subsequent phase III 
trials suggesting improved activity when bevacizumab  is administered in conjunction with CT were numerous 
and randomized thousands of MBC patients. Starting with second line MBC therapy, a phase III trial 
combined bevacizumab  with capecitabine for patients previously treated with anthracycline and taxane 
therapy. The trial randomized 462 patients to receive capecitabine with or without bevacizumab, 25% of 
patients had Her2 positive MBC. There was an increase in overall RR with the addition of bevacizumab  to 
capecitabine (9.1% vs. 19.8%), with no significant improvement in PFS or OS [61]. 
The most important phase III trial combined bevacizumab  with taxanes as first-line treatment for patients with 
locally recurrent or MBC. It was an open label trial called ECOG  2100, 673 patients were randomized to 
paclitaxel plus or minus bevacizumab  [63].In this ECOG  trial the ORR more than doubled (22.2% vs. 48.9%) 
as well as PFS (median, 5.8 vs. 11.3 months) with no improvement in OS (median, 25.2 vs. 26.7 months) 
[63, 66]. Based on the ECOG2100 results, the FDA approved bevacizumab for first-line therapy of MBC 
patients, in the beginning of 2008. This was granted under accelerated approval program, which allowed 
bevacizumab to be approved based on the ECOG 2100 data that were not sufficiently complete to permit full 
approval. The accelerated approval program provided earlier access of BC patients to what was thought to 
be a promising new drug, while confirmatory trials of ECOG 2100 were being conducted.
The similar, placebo-controlled, AVADO trial, randomized 736 patients to three study arms, two dose levels of 
bevacizumab combined with docetaxel. At progression, patients could continue receive bevacizumab  as 
second-line therapy. At a median follow-up  of 25 months, results show that standard dose (15 mg/kg) 
bevacizumab, in combination with docetaxel, increased ORR modestly (46.4% vs. 64.1%), improvement in 
PFS (median, 8.2 vs. 10.1). The addition of low dose bevacizumab did not significantly improve ORR or 
PFS. The final analysis showed no improvement in OS [65]. AVADO  was the first trial not to confirm the 
results of ECOG 2100 and AVADO was a larger trial.
RiBBOn 1 and 2 trials tested chemotherapy with or without bevacizumab  in first and second-line setting in 
1237 patients [64, 67, 68]. The RIBBON trials were placebo-controlled. Data were analyzed based on 
patients receiving: (i) taxane or anthracycline-based CT plus standard dose bevacizumab  versus CT plus 
placebo and (ii) capecitabine plus bevacizumab versus capecitabine plus placebo. The addition of 
bevacizumab to CT resulted in improvements in PFS for both the taxane-anthracycline (median, 8.0 vs. 9.2 
months) and capecitabine cohorts (median, 5.7 vs. 8.6 months). No significant differences in OS were 
observed between treatment arms in either the taxane–anthracycline (HR = 1.03, p  = 0.83) or capecitabine 
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cohort (HR = 0.85, p  = 0.27), although a trend toward improved 1-year survival was apparent when 
bevacizumab was added to capecitabine (74.4% vs. 81.0%, p = 0.076). 
Chemotherapeutic treatment options in the RIBBON 2 trial included taxanes, gemcitabine, vinorelbine or 
capecitabine. A total of 684 previously-treated (3rd line or more) patients were randomly assigned to receive 
either bevacizumab  (15 mg/kg, q3w or 10 mg/kg, q2w) or placebo [67, 68]. There was a statistically not 
significant trend toward improved RR (29.6% vs. 39.5%) in the bevacizumab-containing treatment arms [67]. 
The addition of bevacizumab resulted in a significant improvement in PFS (median, 5.1 vs. 7.2 months; HR = 
0.78, p = 0.0072) [68]. An interim survival analysis showed no improvement in OS (median,16.4 vs. 18.0 
months; HR = 0.90, p  = 0.3741) with the addition of bevacizumab  [68]. However, an exploratory subgroup 
analysis of patients with triple-negative breast cancer (TNBC) demonstrated a highly significant improvement 
in PFS (median, 2.7 vs. 6.0 months; HR = 0.49, p  = 0.0006) and a trend toward improved OS (median, 12.6 
vs. 17.9 months; HR = 0.62, p = 0.0534) [68]. 
Given the results of AVADO  and RIBBON, the confirmatory trials of ECOG  2100, that only show small 
response rates with no survival benefit, the FDA announced that the agency recommended removing the BC 
indication from the label of bevacizumab  in the end of 2010. In June 2011 there was a hearing with 
Genentech to re-appreciate data but the decision was revoked and in the end of 2011 the agencyʼs 
accelerated approval of bevacizumab  for BC was withdrawn. The explanation for the very different results of 
ECOG  2100 and the subsequent confirmatory trials will never be clear but the fact that ECOG  2100 was 
open-label and the other two trials were placebo-controlled has flared up an old discussion in cancer trials.
Neoadjuvant setting
Researchers are continuing to study this drug in other BC settings and BC subtypes, but, outside clinical 
trials, bevacizumab  should not be administered to BC patients. The NSABP B-40 trial added bevacizumab 
(15 mg/kg) and/or antimetabolites to standard neoadjuvant CT in a randomized phase III trial of Her2-
negative BC (n = 1206) [69]. Overall, the pCR rate (breast alone, [ypT0/Tis]) improved with the addition of 
bevacizumab (28.4% vs. 34.5%, p  = 0.027) with the greatest impact observed in the hormone receptor-
positive subset (15.2% vs. 23.3%, p = 0.008).
The phase III GeparQuinto trial randomized 1948 Her2-negative BC patients to anthracycline-taxane CT with 
or without bevacizumab  (15 mg/kg). Adding bevacizumab  did not significantly increase the pathological 
complete response rate (pCR in breast and axilla, 15% vs. 17.5% or pCR breast alone [ypT0/Tis], 21.3% vs. 
23.9%) or rates of breast conserving surgery in patients overall, but did improve the pCR rate in a sub-
population of 684 patients with TN disease (breast and axilla [ypT0, ypN0], 27.8% vs. 36.4%, p  = 0.021) [70, 
71, 72].
As is expected, adding bevacizumab  to CT increases neutropenia, hand-foot syndrome, mucositis and 
hypertension. Again, with these two important trials that randomized more than 3000 neoadjuvant BC 
patients, B40 and Quinto, we see discordant results, not only in response but also in BC subtypes.
Adjuvant setting
The study of the drug in the adjuvant setting started by ECOG  2104, a large randomized phase II pilot trial 
that incorporated bevacizumab  into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in 
patients with lymph node positive breast cancer. It was designed to evaluate the safety of two different 
strategies incorporating bevacizumab; into anthracycline or taxane containing adjuvant therapy, as a 
precursor to a definitive randomized phase III trial. Patients were treated with dose-dense doxorubicin and 
cyclophosphamide, followed by paclitaxel, all patients received bevacizumab  (10 mg/kg every 2 weeks 
during 26 weeks), initiated either concurrently with AC or with paclitaxel. The primary end point was 
incidence of cardiac dysfunction; once the results of the MBC trials had suggested increased cardiac 
adverse events with the addition of bevacizumab. In 226 enrolled patients, grade 3 hypertension, 
thrombosis, proteinuria and hemorrhage were reported for 12%, 2%, 2% and less than 1% of patients, 
respectively. Two patients had grade 3 cerebrovascular ischemia. Three patients in each arm developed 
congestive heart failure. There was no significant difference between arms in the proportion of patients with 
an absolute decrease in left ventricular ejection fraction. Bevacizumab, combined with adjuvant therapy, was 
concluded not to result in prohibitive cardiac toxicity and the definitive, 5000 patient, phase III trial, ECOG 
5103, was started in 2007. Fortunately, despite the optimistic safety signals coming from ECOG  2104, 
systematic and extensive cardiac monitoring was implemented and detected an excess of toxic cardiac 
events in the bevacizumab  containing arm leading to premature termination of the adjuvant trial in 2009 [74, 
75].
Beatrice, was an open-label phase III trial, where 2591 patients with triple-negative operable primary 
invasive breast cancer were randomly assigned to receive a minimum of four cycles of adjuvant 
chemotherapy alone (n = 1290) or with bevacizumab at an equivalent of 5 mg/kg every week for 1 year 
(n =  1301). Beatrice was started in 2008 and has just published final results [76]. Similar proportions of 
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patients received anthracycline and taxane therapy (59% and 58%), nontaxane anthracycline-containing 
therapy (36% and 37%), nonanthracycline taxane-containing therapy (5% of both), and radiation therapy 
(74% and 73%). Chemotherapy was completed as planned in 92% of the chemotherapy group  and 93% of 
the bevacizumab  group, and bevacizumab  was completed as planned in 68%. After median follow-up  of 32 
months, there was no difference between the bevacizumab  group  and the chemotherapy group  in invasive 
disease–free survival (IDFS). IDFS events occurred in 14% of the bevacizumab group vs 16% of the 
chemotherapy group; 3-year IDFS was 83.7% with bevacizumab  and 82.7% with chemotherapy alone. 
Subgroup  analyses showed no evidence of differences. After 200 deaths, there was no difference in OS. 
Sites of recurrence were similar in the two treatment groups, with the most common being distant 
recurrence. The most common sites of distant recurrence were lung (28% and 27%), liver (20% and 15%), 
and bone (17% and 20%). Distant central nervous system or meningeal recurrence accounted for 7% of 
recurrences in the bevacizumab group and 12% in the chemotherapy group. Exploratory biomarker 
assessment in approximately 45% of patients suggested that patients with high pretreatment plasma 
VEGFR-2 levels might benefit from the addition of bevacizumab. The hazard ratios for invasive disease–free 
survival for bevacizumab  vs chemotherapy were 0.61 among patients with levels above the median value 
and 1.24 for those with levels below median (P =  .0291 for interaction). Grade 3 or higher adverse events 
occurred in 72% of patients in the bevacizumab  group  and 57% of the chemotherapy group. The 
bevacizumab group had an increased frequency of grade 3 or worse hypertension (12% vs 1%), severe 
cardiac events occurring at any point during the 18-month safety-reporting period (1% vs <  0.5%), and 
treatment discontinuation (bevacizumabor chemotherapy, 20% vs 2%) [76]. In Beatrice, unlike ECOG 5103, 
the safety data did not require premature termination of the trial, therefore efficacy results of bevacizumab in 
the adjuvant setting in the TNBC subtype are available. With respect to Her2 positive breast cancer, the Beth 
trial randomized 3509 women who had either node-positive or high-risk node-negative disease, with the 
latter group  making up 41% of the population. These results were recently presented at San Antonio Breast 
Cancer Symposium in December 2013. Patients were enrolled in 1 of 2 chemotherapy regimens: 6 cycles of 
docetaxel/carboplatin plus trastuzumab (TCH) with or without bevacizumab  (n = 3231) or an anthracycline-
based regimen involving 3 cycles of docetaxel plus trastuzumab given with or without bevacizumab followed 
by 3 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (n = 278). In both regimens, patients 
continued trastuzumab  with or without bevacizumab  after chemotherapy to complete 1 year of targeted 
therapy. For the primary outcome of the study, which was IDFS, there was no statistically significant 
difference between the patients who received bevacizumab  and those who did not. At a median follow-up  of 
38 months, IDFS rates were 92% for both groups of the TCH cohort (ie, those treated with or without 
bevacizumab) A secondary endpoint compared IDFS in patients in the anthracycline-based vs the TCH-
based cohorts and also found no significant differences between the regimens, whether with or without 
bevacizumab. However, the study was not designed to compare these different chemotherapy approaches, 
and only 278 patients received anthracyclines, less than 5%. The IDFS of 92% is in striking contrast with the 
IDFS of BCIRG  006 Trial of 86% that had the same investigational arm without bevacizumab. These results 
will question the use of anthracyclines in the adjuvant treatment of Her2 BC. In grade 3 or 4 adverse events, 
hypertension was higher in the bevacizumab  group (19% vs 4%; p < .001). There was also a trend for more 
congestive heart failure with bevacizumab  (2.1% vs <1%; p = .0621), and a difference in hemorrhage (2% vs 
<1%; p  < .0001). Proteinuria and gastrointestinal perforations were also more common in the bevacizumab 
group. Contrary to the favorable toxicity results Beatrice trial the Beth trial has again showed important 
toxicity with adjuvant bevacizumab.
Inhibitors of VEGFR coupled tyrosine kinases: Sunitinib and Sorafenib
Small molecule oral TKIs target the intracellular catalytic function of the VEGFR family linked tyrosine 
kinases. The kinases are coupled to the intracellular portion of the transmembrane receptors (e.g., 
VEGFR-1, 2 and 3). VEGFR-2 is the primary signaling receptor for VEGF-mediated angiogenesis. Sunitinib 
is a multi-targeted inhibitor of VEGFR-1, 2 and 3, platelet-derived growth factor receptor, c-Kit, FMS-like 
tyrosine kinase-3 and RET. A recent phase III trial comparing sunitinib  (37.5 mg/day) to capecitabine and a 
small randomized phase II trial evaluating sunitinib  as consolidation therapy following induction 
chemotherapy [77, 78] have both demonstrated inferior outcomes for single agent sunitinib  compared with 
controls in pretreated MBC. Additionally, two randomized phase III trials in the advanced setting evaluating 
the addition of sunitinib (37.5 mg/day) to either capecitabine or docetaxel compared with the respective 
chemotherapies alone demonstrated increased toxicity and comparable PFS with the addition of sunitinib 
[79, 80]. The definitive first line phase III trial of sunitinib  in BC was done comparing docetaxel with or without 
sunitinib  in the first line treatment of MBC. The combination increased response rate but had no effect in PFS 
and OS [81]. Based on these findings, and the early termination of the phase III sunitinib  trial in first line 
MBC, due to a lack of feasibility due to increased toxicity and weak efficacy results [82] the clinical 
development of sunitinib in BC was stopped.
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Sorafenib, a small molecule TKI, has both anti-angiogenic and anti-proliferative effects [83]. Sorafenib  has 
shown single agent activity in pretreated patients [84]. Three randomized, phase IIb  trials have shown that 
sorafenib  in combination with standard chemotherapy significantly improved outcomes from first-line MBC 
treatment (PFS; median, 5.6 vs. 6.9 months; HR = 0.79, p = 0.09 and TTP; median 5.6 vs. 8.1 months; HR = 
0.67, p = 0.017) and second-line (PFS; median, 4.1 vs. 6.4 months; HR = 0.58, p = 0.0006). Sorafenib 
showed activity after bevacizumab  resistance (PFS; median, 2.7 vs. 3.4 months; HR = 0.65, p = 0.01) 
[85-88]. A multivariate analysis of these trials suggested sorafenib  to be an interesting drug to pursue 
development [89]. The toxicity profile includes minimal grade 3/4 hypertension but high rates of grade 3/4 
hand-foot syndrome. A placebo-controlled phase III trial in MBC evaluating capecitabine in combination with 
sorafenib  is currently underway (NCT01234337). Other ongoing randomized trials will evaluate sorafenib  in 
combination with standard chemotherapy (NCT00499525 and NCT01320111), metronomic chemotherapy 
and/or endocrine therapy (NCT00573755, NCT00954135) in the advanced setting. There are obvious 
advantages to an oral drug in this setting, that is why these phase III trials are designed with oral regimens.
Other tirosine kinase inhibitors: Vandetanib and axitinib
Not a lot of trials were subsequently run with small molecules. There was a phase II trial in anthracycline and 
taxane treated patients with vandetanib  an inhibitor of VEGFR2 and HER1. Forty patients were included, 
there was manageable diarrhea, but no responses, the best result was one patient with stable disease 
during six months [90]. There are two more trials with vandetanib: vandetanib  with metronomic CT by the 
Dana Farber and a phase II in first line MBC combined with docetaxel. The results were not enthusiastic and 
the development of vandetanib in BC has been abandoned.
Axitinib  inhibits VEGFR2 and PDGFR. Phase I-II trials were reported in combination with docetaxel. The 
largest trial, randomized 168 first line MBC to docetaxel combined with axitinib  or placebo. There was no 
difference in TTP and toxicity is considerable with 10% diarrhea, fatigue, stomatitis and mucositis and 
hematological toxicity in 15% of patients. There were three serious thromboembolic events and one resulted 
in death [91]. Due to these results, the development of axitinib, as all other TKIs, except sorafenib, has been 
abandoned.
Discussion
Numerous trials have been done and some are still underway, testing the concept of blocking angiogenesis 
in BC. Several thousands of patients were treated with antiangiogenic agents in clinical trials, but their 
results have not been convincing enough for the widespread treatment of patients with advanced BC with 
antiangiogenic agents. Bevacizumab  should not be used in the treatment of MBC patients, despite continued 
regulatory approval by some agencies, including the European Medicines Agency. As for early BC, there is 
no positive adjuvant trial to back up  this treatment strategy and there is no regulatory approval. What has 
failed, why has the promise of blocking angiogenesis not held up  in BC, while it is useful in several other 
solid tumors? The urgent effort to prospectively collect biological material has not been done. There have 
been responses to these drugs, but no data has been produced to know why and in which patients. 
Prospective collection of blood and biopsies at different time points across the continuum of MBC 
progression should have been mandatory.
It might be due to the fact that BC seems to be more heterogenous than coloretal or renal cancer. But BC 
heterogeneity is not solved by the current BC subtype classification, namely, ER positive, Her2 positive and 
TNBC. As we have seen, after the meta-analysis of the bevacizumab phase III trials in MBC, the PFS 
advantage in TNBC patients has not been meaningful, and, finally, the Beatrice adjuvant trial, in TNBC, was 
a negative trial. Possibly because this is a negative definition, that brings us no closer to the driving biology 
of the disease. Alternative angiogenic pathways have not been sufficiently explored in the datasets of non 
responding patients. It should be established, in any given patient, what are the neoangiogenic molecules at 
play in that disease state, there are dozens molecules that could play such roles [92-97]. There is a report 
showing upregulation of hypoxic response mediators in BC patients resistant to sunitinib, and, several 
preclinical models similarly showing this rebound response [98]. The Kerbel lab  showed increased 
metastasis in mice models upon sunitinib withdrawal. 
If there is still opportunity to go forward with antiangiogenic therapy in BC, drugs must be studied in lab 
models to further understand the mechanism of action and resistance to different anti-angiogenic agents [99, 
100]. The hypoxic response through HIF1α inhibition in combinatorial treatment strategies with 
antiangiogenic drugs could be tested [101,102] as well as low dose metronomic chemotherapy in 
combination with antiangiogenic agents [103]. Antiangiogenic strategies have not impacted survival, and, 
they present a challenge in terms of safety issues. If there are no new results coming from specific 
subgroups or specific molecular targets or new drugs, antiangiogenic treatment in BC should be abandoned. 
We have done a poor job  at performing and demanding more thorough research in one of the hallmarks of 
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Statement of translational relevance: 
 We have witnessed the rise and fall of antiangiogenic therapy in breast cancer (BC). Nevertheless, 
clinical remissions were observed in patients and we were interested in studying the activity of 
antiangiogenic drugs in BC. Inefficacy of sunitinib  was observed in mouse models of metastatic BC, where 
evidence of enhanced metastasis was reported, and lack of efficacy of sunitinib-docetaxel combination was 
recently reported in a phase III clinical trial. Our aim was to understand the mechanisms and predictors of 
response to sunitinib  in BC in a cohort of patients with untreated locally advanced or operable BC treated 
with an upfront window of single agent sunitinib, followed by the combination of sunitinib  and docetaxel. We 
observed primary resistance to angiogenic therapy in 4 of 12 patients likely mediated by an adaptive 
transcriptional response to hypoxia in these resistant tumors. In BC patients this is the first demonstration of 
primary resistance to antiangiogenic therapy.
Abstract 
Purpose
The antiangiogenic drug sunitinib  has never been evaluated as single agent in untreated BC patients. We 
aimed to characterize the activity of sunitinib, alone and with docetaxel, in untreated locally advanced or 
operable BC and to uncover the mechanisms of response.
Experimental design
Twelve patients were treated with an upfront window of sunitinib  (50 mg/day, 14 days) followed by four 
cycles of sunitinib  (37,5mg/day, 14 days, q3wk) plus docetaxel (75mg/m2 q3wk). Response, resistance and 
toxicity were evaluated according to standard clinical parameters, magnetic resonance imaging, positron 
emission tomography, pathology characterization and gene expression profiling.
Results
We detected primary resistance to sunitinib  upfront window in untreated BC, as evidenced by four non-
responding patients. At surgery, five patients had viable disease in the breast and axilla, four had viable 
tumor cells in the breast alone and three were taken off study and thus not evaluated, due to unacceptable 
toxicity. Early functional imaging was useful in predicting response. There were no pathologic complete 
responses (pCR). Comparison of gene expression profiling tumor data  between early responders and non-
responders allowed us to identify the up-regulation of VEGF and angiogenic pathways in non responders. 
Specifically, in tumors resistant to the single-agent sunitinib  we detected a transcriptional response to 
hypoxia characterized by over-expression of several HIF1α target genes.
Conclusion
In this report of single-agent sunitinib  treatment of untreated localized BC patients, we found molecular 
evidence of primary resistance to sunitinib likely mediated by up-regulation of hypoxia responsive genes.
Introduction
 Neoadjuvant chemotherapy is standard treatment for inflammatory, locally advanced and large 
operable BC. Randomized trials comparing neoadjuvant to adjuvant chemotherapy (CT) demonstrated 
similar survival outcome for large operable lesions 1 2, 3. Neoadjuvant therapy has three advantages: 1) 10–
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20% increased rate of breast preservation, 2) in-vivo assessment of chemosensitivity and 3) early indication 
of overall survival because survival correlates with pathologic complete response (pCR) rate.
 Angiogenesis is known to play a role in BC growth and metastatic spread. In primary BC the 
expression of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor 
receptor beta (PDGFR) are associated with worse prognosis 4, 5. This led to the concept of early 
antiangiogenic therapy before the development of new cancer-induced vessels..
 Sunitinib  malate (Sutent; Pfizer, New York, NY) is an oral small molecule inhibitor of tyrosine kinases 
coupled to VEGFR, PDGFR, stem cell factor receptor and colony-stimulating factor-1 receptor. Sunitinib  is 
approved as first-line therapy of metastatic renal cancer, where it targets the constitutively activated 
angiogenic pathway, as second-line therapy after imatinib, for inoperable gastrointestinal stromal tumors 
(GIST), to inactivate the mutant c-KIT receptor and for unresectable locally advanced or metastatic 
pancreatic neuroendocrine tumors.
 In preclinical studies using the human BC MX-1 xenograft model, sunitinib  in combination with 
docetaxel, doxorubicin or fluorouracil enhanced the activity of chemotherapy and increased survival 6. In a 
phase II trial in metastatic BC, sunitinib showed activity as a single-agent in heavily pretreated patients 
(N=64; objective response rate (ORR), 11%; median time to progression (TTP), 10 weeks) 7.
 The effect of sunitinib  in combination with docetaxel in patients with human epidermal growth factor 
receptor 2 (HER2)/neu-negative metastatic BC was studied in a phase Ib  and a phase III trial 8, 9. In both 
trials, the therapeutic regimen was sunitinib  (37.5 mg/d 2 weeks starting on day 2 every 3 weeks) in 
combination with docetaxel (75 mg/m² day 1 every 3 weeks). The exploratory study (Phase Ib) gave 
encouraging results (N=22; ORR, 74%; median progression-free survival (PFS), 8.7 months). In the 
randomized phase III trial 296 patients were assigned to combination therapy and 297 patients were 
assigned to docetaxel monotherapy. Median PFS times were 8.6 and 8.3 months with combination therapy 
and monotherapy, respectively (hazard ratio, 0.92; one-sided P = .265). The ORR was significantly higher 
with the combination (55%) than with monotherapy (42%; one-sided P = .001). Duration of response (7.5 vs 
7.2 months) and overall survival (OS, 24.8 vs 25.5 months, one-sided P = .904) were similar in both arms. 
This clinical trial was negative for the primary endpoint 8, 9
 We report the results of a single center phase II neoadjuvant clinical trial where an upfront window of 
single-agent sunitinib  (50 mg/d, 14 days) was used in untreated locally advanced or operable BC patients, 
followed by a combination of sunitinib  and docetaxel, similar to the metastatic BC trials combination. To 
evaluate drug response, we used a combination of clinical, radiological, pathological, molecular and genomic 
techniques. This trial represents a unique opportunity, since it is, to our knowledge, the only one conducted 
with single agent sunitinib in non-metastatic BC. 
Patients and methods
Study design and clinical evaluation
 The trial was approved by the institutional review board, the National Ethics Committee and was 
registered under EudraCT number 2007-007257-31. 
 Patients signed an informed consent stating all aspects of the trial, including extra biopsies and breast 
surgery. This is an investigator designed trial supported by a research grant from Pfizer. The trial design 
included the administration of sunitinib in an upfront window of 14 days, followed by 4 cycles of combination 
therapy with docetaxel and sunitinib  in patients with previously untreated locally advanced or large operable 
BC. 
 Patients underwent a baseline tumor biopsy (t1, day 1), a second biopsy, after the sunitinib  upfront 
window (t2, day 15), and a final tumour evaluation at surgery (t3, day 112±2). The biopsy was performed at 
day 15, the day after the last dose of the sunitinib  upfront window, after reports 10 of noticeable reduction in 
tumour size during the treatment period and tumour regrowth during the off period. Similarly, patients 
underwent breast Gadolinium-enhanced magnetic resonance imaging (MRI) to evaluate tumour 
vascularization and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scan to evaluate BC 
cell survival at t1 (baseline) and at t2 (day 15), before the second biopsy.
 Pre-treatment evaluation included electrocardiography and left ventricular ejection fraction (LVEF) 
assessment by radionuclide angiography, thyroid function tests (fT4, fT3 and TSH) and BC staging. During 
chemotherapy, besides routine blood biochemistry, thyroid function was also evaluated. Similarly, at end of 
study (or at patient withdrawal) evaluation of LVEF and thyroid function were performed. Toxicities were 
assessed using the CTCAE v3.0 11.
Patient Eligibility
 Patients were eligible if: 1) they had histologically or cytologically proven newly diagnosed untreated 
invasive BC (independent of estrogen receptor (ER), progesterone receptor (PgR) and Human Epidermal 
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Growth Factor Receptor 2 (HER2) status); 2) a breast tumor diameter > 3 cm by caliper measurement and/or 
cN2-3 disease plus a palpable breast tumor; 3) recommendation of neoadjuvant CT by the institutional 
multidisciplinary conference. Multifocal and multicentric breast tumours were allowed as long as only two 
tumour foci were identified, since two sequential tumour samples were to be collected from each tumour 
focus. 
 Other eligibility criteria were age ≥18 years, no pregnancy or lactation, Eastern Cooperative Oncology 
Group performance status of 0, 1 or 2 and adequate liver, kidney, cardiac and hematopoietic organ function 
as defined by blood tests and cardiac examinations. 
Treatment protocol
 The treatment protocol timeline is shown in Figure 1. The initial upfront window consisted in oral 
administration of single agent sunitinib  50 mg/d for 14 days, followed by 7 days off drug. On day 22, pre-
operative docetaxel (75 mg/m² every 3 weeks for 4 cycles), combined with sunitinib (37.5 mg/day for 14 days 
starting, 7 days off) starting one day after docetaxel for 4 cycles, were given. Both treatments were stopped 
on study day 100, 11 weeks after beginning taxane preoperative chemotherapy. Two additional drug-free 
weeks were allowed before surgery. After surgery, patients were treated with four cycles of adjuvant FEC100 
CT (5-Fluouracil 500mg/m², Epirubicin 100 mg/m² and Cyclophosphamide 500 mg/m² every 3 weeks). 
Locoregional radiation therapy was administered according to institutional guidelines. Patients with hormone 
receptor positive tumors started tamoxifen or an aromatase inhibitor. Patients with Her2-positive tumors 
received trastuzumab for a year.
Clinical evaluation
 Patients were evaluated for clinical response and toxicity after upfront sunitinib and before each CT 
cycle at days 15 (t2), 22, 43, 64 and 85. Tumours were measured by caliper in two perpendicular diameters 
and the greatest diameter was considered for evaluation. A 10%-30% reduction in the greatest diameter of 
the primary tumor at 22 days was defined as minor response (MR). A clinical partial response (cPR) at t2 
was considered when the decrease in greatest diameter of the primary tumor was ≥ 30%. Progression (PD) 
was established if the primary tumor increased in size or new tumor lesions were observed. Otherwise, was 
considered stable disease (SD).
Pathology and other molecular studies
Evaluation of tumor biopsies and surgical specimen evaluation were performed by an investigator blinded to 
clinical data (S.A.). Three biological samples from each patient (t1, t2 and t3) were studied by histopathology. 
Surgical samples (t3) were evaluated according to ypTNM. Tumor samples were classified according to 
standard pathology criteria for histological subtype, grade of differentiation, Ki67 staining, hormonal receptor 
expression and HER2 expression and/or amplification. Primary antibodies: anti-Ki67 (clone MIB-1; Dako cat. 
7240, 1:300), estrogen receptor (clone SPI; Ventana Roche cat. 790-4324), progesterone receptor (clone 
1E2; Ventana Roche cat. 790-2223) and HER2 expression and/or amplification was evaluated by pathway 
HER-2/neu (clone 4B5; Ventana Roche cat. 780-001) in Ventana BENCHAMRK ULTRA instrument.
Sample collection for molecular studies
Tumor tissue was obtained by image guided biopsy prior to treatment (t1), after 14 days of sunitinib  (t2), and 
from the definitive surgical specimen (t3). Tissue was flash-frozen in liquid nitrogen and stored at −80°C. 
Hematoxylin and eosin stained sections of formalin-fixed paraffin embedded specimen were used to 
evaluate histological characteristics.
 Total RNA was extracted from frozen material with RNeasy Mini Kit with RNase-Free DNase Set “on 
column” DNA digestion (Qiagen), according to manufacturerʼs instructions. RNA concentration was 
determined on a RNA quantity and quality was respectively examined with a Nano Drop  ND-1000 UV-Vis 
Spectrophotometer (Nano- Drop Technologies) and a RNA 6000 Nano Assay Kit (Agilent Technologies) in a 
Bioanalyser 2100 (Agilent Technologies). Only high-quality total RNA samples with a 260/280 ratio > 1.8 and 
containing at least 100 ng were further processed.
Expression profiling
 Sample labeling and GeneChip processing was performed at the Affymetrix Core Facility 144 (Instituto 
Gulbenkian de Ciência, Oeiras, Portugal; http://www.igc.gulbenkian.pt/node/view/131). Total RNA (100 ng) 
was used to generate cDNA with the Ambion WT Expression Kit for Affymetrix GeneChip  Whole Transcript 
WT Expression Arrays 12, (Applied Biosystems, Carlsbad, CA). Biotin labeled cRNAs, produced with the 
Affymetrix GeneChip  WT Terminal Labeling kit according to Hybridization User Manual 13 were hybridized to 
Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA). Liquid handling steps were performed with 
GeneChip Fluidics Station 450 and arrays scanned with GeneChip Scanner 3000 7G (Affymetrix, Santa 




 Data analysis was performed with R Statistical Computing software complemented with Bioconductor 
packages. Microarrays pre-processed using aroma.affymetrix v2.4.0 package (http://aroma-project.org/). 
Heatmaps were plotted using "gplots" 15. 
 Differential expression analysis was obtained with limma package 16 for comparison 1, diagnosis (t1) 
versus single agent sunitinib  (t2) collected samples; comparison 2, non responding versus responding t2 
tumor samples and comparison 3, t2 versus surgery (t3) collected samples. Selection of differentially 
expressed genes (DEGs) were based on limma output parameters LODS >0 (log-odds) and log2-ratio ≥ 
+0.58 or ≤ 0.58. 
 Gene set enrichment analysis (GSEA) of GO  biological processes (GO-BP) among filtered DEGs was 
done with GSEA tools from InnateDB (http://www.innatedb.ca/).
DCE-MRI
 Two MRIs were performed, at days 1 and 15, on a 1.5 T system (Siemens, Medical Solutions, USA, 
IC) using a double-breast surface coil. The protocol corresponds to a 3D gradient-echo, dynamic imaging 
before and after intravenous contrast administration (gadolinium dimeglumine pentatate) and after a 
subtraction technique. Regions of interest (ROIs) were drawn around tumour areas. Wash in and wash out in 
the same point of the tumour was measured to quantify vascular permeability. Tumors were measured in 
their two longest perpendicular axes and were reassessed at day 15 reported using RECIST 11.
FDG-PET
 Two FDG-PET examinations were performed, on days 1 and 15. Imaging was performed on an ECAT-
ACCEL-LSO PET (Siemens, Medical Solutions, USA, IC) one hour after iv injection of 370 MBq 18F-
fluorodeoxyglucose. The PET Scan is equipped with a lutetium oxyorthosilicate crystal (64 crystals/block), 
with an axial extent of 162 mm and a spatial resolution of 6 mm at 1 cm. Standardized Uptake Value (SUV) 
measurement of glucose metabolism was analyzed. Response was defined as a reduction of 20% or more 
(maximum values of SUV) in all lesions present in the baseline timepoint (t1).
Results
Patient and tumor characteristics
 Patients and tumor characteristics are summarized in Table 1. Twelve women (aged 33 to 60 years 
with a median 42.5 years) were included; all but one (african) were caucasians. All tumors were diagnosed 
by self examination. All tumors measured more than 5 cm (≥T3) and four of them were T4 tumors. Four 
candidates had inoperable lesions, the remaining were candidates for mastectomy at presentation.
Toxicity
 The therapeutic regimen used in this trial was considerably toxic. Every patient in the trial 
experienced at least one grade 2 adverse event (Supplementary table S1). 
 During the upfront window of single agent sunitinib  the most frequent toxicities were asthenia (10 
patients, grade 2 in two) and disgeusia (9 patients). There were no grade 3 ou 4 toxicities during the upfront 
window.
 During the administration of sunitinib  and docetaxel there were nine episodes of grade 3 adverse 
events, with 75% of the patients experiencing at least one grade 3 toxic event. The most frequent grade 3 
adverse events were asthenia (two events), hypersensitivity reactions (two events) and gastrointestinal 
toxicity (three events: two mucositis and one diarrhea). Two patients were admitted for grade 3 mucositis 
with dehydration and hypotension. 
 Three patients were taken off study during combined treatment; one per patient request (patient 
number 2), and two due to serious adverse events (patients number 11 and 12). Patient number 2 withdrew 
consent before the second docetaxel cycle (at cycle 1 day 21), due to grade 3 asthenia. Patients 11 and 12 
presented in the same day with grade III anaphylactic reactions during the second administration of 
docetaxel. Both had received premedication with prednisolone 50 mg po in the evening prior and in the 
morning of treatment and dexametasone 20 mg iv just before docetaxel. No other unexpected 
hypersensitivity reactions in other patients treated with docetaxel the same day or with the same batch in 
other days were reported. These patients were withdrawn from the trial and further treated outside protocol. 
The funder, Pfizer, was informed of the anaphylactic events with the request for further information on similar 
events reported in the, at the time, ongoing phase III study (with a docetaxel-sunitinib  arm). Pfizer 
recommended temporary closure of recruitment to the trial, which became definitive based on the efficacy 




 The clinical assessment after upfront 14 days course of sunitinib  treatment is shown in Table 1, 
Figure 2 and Supplementary S2. Eight tumors regressed after the short course of single agent sunitinib (1 
cPR, 7 MR). The largest tumor size decreased 1 cm in three patients, 2 cm in three patients, 3 cm in one 
patient and 4 cm in one patient. Four tumors remained unchanged and no cases of disease progression 
were observed. The median decrease in largest diameter was 20% (range, 0%-60%). In the five patients 
with clinically detectable axillary nodes, the largest diameter reduced more than 30% (cPR) in two patients 
and in three remained unchanged.
 The three patients that were taken off protocol could not be assessed for response at surgery. 
However they were assessed for response at study withdrawal and all had evidence of reduction in tumor 
size. The patient that withdrew consent after the first cycle of docetaxel-sunitinib  had a MR and the other two 
had cPR at withdrawal which was after the third cycle of chemotherapy.
 In the evaluation performed before surgery, the remaining nine patients that completed the study 
protocol, all had clinical evidence of response. Four patients had no palpable tumor in the breast or axilla 
(cCR) and five had cPR.
DCE-MRI assessment
 The evaluation of breast tumor size by MRI after single agent sunitinib  (t1 versus t2) showed 
reduction of the breast tumor lesion in all but one patient, as shown in figure 2B. However, the reductions in 
size were all within the one cm range except for one patient with a 3.5 cm reduction in the largest tumor 
diameter.
FDG-PET assessment
 In the initial PET scan all patients had primary breast tumor 18F-FDG  uptake, ten patients had 
axillary uptake and four patients had thoracic uptake. The later was either in internal mammary nodes or 
mediastinal nodes, with an SUV ranging from 1.8 to 3.4. The protocol response criteria of at least 20% 
decrease in SUV uptake in all lesions was documented in five patients alone (patients number 3, 4, 9, 10 
and 11). Graphical changes in SUV are shown in Figure 2C and D and Supplementary Table 2. 
Overall assessment at 15 days (t2)
 Activity of single agent sunitinib was defined as a clinical decrease of ≥1 cm in tumor largest 
diameter size and either a decrease in tumor size by MRI or a decrease in ≥ 20% metabolic activity with 
PET. Using such criteria there were eight responders (patients 1, 3, 4, 6, 9, 10, 11 and 12) and four non-
responders (patients 2, 5, 7 and 8). These last four patients were considered to have primary resistance to 
sunitinib.
Surgical assessment and follow-up
 All evaluable patients underwent local treatment by surgery, six with breast conservation and three 
with mastectomy. Axillary dissection was performed in all patients. The three patients that were treated off 
protocol (during sunitinib  docetaxel combination therapy) eventually underwent mastectomy. All patients 
enrolled in this trial are followed at the recruitment institution according to guidelines. Patients are currently 
alive without evidence of BC or major toxicity, with a median follow-up of four years.
Pathology
 All BCs were invasive carcinomas of no special type (NST), intermediate or high grade; five were 
HER2-positive (three were also ER positive), five ER-positive HER2-negative and two were triple negative. 
There was one inflammatory BC.
 All nine patients underwent breast surgery. Only two patients had residual tumor cells in the breast. 
One had a 22 mm lesion (patient 4) and another a 12 mm lesion with less than 10% viable cells (patient 6), 
respectively. Seven patients had involved axillary lymph nodes in the axillary dissection specimen, these 
were scored at t3 as non responders.
 Serial scoring of nuclear Ki67 staining is shown in Figure 3. In the initial biopsy, at diagnosis (t1), 
eight tumors had more than 35% Ki67 positive tumor cells (“Ki67 high”  tumors); the other four had Ki67 
staining below 4% (“Ki67 low” tumors). In all patients but one, Ki67 staining decreased at day 15 (t2), after 
single agent sunitinib. In six of the eight “Ki67-high” tumors, Ki67 expression decreased by ≥ 40%. Patient 5, 
a non reponder, increased from 60 to 90% Ki67 positivity. At surgery, all tumors further decreased Ki67 
nuclear staining with all but one tumor with Ki67 staining < 10%.
Gene expression
 Expression profiling on tumor material collected at the three timepoints was used to obtain an 
unbiased view of sunitinib  response. Several tumor biopsies and specimens had no frozen sample available 
or RNA with insufficient quality for expression analysis. Were include in the analysis, at diagnosis (t1), 
replicated material from patients 4, 5, 6, 7 and 11 (patient 10 had no replica), at day 15 (t2) replicated 
material from patients 5, 7, 11 and 12 (patient 4 had no replica) and at surgery (t3) replicated material from 
patients 7, 9, 10, 11 and 12 (patient 6 had no replica).
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 We performed differential expression analysis between t1 and t2 samples, between “responders” 
and “non-responders” to single agent sunitinib  (t2 samples) and before and after combination treatment  (t2 
versus t3 samples).
 Between t1 and t2, after 14 days of treatment with single agent sunitinib, DEGA results highlighted 
85 significant DEGs (Figure 4) - 59 genes with lower expression and 26 genes  with increased expression 
(Figure 4A). Among the downregulated genes, we have found TIMP3 (tissue inhibitor of metalloproteinase 
3), the metalloproteinase ADAMSTS12, DLL4 (delta-like 4), a component of the Notch pathway, that is 
known to be affected by antiangiogenic drugs 17 and FLT1 (vascular endothelial growth factor receptor 1), 
one of the transmembrane receptors coupled to a tirosine kinase and a target of sunitinib18. The 
overexpressed set of genes contained mainly immunoglobulins and inflammatory mediators.
 Interestingly, gene set enrichment analysis (GSEA) with GO biological processes (GOBP) using the 
set of underexpressed genes, revealed among the top 20 GOBP significant categories the negative 
regulation of blood vessel endothelial cell migration, cellular response to bone morphogenic protein stimulus, 
regulation of notch signaling pathway, positive regulation of mitogen activated protein (MAP) kinase activity 
previously 17 associated with anti angiogenic treatment (Figure 4B). Also significant among selected GOBP 
were processes that can be linked directly to manipulation of vascularization such as angiogenesis, 
regulation of vascular endothelial growth factor receptor signaling pathway, cell adhesion, notch signaling 
pathway and negative regulation of epidermal growth factor-activated receptor activity (Figure 4B). Among 
the processes enriched in the set of overexpressed genes we observed several GOBP mainly linked to 
immunological pathways and inflammatory processes (Figure 4B).
 The most relevant expression analysis is the comparison between responding (patients 4, 11 and 
12) and non-responding tumors (patients 5 and 7) to sunitinib  (t2). In total, 147 genes were selected by the 
statistical significance cutoff, of which 110 genes lowered expression and 37 genes increased expression 
(Figure 5A). GSEA highlighted the energy metabolism as top  GOBP categories among upregulated genes 
(Figure 5B). Overexpression of the glycolytic enzymes (ENO2, enolase 2; GPI, glucose 6 phophate 
isomerase, and HK2, hexokinase 2) and the glucose transporter 1 gene (SLC2A1) which are indicative of a 
shift towards anaerobic metabolism in the tumours resistant to the anti-angiogenic drug. In such tumors, the 
upregulation of VEGF and IL8 is also indicative of rebound angiogenic signaling. We also detected an 
increased expression of the anti adhesive transmembrane protein podocalyxin-like 1 (PODXL), a known 
independent predictor of worse outcome in breast cancer 19. 
 The t2 versus t3 comparison (response to combined sunitinib-docetaxel therapy), had more 
pronounced effects in terms of DEGs. In total 1569 genes significantly changed their expression, with 337 
and 1232 genes being respectively less and more transcribed (Figure 6A). We observed a profound 
downregulation in genes and GOBPs induced by CT, similar to prior reports in BC literature20 namely a 
profound downregulation of proliferation, cell division and mitosis (Figure 6B). Upregulation of genes and 
associated GOBPs related with cell adhesion, angiogenesis and wound healing (Figure 6B) were observed.
Discussion
 Neoadjuvant chemotherapy is the ideal clinical experiment to test new systemic treatments. This is, 
to the best of our knowledge, the first neoadjuvant trial of sunitinib  in BC. The upfront window of 14 days of 
sunitinib  provides the only existing data of administration of sunitinib  as a single-agent in newly-diagnosed 
untreated BC. Unfortunately, due to premature study closure only a limited number of paired tumor samples 
were available for several analyses (e.g. gene expression). The closure of the clinical research program of 
sunitinib  in BC means that the herein presented data is a unique opportunity to understand resistance 
mechanisms to sunitinib in BC.
 The patients enrolled in the trial are young women with advanced stage non-metastatic BC with 
tumors larger than 5 cm, reflecting the institution recruitment profile (table 1). The treatment was toxic with 8 
of 12 patients experiencing grade 3 toxicity events (Supplementary Table S1). We were particularly struck by 
the severe hypersensitivity reactions to docetaxel administration which we postulate may be exacerbated by 
sunitinib  co-treatment, although not reported in the phase III metastatic breast cancer trial 8. Regarding the 
constitutional, gastroenterological and hematological toxicity, while reported with both single agent docetaxel 
and sunitinib, they likely represent an additive toxicity effect.
 The clinical evaluation performed at t2 showed the expected results when compared to other trials 
evaluating targeted agents with a short therapeutic course in untreated locally advanced BC 21. It has been 
postulated that anti-angiogenic agents such as sunitinib might be more efficacious in early stage disease, 
which is likely more dependent on neo-vessel formation, compared to advanced stage disease. In the phase 
III metastatic BC trial by Bergh et al. the reported ORR was 52% 8. In our trial all patients had some evidence 
of tumor shrinkage, there were only 4 cPR out of 9 evaluable patients and no pathological complete 
response (pCR) were observed. However, all patients had BC over 5 cm in diameter. This may also explain 
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the contrast with the reported 20 to 30% pCR in trials of more prolonged neoadjuvant anthracycline-taxane 
combination chemotherapy 1, 22-24.
 A decrease in Ki67 tumor cell nuclear staining, a marker of cell proliferation, is an established early 
predictor of response to neoadjuvant systemic therapy 25, 26. Indeed, the only patient (P 5) with an increase in 
Ki67 staining at t2 (Figure 3) was a “non responder”. At time t2, MRI results (Figure 2B) do not add 
information to the clinical assessment while PET (Figure 2C and D) identified two early “non- 
responders” (P2 and P5) by increased axillary uptake.
 The gene expression results suggest potential mechanisms involved in BC sunitinib  activity. The 
downregulated genes in the sunitinib  upfront window are representative of the biological processes 
anticipated to be affected by tirosine kinase inhibition with sunitinib  - angiogenesis, endothelial cell migration, 
negative regulation of blood vessels, Notch pathway and MAP kinase activity - which have been described in 
similar clinical experimental contexts 18. The t2 comparison between responders and non responders to 
single agent sunitinib, although limited by a small number of samples, suggests that resistance may be 
related to an hypoxia generated transcriptional response. Thus the hypoxia responsive elements: the 
glycolytic enzymes, pointing to a shift to anaerobic metabolism and the glucose transporter that enables 
glucose to enter cells as well as to VEGF. It has been shown that 1 to 1.5% of the genome is transcriptionally 
responsive to hypoxia 27. In a large meta-analysis of BC, the hypoxia metagene could be replaced by three 
genes: (hypoxia inducing factor 1 alpha HIF1α, glucose transporter type 1 GLUT1 and vascular endothelial 
growth factor VEGF), considered most informative 28. Two of these genes are overexpressed in sunitinib-
resistant tumors: the glucose transporter (GLUT1) and VEGF. Regarding other genes, not previously linked 
to hypoxia, podocalyxin and IL8 merit attention. Podocalyxin (PODXL), previously associated with worse 
prognosis in breast cancer is an anti-adhesion molecule 19. Low oxygen tension stimulates angiogenesis 
which requires tissue remodeling that could provide a link between this molecule and angiogenesis. As 
reported in renal cell carcinoma cell lines 18, upregulation of IL8 may be one of the mechanisms of resistance 
to sunitinib. IL8 enhances chemotaxis and infiltration or activation of resident inflammatory cells which has 
been associated with anti angiogenic therapy resistance 18. In mice xenografts of lung cancer, circulating 
bone marrow-derived cells are massively recruited to tumor beds after angiogenic treatments due to vessel 
disruption and hypoxia 29. In patients with glioblastoma multiforme that progressed after an anti angiogenic 
drug, the serum levels of inflammatory mediators and circulating endothelial cells (CEC), precursors of new 
vessels, are increased 30. A similar increase in CECs has been reported in patients with renal cell cancer 
progressing on sunitinib 31.
 Lastly, when the effect of the combination of sunitinib  and docetaxel, was studied (t2 vs. t3), we 
found similar effect on gene expression and cellular pathways to those reported by Lindstrom et al. 20: 
downregulation of cell division and upregulation of angiogenesis and survival pathways. Rebound 
angiogenesis through alternative pathways has been reported 32, albeit not in BC, upon anti-angiogenic 
treatment. Since one would not expect nor has it been reported, angiogenic stimulation induced by taxane 
chemotherapy treatment 33 may be a consequence of sunitinib.
 We found evidence, in some patients, of primary resistance of BC to the sunitinib  upfront window. 
After the first two weeks, docetaxel was added to sunitinib. Nevertheless, the combination was less 
efficacious than might be expected, possibly because docetaxel was administered at 75mg/m2, instead of 
100mg/m2. 
 The lower efficacy is concordant with the Phase III data 8. In mouse models, Kerbel and 
collaborators, were able to demonstrate, in several BC settings, resistance and increased metastasis in 
sunitinib  treated animals 34, 35. However, with a median follow-up  of four years, we have no evidence of this in 
our patients, possibly because patients were treated with taxanes and anthracyclines, either before or after 
surgery. 
 While this series supports the inefficacy of sunitinib  in BC, it has the novelty of including treatment-
naive patients and suggesting a mechanism of resistance. BC resistance to sunitinib  can be shown upon two 
weeks of administration in untreated patients, this suggests a rapid adaptation  with an impact on gene 
expression. We found evidence that the mechanisms of resistance to sunitinib  include transcription of 
glycolytic enzymes, a glucose transporter, and VEGF production, which are known transcriptomic 
adaptations to the hypoxic environment, here created by sunitinib. This trial was prematurely closed, 
nevertheless, several hypotheses can be generated by this work. Is the shift to the glycolytic phenotype, the 
hypoxic adaptation generated by sunitinib, a harbinger of non response to other drugs, namely to 
chemotherapy, or will combination treatment overcome the deleterious selection pressure? Would these 
alterations translate into unfavorable prognoses if sunitinib  therapy was given as a single drug and for longer 
periods, similar to Kerbelʼs mouse model? Is our finding of adaptation to hypoxia be the mechanism by which 
the sunitinib  treated mice develop  resistance and increase metastasis34, 35? This hypothesis was tested in-
vitro using a combination of bevacizumab and topotecan, an hypoxia inducing factor 1 alpha (HIF1α) 
inhibitor, and is the rationale for the treatment with bevacizumab plus irinotecan in recurrent high grade 
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glioma, leading to a 70% parcial and 15% complete radiological response36-40. These data provide 
encouragement that, also in BC, the combination of antiangiogenic therapy with antihypoxic drugs may 
synergize in cancer treatment.
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Table 1 - Braga S. et al.
Table 1. Patient and tumor characteristics at evaluated timepoints.
For the distinct timepoints, samples with available RNA for gene expression are represented in bold whereas 
samples without enough RNA due to distinct reasons are represented in italic. Samples without enough 
RNA for replicated measurements are marked with (*). (1) identifies surgical specimens (t3) from patients 
that withdrew from study. 
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 
receptor 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
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Figure 1 - Braga S. et al.
Figure 1. Timeline scheme of sunitinib  and docetaxel administration, tumor collection and evaluation are 
represented in days. Cycles of sunitinib  administration (14 days) are highlighted in white characters, with the 
window of single agent sunitinib  in intermediate grey and off treatment periods (7 days) represented in white. 
The four cycles of docetaxel administration (days 22, 43, 64 and 85) correspond to the dark grey. Timepoints 
of tumor collection and evaluation by physical examination, MRI and PET (t1, t2 and t3) are represented with 
black arrows. Breast cancer surgery was performed on t3 (day 112 ±2 days).
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Figure 2 - Braga S. et al.
Figure 2. Evaluation of response to single-agent upfront Sunitinib, by comparison of measurements 
performed at diagnosis (Pre, day 1) and after Sunitinib  treatment (Post, day 15), by measuring the greatest 
diameter of the primary lesion on physical examination (A, caliper measurement) and by breast MRI (B). The 
largest lesion was assessed when multicentric tumors were examined. Standardized Uptake Value (SUV) of 
glucose on PET was used to assess the metabolic response changes in the primary lesions (C) and 
homolateral axillary lymph nodes (D). Individual patients  are identified by distinct lines and colors as 
indicated on the legend (lower right, panel D).
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Figure 3 - Braga S. et al.
Figure 3. KI67 antigen nuclear staining in each sample was quantified by immunohistochemistry at 
diagnosis (t1, pre-sunitinib  cycles), after the first cycle of single-agent sunitinib  (t2, post-sunitinib) and after 4 
cycles of docetaxel-sunitinib  (t3, day 112 ±2 days, surgery). Individual patients are identified by distinct lines 
and colors as indicated on the legend at the right.
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Figure 4 - Braga S. et al.
Figure 4. (A) Differentially expressed genes (85 genes) between samples t1 (diagnosis) and t2 (single 
agent-sunitinib) correctly assigned samples from patientsʼ  distinct timepoints (outlier sample P4_2) by two 
dimensional hierarchical clustering. Identical sample labels represent replicated samples. (B) The same 
gene set was also used to detect top functional categories enriched in the breast cancer after single agent 
neoadjuvant sunitinib  here illustrated with the top  20 GO Biological pathways associated with up  and down-
regulated genes (red and blue bar plots, respectively). When no gene symbols were not available, were 
replaced by transcript cluster IDs.
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Figure 5 - Braga S. et al.
Figure 5. (A) Response outcome to single agent neoadjuvant sunitinib  was assessed at molecular level by 
gene expression profiling for patients P5 and P7 (non-responders) and for P4, P11 and P12 (responders). 
The 147 selected differentially expressed unique genes correctly segregate responders from non-
responders. Identical sample labels represent replicated samples. (B) Gene set enrichment analysis of 
response-associated genes highlighted GO Biological pathways enriched among up  (red bar plot) and down-
regulated (blue bar plot) genes of which the top  20 GO categories are illustrated. When no gene symbols 
were available, these were replaced by transcript cluster IDs
.
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Figure 6 - Braga S. et al.
Figure 6. (A) Differential expression analysis between t2 (after single agent sunitinib) and t3 (surgery) 
allowed us to select the 1569 most significant genes whose expression changed with sunitinib/docetaxel 
combination treatment as illustrated by two dimensional hierarchical clustering. Identical sample labels 
represent replicated samples. (B) The functional context of this large set of genes significantly enriched GO 
Biological Pathways of which the top  20 categories are illustrated. Categories associated with up  and down-
regulated genes are represented in red and blue bar plots, respectively. 
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Supplementary Materials 
Supplementary Table S1 – Braga S. et al.
Table S1 – Adverse events according to NCI Common Terminology Criteria v3.0 grading.
(1) One patient withdrew consent due to event;
(2) Patient enrollment was stopped after these two anaphylactic events;
(3) Both patients had mucositis accompanied with dehydration, hypotension leading to hospital admission;
(4) An isolated asymptomatic episode in an otherwise well controlled diabetic patient.
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Supplementary Table S2 – Braga S. et al.
Table S2 – Overview of response outcome scoring at distinct timepoints.
The values are for absolute differences in cm of breast tumor size for clinical and MRI assessment and in 
SUV uptake for PET. Patients are scored as responders at t2 if they responded clinically and by either MRI 
o r P E T. C o l u m n t 3 s h o w s t h e n u m b e r o f i n v o l v e d a x i l l a r y n o d e s a t s u r g e r y.
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Background: There is concern that terminally ill cancer patients are over treated with
chemotherapy, even when such treatment is unlikely to palliate symptoms. The study objective
was to evaluate the use of chemotherapy in the last three months of life in a cohort of adult
patients with advanced solid tumours.
Methods: All adult patients with solid tumours who died in our hospital in 2003 and received
chemotherapy for advanced cancer, were included. Detailed data concerning chemotherapy and
toxicity, in the last three months of life, were collected from patients’ clinical charts.
Results: A total of 319 patients were included. Median age was 61 years. Median time from
diagnosis of metastatic disease to death was 11 months. The proportion of patients who received
chemotherapy in the last three months of life was 66% (n ! 211), in the last month 37% and in
the last two weeks 21%. Among patients who received chemotherapy in the last three months of
life, 50% started a new chemotherapy regimen in this period and 14% in the last month. There
was an increased probability of receiving chemotherapy in the last three months of life in
younger patients and in patients with breast, ovarian and pancreatic carcinomas.
Conclusion: There was a large proportion of patients who received chemotherapy in the last
three months of life, including initiation of a new regimen within the last 30 days. Thus, further
study is needed to evaluate if such aggressive attitude results in better palliation of symptoms at
the end of life.
Copyright # 2007 John Wiley & Sons, Ltd.
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Background
There is growing concern that the treatment of
patients with advanced cancer is becoming increas-
ingly aggressive near the end-of-life but there are
few published data on this topic [1,2]. One of the
reasons is the di!culty in designing, implementing,
conducting and analyzing studies in these termin-
ally ill patients [3]. While we acknowledge the
necessity of symptom and quality of life evaluation
in clinical practice, we are confronted with the
shortcomings of these endpoints when used in
research [4,5].
The possible aggressiveness of cancer care near
the end of life is mostly documented by an
increasing use of palliative chemotherapy [1].
Earle et al. analyzed the administration of systemic
chemotherapy in terminally ill patients over a four
year period, from 1993 to 1996, and concluded that
there was increasing propensity to use aggressive
interventions over time, although the absolute
change from one year to the next were small.
While the use of palliative chemotherapy in this
setting has limited impact on survival, clinical trials
have shown that better quality of life and palliation
of symptoms can be achieved in the treatment of
the most frequent solid tumours of adults [4–14].
Prescription of palliative chemotherapy represents
a very delicate equilibrium between toxicity and
potential clinical benefit that is even more complex
when treating patients with a short life expectancy,
therefore there should be a clear definition of
treatment goals. Simultaneously, the importance of
high quality of end-of-life care, including symptom
control, end-of-life decision making, choice of
place of death, need for psychological and social
support is increasingly valued by health care
providers.
Other indicators of aggressiveness of care in
patients with advanced cancer include the number
and frequency of emergency room visits, hospital
and intensive care unit admissions and treatment
with surgery or radiotherapy [2,15–20]. These may
reflect the expansion of therapeutic possibilities for
patients with advanced cancer and there are data
suggesting that terminally ill patients are frequent
users of health care system resources, irrespective
of treatment modalities [3,21]. There is striking
regional and national variation in such use reflect-
ing cultural di"erences, including the acceptance of
death, and di"erence in health care systems [22–24].
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This study’s objective was to measure indicators
of potential aggressiveness of end-of-life care in a
cohort of adult patients with advanced solid
tumours. It is a retrospective single institution
study on the administration of chemotherapy and
other potential indicators of aggressive care in the
last three months of life.
Patients and Methods
Eligibility criteria
All adult patients with solid tumours that were
treated in the medical oncology department of our
institution with palliative systemic chemotherapy,
that is systemic chemotherapy for non-curable
locally advanced or metastatic cancer and had died
in 2003 were included. Primary central nervous
system tumours were not included.
In an attempt to quantify the proportion of
patients with advanced solid tumours that were
treated with systemic chemotherapy in the medical
oncology department, we also collected data on
cancer diagnosis in all patients treated in the cancer
centre who died in 2003. This review was con-
ducted with the approval of the institutional ethics
committee.
Collected data
Demographic data included sex, age and residence.
Cancer-related data included date of diagnosis and
death, cancer diagnosis and date of documentation
of advanced/metastatic disease. Regarding admin-
istration of chemotherapy, data were collected on
its use in the treatment of advanced disease and
during the last three months of life. Due to
incomplete documentation in patients’ clinical
charts, data were not collected on the purpose of
chemotherapy administration.
For those patients that were treated with
chemotherapy in the last three months of life
further data were collected on potential indicators
of aggressiveness of treatment. These included: (i)
the number of chemotherapy regimens as treatment
for advanced disease, with date of initiation and
ending; (ii) the number of emergency room visits
and hospital admissions for all causes in the last
three months of life, with identification of toxicity
related events; (iii) treatment with surgery or
radiation therapy in the last three months of life
with identification of its purpose, date and
hospitalization requirements. The duration of a
chemotherapy regimen was defined as the time
between the first and the last day of administration
of the drug(s) that were part of each regimen.
Data source
Data were collected through the institutional
database and from patient clinical charts. Popula-
tion-based death certificates were used to comple-
ment clinical chart data, assuring that no deaths
were missed, although only rarely are patients
referred from our cancer centre to other institu-
tions for end-of-life care.
Statistical Methods
Median and ranges were used as descriptive
statistics. Chi-square statistic was used to compare
categorical data. Logistic regression analysis was
used to test the association between administration
of palliative chemotherapy and patient or cancer
related characteristics. The statistical software
Stata 6.0 was used.
Results
Demographic data
Three hundred and nineteen adult patients with
solid tumours other than primary central nervous
system tumours (195 women and 124 men) who
died in 2003 were treated in the medical oncology
department with palliative chemotherapy. The
median age was 61 (range 21–92). Their place of
residence was less than 30 km away from the
hospital in 67% and more than 30 km in 33%.
The total number of patients treated in the cancer
centre who died in 2003 was 639.
Cancer-related data
For the 319 patients treated with palliative
chemotherapy who died in 2003, the median
survival from the time of documentation of
metastatic disease was 11 months (range 18 days
to 15 years). The most frequent diagnoses for such
population were breast (31.7%), gynaecological
(14.7%), lung (11.9%) and head and neck cancers
(9.7%) (Table 1).
A total of 639 adult patients with solid tumours
treated in the cancer centre died in the year of 2003.
Not all of them were cared for in the medical
oncology department. The proportion of such
patients who were primarily treated with palliative
systemic chemotherapy in the medical oncology
department were 86% for breast cancer, 82% for
melanoma, 53% for gynaecological cancer and
for lung cancer, 44% for colorectal cancer, 48% for
sarcomas and 50% for pancreatic cancer (Table 2).
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Indicators of potential aggressiveness of
treatment
Indicators were developed empirically to identify
clinical interventions, which could be considered
inappropriately aggressive for the treatment of
patients with advanced cancer in the last three
months of life. Such indicators were the adminis-
tration of chemotherapy in the last three months of
life, number of emergency room visits and hospital
admissions, including to the intensive care unit,
and treatment with surgery and radiation therapy.
Administration of chemotherapy
Two hundred and eleven of the 319 patients treated
with palliative systemic chemotherapy (66%) re-
ceived chemotherapy in the last three months of
life. Of these 211 patients, 120 (37%) were treated
with chemotherapy in the last month of life and 68
in the last two weeks (21%). One hundred and fifty
nine of the 211 patients (75%) were treated with
only one chemotherapy regimen in the last three
months of life, 48 patients (23%) with two
chemotherapy regimens and four patients (2%)
with a total of three regimens. The median number
of days between the last administration of
chemotherapy and patient death was 27 (range
0–90). The median duration of administration of
the last chemotherapy regimen was 31 days (range
0–319).
A new chemotherapy regimen was started in the
last three months of life in 106 patients (50.2%). In
the remaining 105 patients who received che-
motherapy in the last three months of life, the
chemotherapy regimen had been started earlier.
A new chemotherapy regimen was started in the
last month of life in 30 patients (14.2%). Of these
30 patients, 28 (93%) were treated with palliative
chemotherapy for the first time.
In 67 patients the first chemotherapy regimen for
treatment of advanced disease was initiated during
the last three months of life and in 28 patients in
the last month of life. The diagnoses for the 67
patients are shown in Table 3. The most frequent
primary tumor was breast cancer. Of these 67
patients, 10 of them received a second line of
chemotherapy (three patients with breast cancers,
two with cervical cancer and with sarcoma and one
each with ovarian cancer, non-small cell lung
cancer and colorectal cancer). A patient with an
alveolar rhabdomyossarcoma started palliative
chemotherapy in the last three months of life and
received three lines of treatment.
The cancer diagnoses of the 28 patients who were
treated for the first time with palliative systemic
chemotherapy in the last month of life was breast
cancer (9), head and neck cancer (4), lung cancer
(4), cervical cancer (3), colorectal cancer (2),
pancreatic cancer (2), stomach cancer (2), ovarian
cancer (1) and epitheliod sarcoma (1).
There was an association between the adminis-
tration of palliative systemic chemotherapy in the
last three months of life and decreasing patient age
(OR! 0.96, for each additional year of life; 95%
confidence interval 0.94–0.98) and diagnosis of
breast, ovarian or pancreatic cancer (OR! 3.3,
Table 2. Proportion of patients who received palliative chemotherapy
Diagnosis Number of patients treated with chemo therapy Total number of patientsa Proportion
Breast 101 118 0.86
Gynaecological 47 88 0.53
Lung 38 71 0.53
Head and Neck (H&N) 31 119 0.26
Colorectal 27 62 0.44
Oesophagus and Stomach 24 76 0.32
Melanoma 14 17 0.82
Urinary tract 13 33 0.39
Sarcoma 10 21 0.48
Pâncreas 8 16 0.5
Other 6 18 0.3
All 319 639 0.5
Number of patients who received palliative chemotherapy and overall number of patients who died in the same year with the same diagnosis in the cancer centre.a The
determination of overall cancer centre death data were obtained from patient medical records only, without supplementation with death certificate data.
Table 1. Cancer diagnoses of the overall population




Head and Neck (H & N) 31 9.7
Colorectal 27 8.5
Oesophagus and stomach 24 7.5
Melanoma 14 4.4





Cancer diagnoses of all 319 adult patients with solid tumours, other than primary
CNS tumours, who died in 2003 and had received palliative chemotherapy.
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95% confidence interval 2.0–5.5) but no relation-
ship with duration of metastatic disease or distance
between cancer centre and area of residence.
Emergency room visits and hospital admissions
Eighty percent of patients (169/211) had at least
one emergency room visit in the last three months
of life and the median number of visits during this
period was 2 (range 1–10). Fifty patients had 67
emergency room visits (15% of all emergency room
visits) due to treatment-related toxicity}32 for
haematological toxicity and 35 for non-haemato-
logical toxicity.
Ninety-six percent of patients (201/211) had at
least one hospital admission in the last three
months of life and the median number of days
spent in the hospital was 16 (range 2–90). Thirty-
four patients had 40 hospital admissions (16% of
the total number of admissions) due to treatment-
related toxicity}29 for haematological toxicity
and 11 for non-haematological toxicity. These
hospital admissions resulted in 12 toxic deaths, all
from neutropenia with sepsis. The median duration
of hospital admissions due to treatment related
toxicity was 7 days (range 2–31).
Five patients were admitted to the intensive care
unit in the last three months of life. None were
discharged from the hospital alive. Two patients
were admitted in the post-operative period, and
one each with aspiration pneumonia, cancer-
related hemorrhagic shock and treatment-related
septic shock.
Surgery and radiation therapy
Thirteen patients (6%) underwent surgical proce-
dures in the last three months of life}10 abdom-
inal and 3 of the central nervous system. All
surgeries were due to cancer related complications
and not due to treatment related toxicity.
Fifty patients (16%) received radiation therapy
in the last three months of life (20 as outpatients,
30 as inpatients), mostly for palliation of cancer-
related symptoms. The median number of days
between the end of radiation and death was 39
(range 0–90).
Discussion
There are little objective data on the evaluation of
aggressiveness of cancer care in the end of life. To
our knowledge this is the first hospital-based study
that characterizes the aggressiveness of cancer care
in terminally ill adults with solid tumours. This
study represents the experience of a single institu-
tion during one year. In contrast, other studies
collect administrative data from the National
Cancer Institute’s Surveillance, Epidemiology and
End Results (SEER) registries and from Centres
for Medicare and Medicaid Services Medicare
claims data [1,2]. These studies are population
based and characterize the care given to thousands
of patients. The study by Earle et al. [1] analysed
claims of 28777 patients and the study by Emanuel
et al. [2] analysed claims of 8875 patients.
The present study documents that palliative
chemotherapy is administered until very late in
patients’ lives. A large proportion of patients ever
treated with palliative chemotherapy are still on
active anti-neoplastic treatment in the last three
months of life and, similarly, a large proportion
start a new chemotherapy regimen in that period.
In this study 21% of the patients treated with
chemotherapy in the last three months of life were
still being treated within two weeks of death. In the
large study by Earle et al. [1], with a population
over 65 years-old and restricted to Medicare or
Medicaid beneficiaries with lung, breast, colorectal
or other gastrointestinal cancers, this proportion
was 13.8% in 1993 and rose to 18.5% in 1996.
Patients who received the first chemotherapy
regimen for advanced disease represent 32%
(67/211) of the patients treated in the last three
months of life. Of the 30 patients that started a new
chemotherapy regimen in the last month of life, 28
(93%) were treated with palliative chemotherapy
for the first time. The prescription of a new
chemotherapy regimen within one month of death
occurred in 13.3% (28/211) of this population.
Thus, the second conclusion of this study is that a
sizeable proportion of patients start palliative
chemotherapy near the end of life. This same
indicator was reported by Earle et al. [1] and, in
their series, rose from 4.9% in 1993 to 5.7% in
1996. However, the characteristics of the popula-
tion in their study are di!erent from ours, as
previously mentioned.
The proportion of patients who received che-
motherapy for the treatment of advanced cancer
di!ers widely dependent on cancer diagnosis.
While 86% of patients with breast cancer received
Table 3. Cancer diagnosis of patients that started palliative
chemotherapy in the last three months of life




Head and Neck 6
Colorectal 4
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chemotherapy for metastatic disease, only 26% of
similar patients with head and neck cancers did.
Likewise, only 32% of patients with upper
digestive tract cancer (stomach and oesophagus)
and 39% of patients with urothelial cancer received
chemotherapy for advanced disease. These findings
probably reflect not only the chemo sensitivity of
each disease but also the performance status and
age group of the patients. The fact that 82% of
patients who died from metastatic melanoma were
treated with systemic chemotherapy, despite its
very limited sensitivity to such treatment, is likely
due to the few systemic therapeutic options
available to these patients.
Many reasons could justify the use of chemotherapy
in terminally ill patients. One potential explanation for
the protracted use of chemotherapy is that it may
impact on quality of life and symptom control, even
without any measurable change in tumour bulk and
there are data supporting this in metastatic breast,
lung, colon, pancreatic, stomach and ovarian cancers
[8–16,25–27]. It is a good reason for the prescription of
chemotherapy although, unfortunately, such conclu-
sion cannot be drawn from our data. Similarly, the
trials that showed that palliative chemotherapy is
beneficial to patients with these common adult solid
tumours do not adequately reflect the use of
chemotherapy in terminally ill patients where the
balance between e!cacy and toxicity is less favour-
able. Patients in such trials have better performance
status, less symptoms, shorter duration of advanced
disease, better organ function to overcome toxicity
and are not heavily pre-treated. Furthermore, there
are studies showing the relative lack of e!cacy of
second and subsequent lines of chemotherapy in
patients with metastatic breast cancer that, in our
series, represents nearly half of the patients [22].
It is frequent in our daily practice to see anxious
patients and families who are willing to endure
toxicity in the hope of small prolongations of life.
Sometimes oncologists start chemotherapy while
patients and families adjust to cancer diagnosis and
prognosis [6,7]. Obviously, these subtle interactions
are not retrievable from these data. However, it
shows that in our cancer centre half of the patients
with cancer poorly responsive to chemotherapy
(lung, melanoma and pancreas) received such
treatment in the three last months of life.
Some publications have focused on physician-
related causes of aggressiveness in treatment of
terminally ill cancer patients. They raise the
possibility that the professional’s feelings of failure,
helplessness and frustration as well as stresses in
their private life might have impact the treatment
of patients [23,24]. In a study where psychiatric
morbidity was estimated with a questionnaire
administered to 1133 English consultants in gastro-
enterology, radiology, surgery or oncology, its
prevalence was 27% in the 882 questionnaires
retrieved [28]. Albeit being a possible explanation
for the observed results, we have no data to support
that physician’s emotional exhaustion played a role
in the management of this cohort of patients. The
evaluation of burnout in this group of oncologists is
an interesting topic for further research.
One critical question in the care of patients with
advanced cancer is the ability to estimate individual
patient survival. Published data show how inaccu-
rate oncologists are in predicting their patients’
survival and how they overestimate it [29–31],
leading to overly aggressive anti-cancer treatment.
In our study, deaths due to toxicity represented
5.7% of all deaths and 16% of patients treated with
chemotherapy in the last three months of life were
hospitalized due to toxicity. This toxicity rate is
higher than that of published clinical trials in
advanced cancer, but the characteristics of the
patients included are very di"erent. In the study by
Earle et al. [1] there are data on emergency room
visits and ICU admissions but without separation
of cancer-related complaints from toxicity. In our
study the majority of emergency room visits,
hospital admissions and ICU admissions were
due to cancer related symptoms and not toxicity.
Similarly, surgical procedures and radiation treat-
ments were only used for the relief of cancer related
complications.
Can predictors of the likelihood of chemother-
apy administration be identified in this patient
population? Similarly to other studies [17], the
probability of chemotherapy administration varied
inversely to patient’s age. Some [6,7] but not all [17]
studies, found an inverse relationship between
distance from patient’s home to the cancer centre
and both the probability of administration of
chemotherapy as well as increased likelihood of
hospice care referral [6,7]. Such relationship was
not seen in our study. Cancer diagnosis also
influences the decision to treat advanced disease
with chemotherapy in the end of life. Chemother-
apy-sensitive cancers, such as breast and ovarian
cancer, as well as cancers that are generally
diagnosed in advanced stages, such as pancreatic
cancer, are more likely to be treated with systemic
chemotherapy late in patients’ lives.
This study has important limitations. Firstly, we
do not have data on the reasons for the protracted
use of chemotherapy or on its palliative e!cacy.
Although this is a critical question, we did not
collect these data because of heterogeneous doc-
umentation in patients’ charts. Thus, we cannot
draw conclusions on the appropriateness of the
prescription of the palliative chemotherapy. Col-
lection of data on treatment goals and symptom
control are vital to characterize the aggressiveness
and/or appropriateness of such treatment. Sec-
ondly, patients were included based on the
occurrence of death and this might represent a
bias since we have no data on patients that may
have obtained sustained clinical benefit and
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objective anti-tumour response with palliative
chemotherapy. Further studies should evaluate
prospectively the appropriateness of chemotherapy
prescription in terminally ill cancer patients mea-
suring clinically meaningful quality of life para-
meters, performance status, symptom description
and control and use of concomitant medication.
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Abstract
Background
There is overuse of palliative systemic therapy in the end of life (EoL) of advanced breast cancer (ABC) 
patients but the growing awareness of this practice and the emphasis put in quality of care in the EoL might 
be shifting this practice. We consider three hypothesis concerning EoL care in ABC: (1) that there is more 
evidence of palliative strategies being implemented in this group  of patients; (2) that there is less usage of 
palliative systemic anti-cancer therapy and (3) that other indicators of aggressiveness of care in this 
population show a decrease.
Patients and methods
We aimed to characterize the shifting trends in use of anti-cancer chemotherapy and palliative care 
approaches in the EoL of ABC patients in different institutions and times. 
For this, we selected women that died of advanced BC during six years, from 2007 to 2012, and were 
treated in a central acute care general hospital and compared it with the BC patients that died in 2003 and 
were treated in a large cancer center. We analyzed a total of 232 patients: the more recent group  has 114 
women and the older cohort has 118. We used descriptive statistics to characterize the use of CT in the EoL 
and the use of palliative care resources.
Results
Both populations were similar in terms of BC characteristics. In the latter cohort there was more utilization of 
palliative care resources, pain clinic, palliative care team intervention and palliative radiotherapy involved in 
the care of advanced BC patients and there were also more deaths at the hospices. Systemic anti cancer 
treatments continue to be prolonged until very late in patientsʼ lives, but in the last cohort there was a 
tendency for decrease. Other indicators of agressiveness, namely hospital admissions also show a 
decrease.
Conclusion
In the two distinct institutions analyzed and with the time interval considered, we confirmed our hypothesis 
that there is more integration of multidisciplinary palliative care and less aggressiveness in the treatment of 
ABC patients, namely, use of palliative anti-cancer treatment and hospital admissions. Nonetheless, in both 
cohorts patients still receive systemic therapy until too late and there is still a deficit or underutilisation of 
palliative medicine.
Introduction
Cancer remains a leading cause of death in developed countries. Breast cancer (BC) is a very significant 
public health problem since it is the most frequent cancer in incidence, prevalence and in mortalityit is 
second to lung cancer in women {Malvezzi et al., 2013, Ann Oncol}. Metastatic breast cancer (MBC) patients 
have a longer median survival than other metastatic solid tumors, making this population a challenge for the 
practicing oncologist {Chung and Carlson, 2003, Oncologist, 8, 514-20}. Overuse of anti-cancer therapy is an 
important quality-of-care issue as are other indicators of aggressiveness in EoL cancer care, like the use of 
acute care hospital facilities . An aggressive approach to treatment can have negative effects on quality of 
life, cost and possibly on survival.
In the last decades, more emphasis has been put on directing patients towards a more symptom and care 
oriented approach. In Portugal there are very little hospice care beds. Most cancer patients die in acute care 
beds, although increasing awareness is prompting the creation of chronic and palliative care beds. There are 
very few physician home care visits and specifically the interaction between acute care hospitals and primary 
care teams that provide home care visits is lacking.
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We had previously presented data regarding aggressiveness of cancer care in the EoL using data from a 
comprehensive cancer center {Braga et al., 2007, Psychooncology, 16, 863-8}. At the time, a third of our 
sample size was composed of advanced (A) BC patients. We now analyzed another population of similar 
size from a central acute care hospital, circa 6 years later. With this data we aim to (1) characterize EoL care 
to ABC patients in different institutions and in different time points; (2) show trends in implementation of 
palliative care strategies; and in aggressiveness of cancer care through systemic anti-cancer treatments, 
emergency room, hospital and intensive care unit admissions.
Patients and methods
Eligibility criteria
We analyzed two cohorts of patients. The oldest cohort, from a comprehensive cancer center, included all 
patients with ABC that were treated in the medical oncology department with palliative systemic 
chemotherapy, that is systemic chemotherapy for non-curable locally advanced (LA) or metastatic (M) BC 
and died during the year 2003. This review was conducted with the approval of the institutional ethics 
committee. 
The more recent cohort, from the general hospital, included all patients with ABC that were followed in the 
medical oncology unit and that died between 2006 and 2012. In this cohort we similarly selected BC patients 
that received palliative systemic chemotherapy, that is systemic chemotherapy for non-curable LA or MBC. 
This review was conducted with the approval of the institutional ethics committee. Because estrogen 
receptor (ER) positive BC is amenable to endocrine manipulations during long periods of metastatic disease 
we chose to define therapy as systemic anti-cancer therapy for ABC that includes chemotherapy and not 
endocrine therapy.
Collected data 
Demographic data included sex and age. Cancer-related data included date of diagnosis and death and date 
of documentation of ABC. Regarding administration of systemic therapy, data were collected on its use in the 
treatment of ABC. For those patients that were treated with CT for ABC further data were collected on 
potential indicators of aggressiveness of treatment. These included the number, and duration of each CT 
regimens, CT toxicity and CT response. CT response was considered as clinical or radiological response. In 
the older cohort we only collected data on the systemic therapy regimens used in the last three months of 
life, in the recent cohort we collected data throughout the course of ABC. The duration of a chemotherapy 
regimen was defined as the time between the first and the last day of administration of the drug(s) that were 
part of each regimen. In this group  of ABC we also recorded palliative care interventions, namely, 
consultations with other health care providers part of the cancer multidisciplinary team: pain clinic, palliative 
care specialists, psychiatry and use of palliative radiotherapy (RT) for ABC. 
Data source 
Data were collected through the institutional database and from patient clinical charts. Population-based 
death certificates were used to complement clinical chart data, assuring that no deaths were missed. 
Statistical Methods 
Median and ranges were used as descriptive statistics. Chi-square statistic was used to compare categorical 
data. All data were collected and treated in IBM SPSS Version 20.0.
Results
Patient related data
The whole cohort has 232 patients. The older cohort has 118 and the more recent one has 114. The median 
age of the population at diagnosis was 60 years, for both cohorts. The age range is between 18 and 95 
years (Table 1). The oldest cohort had no men and the recent cohort had 2 men. There were 0.8% in the 
analyzed group, which is in accordance to the frequency of BC in men.
Cancer related data
The BC characteristics are similar between the two populations (Table 1). Regarding early disease, we 
recorded data on histologial subtypes, staging, ER status and treatment modalities. Concerning ABC, we 
recorded data on median survival and locoregional or distant organ relapse. 
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Palliative treatment related data
In the more recently treated patients the referral to the pain clinic increased significantly, as well as shared 
care by a multidisciplinary palliative team. The use of palliative RT has also increased. Only psychiatric 
referral remained constant through time and both institutions. The great majority of MBC patients are still 
dying in the hospitals that first treated their BC, in our case, the comprehensive cancer center and the 
general acute care hospital where they were initially treated. However, in this time interval, there are 
significantly more patients dying in hospices and there has been a shift towards dying more at home. 
Chemotherapy in the end of life
In the initial sample, nearly 30% of patients were treated with CT in the last two weeks of life, nearly 40% of 
patients were treated in the last month, nearly 60% were treated in the last two months and nearly 70% in 
the last three months of life (Table 2). This trend is changing. In the recent cohort we show only 11% of 
patients are being treated with CT in the last two weeks of life, nearly 30% in the last month, 43% in the last 
two months and nearly 50% in the last 3 three months. These are the most relevant results of our study. 
There is a statistically significant change towards less systemic anti-cancer therapy administration in the last 
15 days of life of ABC patients. There is less administration in the last month, two months and three months 
but the difference is not statistically significant.
We analyzed systemic therapy regimens in the last three months of life in greater detail (Table 2). The 
median amount of different regimens in both groups is 1. In the older cohort there is one patient undergoing 
a third regimen of chemotherapy but it was one administration on the day of death. In the more recent 
cohort, there is no patient with a third regimen.
Of interest is the fact that patients are starting new regimens of CT in the last three months of life. We 
observed this and still observe this trend. Thirty-eight patients in the older cohort and 28 in the recent one 
are starting new CT regimens in the last three months of life. Another indicator is if ABC patients are being 
treated for the first time with systemic CT in the last three months of life. This indicator had been observed in 
our previous report and continues to be observed in the recent cohort. Although this practice is decisively 
decreasing with the comparison of these two datasets. The older cohort has 16% patients in this condition 
and the recent one only has 4%. In those 19 (16%) patients that started palliative CT for the first time three 
months before death, there were three women that started a second regimen after the failure of the first.
As has been said, in the more recent cohort we collected data on the whole spectrum of systemic anti-
cancer treatments for ABC. Without focusing only on the last three months like we did in the earlier cohort. 
As such, we have data on the number of regimens administered during the whole duration of ABC. The 
number of regimens most frequently used in ABC patients is six, this happened in 20% of the patients (Table 
3). With reference to duration of each subsequent regimen we could show that the median duration 
decreases in a statistically significant way, as decreases the number of treated patients, as would be 
expected. We were able to show a trend towards less clinical response and more resistance to subsequent 
regimens as is empirically observed in ABC clinics, although not statistically significant.
Other indicators of aggressiveness: 
For the patients treated in the last three months of life, we were able to show a significant decrease in the 
admissions to the medical oncology ward and a decrease in the duration of admission. We saw a trend 
towards more emergency room visits and less intensive care unit admissions. This data corroborates our 
hypothesis but it is not statistically significant (Table 2).
Discussion
The stage distribution and ER status is different in this population than in a population of BC patients 
because these women died of BC, therefore they tend to have a higher TNM stage at presentation and less 
ER positive tumors. The median survival of this cohort of ABC patients is two years, which is as reported in 
the literature {Chung and Carlson, 2003, Oncologist, 8, 514-20}.
Pain clinic referral is higher in the recent cohort than in the initial one, it took place in 50% of the patients. 
The very different percentages of pain clinic referral are not only due to a change in practice but due to the 
fact that we are analyzing two different institutions. The robust implementation of pain clinics in the 
multidisciplinary team that takes care of advanced cancer patients has increased and our data reflects this. 
There is a statistically significant difference between palliative care consultation in the older and recent 
cohorts the trend is not only explained by more awareness of these health care providers but also that the 
acute care hospital happens to have a more robust palliative care team. We found only 2.6% of women 
dying at home. This percentage is low. In Canada, for example, this percentage was already 6.9% 10 years 
ago {Gagnon et al., 2004, J Clin Oncol, 22, 3458-65}. There is still shortage of home care teams with ability 
to provide care for dying cancer patients.
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Concerning palliative radiotherapy the difference is possibly due to change in awareness of radiotherapy, the 
referral to radiotherapy is greatly increased and it is not an issue of availability or logistics because both 
institutions have such facilities in place. 
Mental health practicioner intervention, measured by psychiatric consultations, is unchanged between both 
cohorts, although with an increasing trend in the recent cohort. It is notable, that there is shortage of mental 
health practitioners working with metastatic cancer patients in both institutions, therefore these percentages 
might mitigate the true need of these professionals. The emergency room visits are higher in the acute care 
hospital cohort because there is less access to the medical oncologists in the acute care hospital where 
every non elective admission is centralized through the emergency department.
Despite the constant increase of therapeutic armamentarium available to treat ABC patients we were able to 
show a trend towards less use of systemic therapy in the end of life of ABC patients. Unlike other frequent 
solid tumors with high mortality, like lung, colon, gastric, head and neck and pancreatic carcinomas, where 
CT in the main systemic treatment, in ABC endocrine therapy represents a sizable proportion of systemic 
treatments. And once endocrine resistance supervenes there are numerous CT drugs available to treat ABC 
patients. In this dataset, 20% of the patients were treated with six different regimens, these are more 
regimens than there are available to treat other disseminated carcinomas. The median duration of different 
systemic chemotherapy regimens in MBC is also higher than in other disseminated carcinomas. In this 
cohort of ABC patients, the median duration of the different regimens is 3 months, higher than another of our 
datasets from the same institution of patients with lung carcinoma {Cassiano et al., 2013, Why do we treat 
lung cancer patients with chemotherapy until the end of life, World lung cancer congress}. In ABC patients, 
there is response to systemic CT until very late in the natural history of the disease. Confirming this, we were 
able to show 20% patients exhibiting response to most CT regimens. Opposed to our study, a North 
American study looking at trends in aggressiveness of cancer care in patients from the United States and 
Canada, shows more aggressiveness over time {Ho et al., 2011, Journal of Clinical Oncology, 29, 
1587-1591}. The sample size is much greater and the years and intervals are not the same, but, in this study, 
the diagnosis of BC is an independent predictor of aggressiveness. Our work has an important weakness, 
we do not compare equivalent populations. The two institutions are unrelated and so are the majority of the 
physicians caring for the patients. The characteristics of the institutions are different, one is a comprehensive 
cancer center and the other an acute care hospital. Although they are both in the same geographical area of 
the country and have the same funding from the Ministry of Health. The comprehensive cancer center, as 
expected, treats more BC patients. To overcome the different numbers of patients, we joined the patients 
who died of BC during six years in the acute care hospital to have a similar sample size to our older cohort. 
Another important weakness is the small sample sizes, we are studying just over 200 patients and this 
population is not large enough for statistical testing.
It is vital to start conducting prospective research in end of life questions in cancer. Continuing to work 
retrospectively with patient clinical records that are not standardized, in different institutions, and, with 
different physicians, we might be comparing different realities and collecting incomplete data. Research with 
data collected in electronic medical records and in population based cancer registries will not have the fine 
granularity needed to understand decisions in the end of life of cancer patients. 
Novel anti-cancer drugs appear daily and that is what patients, society, scientists, pharmaceutical companies 
and oncologists strive for. What about the end of life of cancer patients, are we providing the best possible 
care? There are no prospective data collection instruments to assess care in the end of life of cancer 
patients. We do not measure the delivered care routinely in a standardized approach. We are not changing 
the focus of health professionals, patients and families from the next new drug to prolong life to adress the 
issues of end of life. Are oncologists the best trained professional group  for this task? {Braga, 2011, Ann 
Oncol, 22, 2345-8} It is time for oncologists to discuss terminal patients in a specific end of life 
multidisciplinary round, similar to the decision forum for early cancer cases. In this meeting, every new 
patient should start prospective data collection on the quality of end of life management in institutions with 
research groups interested in end of life in cancer. Institutional multidisciplinary decision is an established 
indicator of quality of cancer care. Cancer patients reaching the end of life should be discussed routinely in a 
meeting with attendance composed by medical oncology physicians and nurses, palliative medicine, pain, 
mental health, nutrition and radiotherapy health care providers: The end of life multidisciplinary round. When 
possible, every newly diagnosed patient with a metastatic solid tumor should be similarly discussed. Our 
data is telling us the time is ripe for the onset of such practice.
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Age incidence median (range) 60 (32-92) 60 (18-95) 1
Histology
Invasive carcinomas of no 
special type (NST)
110 (93%) 107 (94%) 0.8
Lobular carcinoma 3 (2.5%) 3 (2.6%) 1
Mucinous carcinoma 2 (1.7%) 2 (1.7%) 1
Metaplastic carcinoma 2 (1.7%) 1 (0.9%) 0.5
Medullary carcinoma 1 (0.9%) 1 (0.9%) 1
Disease stage at 
presentation
I (T1N0) 1 (0.9%) 2 (1.7%) 0.5
II (T1-2 N1) 64 (54%) 68 (60%) 0.0002
III 22 (19%) 25 (22%) 0.6
IV 31 (26%) 19 (17%) 0.08
ER status 
positive 63 (53%) 56 (49%) 0.5
negative 37 (47%) 44 (51%) 0.5
Treatment at 
presentation
Surgery 93 (79%) 83 (73%) 0.5
Chemotherapy 94 (80%) 83 (73%) 0.0002
Radiotherapy 94 (80%) 90 (79%) 0.6
Endocrine therapy 65 (55%) 56 (49%) 0.08
MBC median survival (months) 24 20
Location of 
organ metastasis 
Bone 36 (32%) 46 (40%) 0.2
Locoregional 37 (30%) 35 (31%) 0.8
Lung 24 (20%) 15 (13%) 0.1
Liver 10 (9%) 11 (10%) 0.8
Brain 4 (3.5%) 4 (4%) 1
Ovaries & peritoneum 3 (1.7%) 3 (2.6%) 1
Table 1 Comparison of the two populations: demographics, early BC and MBC variables. Chi-square test 
was used to show populations are comparable. P values lower than 0.05 are considered significant. 
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Palliation, location of death, systemic 
anti-cancer treatment and other 






p value of chi-




Pain clinic 12 (10%) 58 (51%) 3.8x10-⁸
Palliative care 
consultation 5 (4.2%) 26 (23%) 1.6x10-⁴
Psychiatry 10 (8.4%) 18 (16%) 0.1
Palliative radiotherapy 8 (6.8%) 63 (55%) 6.7x10-¹¹
Location of 
death
Hospital where was 
treated 108 (91.5%) 80 (70%) 0.04
Another hospital 0 (0%) 5 (4.4%) 0.02
Hospice 0 (0%) 16 (14%) 6.3x10-⁵
Home 2 (1.7%) 3 (2.6%) 0.6





15 days 32 (27%) 13 (11%) 0.004
last month 45 (38%) 31 (27%) 0.1
last 2 months 67  (57%) 49 (43%) 0.09




in the patients 
treated in the 
last three 
months
Patients admitted 74/80 (93%) 53/58 (91%) 0.06
Hospital admissions 284 174 2.7x10-⁷
Days in hospital 1725 1002 2.2x10-¹⁶
Patients ER visits 66/80 (83%) 51/58 (88%) 0.16
Emergency room 
admissions 166 201 0.06
Intensive care unit 




the last three 
months
A new regimen 38 (32%) 28 (24%) 0.2
A 2nd regimen 6 (5%) 2 (1.7%) 0.1
First ever regimen for 
MBC 19 (16%) 5 (4.4%) 0.004
Table 2 Comparison of the two populations: MBC care variables. Chi-square test was used to show 






No systemic therapy 28 (25%)
1 regimen 18 (16%)
2 regimens 16 (14%)
3 regimens 14 (12%)
4 regimens 10 (8.8%)
5 regimens 5 (4.4%)
6 regimens 23 (20%)
Median regimens 2









of regimens & 
range (days)
Number treated 










1st 87 (1-736) 86 (75%) 22 (26%) 64 (74%)
2nd 92 (1-562) 68 (60%) 20 (29%) 48 (70%)
3rd 96 (7-1360) 52 (46%) 13 (25%) 39 (75%)
4th 54 (1-511) 38 (33%) 10 (26%) 28 (74%)
5th 67 (1-790) 27 (24%) 4 (15%) 23 (85%)
6th 59 (1-331) 23 (20%) 3 (13%) 20 (87%)
p-value chi 
square test
0.001 5.5x10-¹² 0.08 0.7
Table 4 Characteristics of each subsequent systemic anti cancer treatment regimen used to treat the MBC 
patients of the recent cohort. Median duration, numbers of patients and response or progression are 
recorded. Response is defined by objective response or symptomatic response. Objective response is 
assessed by observation or imaging.
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Why do our patients get chemotherapy
until the end of life?
the patient
Some years ago, I treated a 21-year-old woman. During her first
pregnancy, an enlarging mass appeared in her right leg.
Diagnostic procedures done after delivery indicated that she
had alveolar rhabdomyosarcoma. She was referred to the cancer
center for isolated limb perfusion, which was deemed
impossible due to inguinal masses encountered during the
attempt to canalize the femoral vessels. A computed
tomography scan showed peripheral micronodules in both
lungs, after which she was referred to the medical oncology
department for systemic chemotherapy. By then, the primary
tumor was a fungating mass requiring morphine for pain
control. Treatment with cyclophosphamide, doxorubicin and
vincristine led to a prolonged hospital admission for bacterial
sepsis, during which she was visited by her husband daily late
after work and on Sundays by her family and the baby. On the
subsequent cycle, and despite reduced chemotherapy doses, she
again experienced severe hematological toxicity and no
antitumor effect or decreased requirement of narcotics. Next,
single-agent doxorubicin was administered in the outpatient
clinic as an attempt to preserve quality of life. Still, no
antitumor or symptom response was achieved and multiple
hospital admissions due to hematological toxicity ensued.
Eventually, ifosfamide was prescribed in progressively lower
doses due to increasing hematological toxicity but still without
clinical benefit. She finally died of fungal sepsis, 3 months after
being referred to the medical oncology department.
the problem
This case illustrates therapeutic futility at the end of life. Why
are we not ceasing chemotherapy when it is useless, toxic,
logistically complex and expensive? Are we prescribing
chemotherapy until too late in solid tumor patients’ lives?
Medical oncologists have overly optimistic predictions and,
sometimes excessive, treatment-prone attitude and they are
criticized by other health care providers for this. Increasingly,
patients, their families, advocacy groups, policy makers,
journalists and society at large dwell on this topic, which is
a perplexing conundrum, because sometimes they are the ones
demanding not to stop aggressive systemic anticancer
treatments. There is a growing culture of awareness toward
preserving quality of life, palliative care, symptom-directed
care, hospice referral and end-of-life issues regarding terminal
cancer patients. Sadly, this issue is gaining momentum, not
because oncologists are questioning their practice but because
health care costs are soaring. Whatever the motive, the reasons
for administering chemotherapy at the end of life should be
known. Striking a balance is not easy. Hippocrates in 400 BC
wrote, about medicine in general, an aphorism that illustrates
this difficulty: Life is short, the art long; the occasion fleeting;
experience fallacious and judgment difficult. Medical decision
making on ceasing systemic chemotherapy remains a very complex,
intimate and subjective process. There are few and conflicting
scientific data to guide treatments in this delicate setting.
the available data
What data do we have that characterizes the situation? Most of
available data are retrospective death-centered studies,
population or institution based [1]. The institution-based
studies have access to the complete medical records where
eventually data can be retrieved regarding decisions and goals
of interventions. On the other hand, population-based studies,
such as the one by Näppä et al. (this issue), and the Medicare
system-based studies claim to picture reality in a more unbiased
way.
In the current issue, Näppä et al. [2] examine chemotherapy
administration in the last month of life. They have chosen
a population-based cohort from Northern Sweden in which
they were able to characterize 374 adults affected by solid
tumors that were treated with chemotherapy in the last month
of life. Their results show that one-fourth of Swedish terminal
cancer patients still receive chemotherapy, which is in
agreement with reports from other geographies. In this study,
patients that receive chemotherapy have a shorter duration of
metastatic disease, more hospital admissions and often lack
a documented decision to stop chemotherapy.
Regarding other similar reports, two studies based on
Medicare claims, encompassing roughly 8000 patients each,
reported that 15% of terminal cancer patients receive
chemotherapy in their last 2 weeks of life [3, 4]. In an
institutional report from England, only 8% of the patients
received chemotherapy in the last month of life but 7.5% and
4.3% of these patients had a toxic death or died of neutropenic
sepsis, respectively [5]. Two institution-based studies from Italy
showed that 23% and 15% of advanced cancer patients are
receiving chemotherapy in the last month of life [6, 7]. Two
similar Portuguese studies showed 37% and 13% of the patients
being treated with chemotherapy in the last month of life [8, 9].
Further examples include two Korean reports, one where 30% of
the patients receive chemotherapy in the last month of life and
another where 50% receive treatment in the last 2 months of life
[7, 10], and an Australian publication showing that 18% of
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In these studies, the parameters presented as being predictors
of receiving chemotherapy were young age, short metastatic
disease course, tumor type and chemosensitivity of the tumor.
Tumor type data show that lung cancer patients are
overrepresented possibly because of frequent metastatic disease
at diagnosis and short life span. In fact, 43% of non-small-cell
lung cancer patients treated by community oncology clinics
across the United States receive chemotherapy in the last month
of life and 20% in the last 2 weeks [12].
In summary, up to a fifth of cancer patients are treated with
chemotherapy in the last month of life without clear benefits
(e.g. no prolongation of life) and sometimes even with visible
negative consequences (increased toxicity, costs and decreased
quality of life). The need to critically evaluate chemotherapy
prescription in this context evokes four questions discussed
below.
will the patient benefit?
Can doctors estimate patient survival in an accurate way? Most
likely no; all physicians, oncologists in particular, tend to
overestimate survival due to multiple reasons: strong emotional
bonding, underestimating catastrophic complications and
relative or forced stability during the doctor visit. A strategy to
overcome this is to make frequent reassessments and ask
experienced colleagues who have been shown to make more
accurate predictions. It may also be beneficial to use evaluators
like the Karnofsky performance score, the World Health
Organization performance status, specific palliative scores or
the assessment of specific symptoms. In the case of symptoms,
the most informative are anorexia, weight loss, xerostomia,
dysphagia and dyspnea. Among other validated variables are
blood biochemical tests (e.g. low albumin, high lactate
dehydrogenase, high interleukin-6) and cell counts (e.g. high
white blood cell counts, low lymphocyte counts) [13]. Several
attempts have been made to use algorithms for death prediction
in terminal cancer patients but these have not met with general
acceptance because of inefficacy, difficult implementation and
ultimately because in terminal care the patient is viewed
globally and thus such scoring systems are viewed as an
oversimplification.
Is it appropriate to start or to continue chemotherapy? What
are the symptoms? Are they cancer or toxicity related? If the
main problems are pain, asthenia and cachexia, chemotherapy
may not be the only and sometimes not even the most
appropriate solution for them since it may exacerbate them.
Performance status; asthenia; weight loss; marrow, cardiac and
lung reserve as well as kidney and liver function help guiding
the evaluation of the relative risks and benefits of using
chemotherapy. If chemotherapy is agreed upon, this decision
should be reevaluated frequently. The careful weighing of
clinical benefits and risks is the core of this issue: Primum non
nocere. In the majority of solid tumors of adults, a classic rule
still stands that after three failed lines of chemotherapy the
possibility of benefit with a fourth line is minute. However,
there are exceptions, for example, in breast cancer, especially
Her2-positive disease [14].
In short, chemotherapy should be limited to ambulatory
outpatients with good performance status, except in untreated
chemosensitive solid tumors or malignancies that are
specifically affecting the ability to walk. The goals of palliative
chemotherapy differ from those of curative chemotherapy
because metastatic solid tumors are generally incurable; the aim
is to increase survival. Furthermore, instead of focusing on
lesion diameter shrinkage, a clinical trial end point, clinically
relevant outcome measures like symptoms are possibly more
adequate.
what does the patient want?
There are important cultural and religious variations in the
acceptance of death. Data show that patients with high levels of
positive religious coping tend to receive intensive life-
prolonging care possibly because they believe in miracles and
divine interventions [15]. However, if a religious counselor is
provided from within the oncology staff, it reduces aggressive
end-of-life care and increases hospice use [16]. Does the
acceptance of death mean that all hope is lost? Hope is an
important defensive mechanism. Somewhat paradoxically,
there are data showing that giving honest information, even
bad, maintains hope [17]. Some patients want to live a specific
event before feeling prepared to die. If not possible, patients can
find other ways to get a sense of purpose out of the event, such
as writing a letter or recording a legacy. Many patients and
families get great satisfaction from this.
There are tools and checklists for communicating bad news.
During consultation, one can follow the stepwise approach of
the SPIKES acronym: choose a setting (i), assess perception of
the disease (ii), invite the patient to hear (iii), transmit
knowledge (iv), assess emotional reaction with empathy (v) and
summarize the care plan (vi) [18]. Why is not communication
more effective? It is not because patients and families cannot
bear to be informed on prognosis, it is because oncologists are
insufficiently trained and, even for experienced physicians,
giving bad news is just too hard. A simulated consultation
study reported that poor performance was correlated with
emotional burnout and fatigue but not inexperience [19]. In
a study that recorded hematological oncology consultations in
tertiary centers, cure was not discussed quantitatively or at all in
half of them [20]. A prospective study on palliative
chemotherapy versus watchful waiting in advanced cancer
patients showed that only 39% of patients reported discussing
prognosis with the attending oncologist. In a longitudinal
study, in admitted terminally ill cancer patients, 39% of the
patients and 62% of the families said that the possibility of
death had not been discussed [21]. Research shows that patients
know more about their disease and their treatments at the time
of diagnosis than at the time of relapse, progression and near
death. One of the reasons for this discrepancy is that the
established closer proximity between doctor and patient
interferes with the phycisians’ capacity to communicate
unpleasant news [22]. Data show that when information is
given to patients, it is provided with a range of values and
patients cope with it by hoping to belong to the favorable tail of
the distribution [21].
Information pays off. If physicians have discussed care at the
end of life with their patients, patients are more likely to receive
care according to their needs and preferences [23].
































































Additionally, when informed about their terminal illness,
patients more often choose symptom-directed care [23].
Regarding biased or lack of information, a randomized trial of
the use of the decision aid Adjuvant! for adjuvant breast cancer
chemotherapy prescription concluded that only 58% (35 of 60)
of the women who used the tool chose chemotherapy, while
87% (33 of 38) of the women that were informed by physicians
chose it [24]. This is an indication that patients have
unrealistically optimistic expectations on the benefits of
chemotherapy.
In summary, fully understanding terminal patients’ wishes
and goals, realistically addressing the potential and limitations
of palliative chemotherapy and discussing end-of-life logistics
are items of successful communication that might help spare
useless treatments.
can the patient get better care?
It is harder to provide a good death than to cure a patient.
Research has shown that terminal patients want to die at home,
with loved ones, with symptom control, feeling independent
and as conscious as possible [25]. For most cancer patients, this
is difficult but achievable with the aid of specific skills that
unfortunately are not widespread. For example, in a survey to
second-year oncology fellows, only 23% carried out correctly an
opioid conversion [26]. Cancer death is predictable, i.e.
bedridden, pain, dyspnea, cachexia, anorexia, constipation,
dehydration, fleeting consciousness and coma; therefore, it is
easy to prepare families for it. After death, there might be an
urge to move on, but, families in bereavement need follow-up,
provide feedback and studies show it to be insufficient [27].
In the last decade, there was an expansion of palliative care
units with doctors, nurses and supportive staff, dedicated full
time to the terminally ill, that have shifted gear from a cancer-
centric approach to a patient-centered approach. Palliative care
should be gradually integrated so that the patient, family and
medical oncology team do not feel as they are getting rid of the
patient to die under the care of another team, away from the
environment they lived in during the most extensive and easier
part of the disease. The intervention of a palliative care team
should start at the time of distant dissemination because the
majority of metastatic patients are incurable. As the disease
progresses, the emphasis slowly shifts from one of aggressive
antitumor treatment to more focus on palliation. Near death,
the only treatment is palliation with no blood tests, artificial
feeding, emergency room or intensive care unit admissions
because families communicate by phone with the staff that
visits at home. Why, then, are patients and families sometimes
reluctant to accept this? Apparently due to lack of information.
Studies have shown higher use of hospice care by informed
patients [21]. Additionally, palliative care should not be a one-
way road. Different reimbursement systems in some countries
might preclude the utilization of hospice care because patients
transferred to hospice loose the rights to cancer center care. It
would be an improvement if in this setting patients gained
rights instead of loosing rights.
Is chemotherapy more effective than best supportive care as
treatment of metastatic cancer? This depends on how one
defines ‘effective’. If it is survival, then, yes, chemotherapy
prolongs survival in the majority of metastatic solid tumors of
adults. So the question is not if it should be administered but
rather until when should it be administered. On the other hand,
if effective means achieving a ‘good death’, with symptom
control and quality of life, chemotherapy is not as good. But,
do hospice patients die sooner? A retrospective study designed
to answer this question actually found either prolongation of
life, in case of lung cancer, or no difference, in case of three
other common solid tumors (breast, colon and prostate
carcinomas). This study is based on Medicare records and the
inclusion criteria for the hospice care group is one Medicare
claim. Therefore, it might reflect better care in general and not
necessarily capture the dichotomy between chemotherapy
administration and symptom control [28].
Finally, research must be conducted regarding end-of-life
care to identify which patients are best managed with
etiological versus symptomatic approach. Qualitative outcomes
and health services research increased through the 90s and
peaked in 2000 [29]. Futility, toxicity and aggressiveness are
measured by following patients with a predicted reduced life
span prospectively and collecting data on the justifications,
decisions and goals of terminal care interventions and
recording indicators of aggressiveness, like emergency room,
intensive care unit admissions and surgeries.
are there conflicts?
Oncologists are frequently subject to pressure sometimes from
patients but more often from families to continue therapies of
doubtful efficacy [30]. Conflict often starts with members of the
family that are absent or health illiterate [31].
There are health care systems in which the physician and the
institution are better reimbursed for chemotherapy
administration and by requesting radiological examinations
than for carrying out a complex cognitive discussion. In fact,
there are systems where burdensome family conferences are not
reimbursed. This creates a perverse incentive because the
hardest actions are poorly compensated, while the easier ones
are more lucrative. This would be avoided if reimbursement
was done on the basis of consultation with the physician with
no link to drug administration. Additionally, admitting that
there are better alternatives for symptom control and quality of
life preservation might include the referral to another team of
physicians and the potential loss of the patient as client of the
clinic.
Lastly, why is not there more research on terminal cancer
care, as has been discussed? Clinical cancer research mainly asks
drug-oriented questions by doing clinical trials. But even
academic trials led by institutions and collaborative groups are
exquisitely dependent on pharmaceutical industry funding to
happen. It is extremely difficult to fund applied clinical research
questions that do not involve drugs; this might be one of the
reasons it is less attractive.
the patient, again
At this point, I return to the initial story and imagine how I
could have done better. Regarding the first question, I should
have assumed that widely metastatic alveolar
































































rhabdomyosarcoma was likely to be chemoresistant. The
specific disease had taken an aggressive biological behavior, the
lesion was increasing daily and the natural history of the
untreated primary had only 4 months. I should have set my
goals accordingly. The patient, who was supposedly a fit young
woman, had feeble marrow reserve, possibly because of
infiltration, which I should have diagnosed. Her performance
status was three, i.e. she was partially bedridden, with lung
metastases, so the potential for infectious complications, with
the regimens used, was high. Her symptoms were pain in the
primary lesion, which was well controlled with morphine, and
she was not dyspneic.
Regarding the three other questions: What did she want? She
wanted to be with her baby daughter, husband and parents, at
home. Was there a better team to care for her? Possibly, yes.
I donot think that she would have objected to a discussion
about therapeutic futility and end-of-life care by different staff,
provided the medical oncology team could remain available.
Were there conflicts? Not at all. They had accepted distressingly
peacefully the catastrophe of incurable cancer at a young age.
What went wrong? Why did this young woman get
chemotherapy until the end of life? Clearly because I failed.
I hope I have learned the lesson.
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Conclusion: What is the future of breast cancer care?
Diagnosis: mammography wars
Screening mammography has changed breast cancer. All of us, breast cancer clinicians, see that every day 
in the clinic. Growing numbers of patients are diagnosed with non palpable lesions that lead to less 
mutilating surgery, usually enabling breast conservation, adjuvant radiotherapy and hormonal therapy, 
avoiding chemotherapy. Screening mammography has lowered mortality. But at what price? Critics say that 
the radiation received by 17 mammographies is enough to cause a cancer. Others say we are creating a 
breast cancer pandemic and are treating in situ lesions that would never become clinically relevant, with 
aggressive modalities like surgery and radiotherapy and, on a more subtle level, creating phobic behavior in 
patients. In other words, breast cancer physicians are behaving like prostate cancer physicians and the 
doubts cast on PSA evaluation can eventually be shared by mammography. The impact of mammography in 
the group  aged 40 to 50 has specially been challenged because, critics say, we are diagnosing only the 
slower growing lesions and those that will kill these women will not be effectively diagnosed in an early stage 
with such annual screening. Unfortunately, we have witnessed such examples. Also, the relative rarity of 
breast cancer before age 50 makes the number of mammographies necessary to save one life close to a 
thousand. Proponents of screening mammography before 50, say that these are the women that die of 
breast cancer. Half a century after screening mammography, physicians and epidemiologists have not 
reached consensus if mammography should be done routinely and since what age. 
Risk: The rise and fall of hormone replacement therapy, lifestyle and the search for “BRCA3”
The Womenʼs Health Initiative (WHI) trial of combined estrogen plus progestin was stopped early and 
published in 2003, when overall health risks, including invasive breast cancer, exceeded benefits. In this trial, 
16608 postmenopausal women aged 50 to 79 years, with an intact uterus, were randomly assigned to 
receive combined conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d), 
or placebo, for five years. Screening mammography and clinical breast examinations were performed at 
baseline and yearly thereafter. Estrogen plus progestin increased total and invasive breast cancers 
compared with placebo. The invasive breast cancers diagnosed in the estrogen plus progestin group  were 
similar in histology and grade but were larger and at more advanced stage compared to with those 
diagnosed in the placebo group. The WHI results had strong impact in the field of womenʼs health and since 
2003 breast cancer incidence has dropped in the United States. This important result was published in 2007. 
The SEER registries showed that the age-adjusted incidence rate of breast cancer in women in the United 
States fell sharply (by 6.7%) in 2003, as compared with the rate in 2002. Data from 2004 showed a leveling 
off relative to the 2003 rate, with little additional decrease. The decrease began in mid-2002 and had begun 
to level off by mid-2003. A comparison of incidence rates in 2001 with those in 2004 showed that the 
decrease in annual age-adjusted incidence was 8.6%. The decrease was evident only in women who were 
50 years of age or older and was more evident in cancers that were estrogen-receptor-positive than in those 
that were estrogen-receptor-negative. This decrease seems to be coincident to the first report of the 
Women's Health Initiative and the ensuing drop in the use of hormone-replacement therapy among 
postmenopausal women in the United States. These data were practice changing in womenʼs health 
management and currently no post menopausal women should take hormone replacement for more than two 
years and that is if she has severe menopausal symptoms.
Besides estrogen, undoubtedly the most powerful modifier risk factor for breast cancer, obesity is a powerful 
risk factor in raising the risk of breast cancer. Several mechanisms might be at play: fat tissue pumps out 
tumor-nurturing molecules such as estrogen. Many obese people have insulin resistance or overt diabetes, 
and insulin and IGF may spur cancer cell growth as well. Cholesterol that accumulates in our arteries and 
contributes to cerebrovascular and ischemic heart disease, has other deleterious health effects. When 
metabolized by the body, it turns into a potent estrogen-like molecule that spurs the growth of breast cancer 
in mice, and in women. Besides cholesterol, and possibly through cholesterol, there are several 
epidemiological studies showing the influence of diet and physical activity on breast cancer risk. These 
studies are seldom performed in healthy women, they recruit breast cancer survivors, so the effect seen is 
mostly on breast cancer recurrence.
Regarding genes, the discovery of BRCA1 and BRCA2 were immensely helpful, but questions regarding 
familial risk of breast cancer persist. BRCA mutations are rare high penetrance mutations but moderate and 
low-penetrance genetic variants implicated in breast cancer etiology are known to exist. Other high 
penetrance alleles have been identified as part of inherited cancer syndromes. These include germ-line 
TP53 mutations found in Li-Fraumeni cancer syndrome, PTEN germ-line mutations in Cowden syndrome, 
and STK11/LKB1 mutations in Peutz-Jegher syndrome. In spite of the high risks conferred by high 
penetrance mutations, these mutations are rare in the population, and are estimated to account for only 20 to 
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25% of the familial risk. Another group of genetic variants associated with breast cancer risk are uncommon 
variants minor allele frequency with moderate effects on risk. Four such genes are ATM, CHECK2, BRIP1 
and PALB2. Lastly, most of the unexplained familial risk is accountable by a polygenic model involving a 
combination of many individual variants with weak associations with risk, the so called low-penetrance 
polymorphisms. Whole genome sequencing and the mapping of single nucleotide polymorphisms (SNP) 
have advanced discovery of common genetic susceptibility factors. The current approach is to evaluate 
genetic variation in candidate cancer pathways and perform genome-wide association studies (GWAS) in 
very large study populations. With GWAS, in the last 6 years, several common variants that contribute 
polygenically to breast cancer risk have been discovered in specific genes: FGFR2, TOX3 MAP3K1, c-MYC, 
LSP1, NEK10, COX11, CASP8, IGFBP5, NOTCH2, RAD51L1, FGFR10 and ESR1d. Genome-wide linkage 
studies have failed to map  cancer susceptibility genes with high penetrance, suggesting that no further 
genes of comparable importance to BRCA1 and BRCA2 exist. So, the search for BRCA3 has been elusive.
Local treatment: Less and less 
After having established that there is no extra benefit of mastectomy, the need for axillary clearance was 
questioned. The widespread adoption of sentinel lymph node (SLN) biopsy as standard care for axillary 
staging in cN0 breast cancer is supported by the results of at least 69 observational studies, seven 
randomized trials, 3 meta-analyses, international societal guidelines, and an extensive literature covering all 
aspects of the procedure. These studies established that patients with negative SLN do not require axillary 
dissection (ALND), that axillary local recurrence after a negative SLN biopsy is rare (0.3%), that disease-free 
(DFS) and overall survival (OS) are unaffected by the addition of ALND to SLN biopsy, and that the morbidity 
of SLN biopsy is less than that of ALND. The next logical question in the evolution of axillary staging is to ask 
whether there are SLN-positive patients who can avoid ALND, and it is clear that there are 50% of SLN-
positive patients have disease limited to the SLN.
With the widespread use SLN procedure, patients who did not require ALND were increasingly frequent. To 
answer the question if we could omit ALND, ACOSOG Z0011 was designed. In Z11, 6-year locoregional 
control and survival were equivalent with or without ALND in cT1–2N0 patients with 2 positive SLN treated by 
breast conservation with whole breast radiation therapy. A small but growing body of data now suggest that 
ALND may not be required for selected patients outside the Z0011. Specifically those treated by mastectomy 
without post-mastectomy radiation therapy, by partial breast irradiation, and by neoadjuvant chemotherapy. 
Looking ahead, the principal goals of axillary staging, prognostication, and local control will be accomplished 
by SLN biopsy for a substantial majority of patients, and the role of ALND will continue to diminish. 
After breast-conserving surgery, 90% of local recurrences occur within the index quadrant despite the 
presence of multicentric cancers elsewhere in the breast. Thus, restriction of radiation therapy to the tumor 
bed during surgery might be adequate for selected patients. To answer this question, the intraoperative 
radiotherapy trial was conceived with a non inferiority design. The trial compared targeted intraoperative 
radiotherapy with whole breast external beam radiotherapy in 2232 women aged 45 years or older with 
invasive ductal breast carcinoma undergoing breast-conserving surgery. At 4 years, there were six local 
recurrences in the intraoperative radiotherapy group and five in the external beam radiotherapy group. The 
Kaplan-Meier estimate of local recurrence in the conserved breast at 4 years was 1.20% in the targeted 
intraoperative radiotherapy and 0.95% in the external beam radiotherapy group. The frequency of any 
complications and major toxicity was similar in the two groups. Radiotherapy toxicity was lower in 
intraoperative radiotherapy group than in the external beam radiotherapy group. The majority of professional 
societies of radiotherapists, surgeons and medical oncologists have endorsed partial breast irradiation (PBI) 
for limited situations. Nowadays, for patients who are over 45 years, have non lobular histology in a lesion up 
to 3 cm in size with negative microscopic surgical margins and where the sentinel lymph node is negative we 
can propose PBI with obvious logistic benefir.
We are well aware that the most frequent neoplastic disease early breast cancer survivors may develop  is 
another breast cancer, homolateral or contralateral. The reasons are not clear but include genetic makeup, 
lifestyle and the effect of adjuvant chemotherapy used to treat the first carcinoma. The role of RT to the 
remaining breast tissue after breast conserving surgery might also be relevant. Therefore, the continuos 
follow-up of breast cancer survivors by trained breast cancer physicians, if possible, is strongly advocated.
The future of breast cancer surgery, because, no matter how non invasive we strive to make it, it is still a 
highly mutilating intervention, is minimalism. We are eager with the possibly of safely proposing no surgery in 
the near future to some patients.
Systemic treatment: Designer drugs
Since 2000, the endocrine therapy of breast cancer completely changed. Tamoxifen is still the backbone of 
therapy in premenopausal patients and the ever lasting question of chemical castration with LHRH analogs 
has not yet been solved. Surgical castration remains in itself a secure and very cost effective strategy. 
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Specifically, we have not established if some premenopausal patients can securely be treated just with 
castration and endocrine therapy omitting chemotherapy. That question is trying to be answered by a group 
of academic trials called the SOFT (Suppression Ovarian Function Trial), TEXT and PERCHE, where 
questions are mainly addressing endocrine therapy of premenopausal patients. Because physicians are not 
comfortable randomizing for omission of chemotherapy, PERCHE trial, that asked that question, was closed 
for inadequate accrual.
The tamoxifen duration of treatment question has been answered by another contribution of Richard Peto, 
the ATLAS trial. It has been established as useful beyond 5 years, currently for 10 years. Side effects of 
tamoxifen should be carefully taught to women and cautiously monitored, but, relapse, breast cancer 
survival, and bone health were documented to be as predicted.
An alternative to tamoxifen in post menopausal women are aromatase inhibitors, these have showed impact 
on relapse, never on survival, with different toxicity profiles. Aromatase inhibitors have frequent cumbersome 
side effects, while tamoxifen has rare serious side effects. The view of breast cancer physicians that treat 
hundreds of such women, and help  them navigate through side effects, might still favor tamoxifen. Plus, for 
health economic reasons, absolutely vital nowadays, tamoxifen is still cheaper.
A new group  of cytotoxic chemotherapy has also changed the landscape of breast cancer treatment: the 
taxanes. Since 2000, these drugs are used for early breast cancer treatment and there are adjuvant clinical 
trials showing we can replace alquilating agents and anthracyclines for taxanes, postulated to have a more 
favorable long term toxicity profile with no cardiotoxicity and no increased risk of acute leukemias. However, 
the most appealing strategies have been to increase the power of combination chemotherapy in high risk 
patients, adding taxanes to an alquilating agent and anthracycline backbone.
Since the 1970s, two types of breast cancer have been established: those that express ER and those that 
donʼt. Since 2000, two other subtypes of breast cancer were characterized. Tumors with amplification of the 
Her2 oncogene and tumors without overexpression of ER, PgR or Her2, triple negative tumors. The story of 
targeting Her2 has epitomized the “tell me the target, Iʼll tell you the drug” strategy. The adjuvant trials, that 
reported in 2005, were criticized for being unethical because it was so clear that they would be positive. 
Indeed, in the era of evidence-based medicine, and, with the current regulatory landscape, this is an 
extremely controversial opinion. Other drugs are being used today after trastuzumab failure or as double 
blockade: lapatinib, pertuzumab and TDM1. It has actually been said and written that what was bad news in 
the preceding decades, to have Her2 amplified breast cancer, is nowadays regarded as good news. Triple 
negative breast cancers remain without any targeted therapy available, despite vast efforts.
Metastatic breast cancer: Diversity generation
Inspirational scientists like Melvin Greaves and Mike Stratton have taught us, that cancer is “just” a problem 
of evolution. Greaves wrote an amazing book called “Cancer, the evolutionary legacy” where he elegantly 
shows that systemic therapy is fueling diversity and selecting the most aggressive clones. In the recent 
years, several large scale sequencing projects have shown what Greaves predicted in his book. The 
evolving landscape of cancer mutations after recurrence, metastasis and upon therapy is towering. As 
Darwin would view it, when we fail our patients the cells have acquired increased fitness. BC cells surviving 
through years of endocrine manipulations and chemotherapy are truly aggressive. We have circumstantial 
evidence of this in our patients.
My final concerns go to metastatic breast cancer (MBC) patients, our daily challenge. 
The directions for MBC are to biopsy each and every new metastatic breast cancer patient, if possible, even 
in bone lesions. The rate of change of the four actionable items, ER, PgR, Her2 and proliferation indicators, 
is between 10% to 20%. The tendency is mostly to loose the targetable molecules. Metastatic lesions tend to 
loose ER expression in 20% and Her2 in 10% of the cases. Loosing differentiation is most frequent. If 
possible, MBC patients should be enrolled in gene mutation directed clinical trials. There is interest in 
circulating tumor DNA to monitor metastatic disease. In the preceding years, circulating tumor cells seemed 
to be promising. Nowadays we know these are rare, they are difficult to study and specially difficult to 
standardize between labs. Today, circulating DNA is analyzed for copy number profiles and mutations, for 
exome sequencing and low coverage full genome sequencing. The quantification of circulating tumor 
material will be an interesting way to monitor therapy and the qualitative analysis of predominant clones will 
reflect the selection pressure.
We know that breast cancers generally harbor a few hundreds of somatic mutations. In the phylogenetic tree 
context, we consider trunk mutations as essential or drivers, actionable or targetable genomic alterations and 
branches or even leaf mutations as non essential or passengers. We test for their presence in primaries and 
metastases, we test for intralesional consistency. In oncogene directed disease, we must find the target. 
These patients are for oncogene de-addiction therapy. Anti angiogenesis, immune boosting and epithelial 
growth factor inhibition are examples of this. The goal is for de-addiction for the most relevant cancer 
hallmark. But, in patients with tumors with high genomic instability that have profound intratumor 
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heterogeneity this might be an indication that no specific target is actionable and that we should treat with 
cytotoxic chemotherapy. Unstable tumors should correlate with high grade and high Ki67 staining.
The treatment of each MBC patient should be turned into an experiment in itself, it is a memorable task but 
that is the way forward.
Final comment
It is impossible to precisely enumerate the impact of these interventions on the survival of each individual 
patient. The shifting landscape of knowledge, diagnosis, screening and therapeutic trials of techniques and 
drugs does not allow the comparison of breast cancer treatments yesterday and today. But screening, 
surgery, radiotherapy, chemotherapy, endocrine and targeted therapy have likely added anywhere between 
17 and 30 years to the survival of each women with breast cancer. In the beginning of last century a breast 
cancer diagnosis meant the patient would die; today, a breast cancer diagnosis is possibly the diagnosis of 
the most curable carcinoma. 
I recall a story that illustrates dynamism and change. I met, in the medical oncology ward, a young, albeit 
postmenopausal, woman with locally advanced breast cancer. She was being treated by another oncologist 
and I was attending her in the ward because of grade 4 febrile neutropenia during neoadjuvant 
chemotherapy. She had a large inoperable breast tumor with palpable axillary nodes. After minimal response 
to full dose anthracyclines she was being treated with taxanes. She was oblivious of her ominous stage III 
breast cancer. She was a happy, energetic, small, slim woman, always accompanied by her daughter, taller, 
and trying not to be anxious. After 5 days with no neuthrophiles and 5 more to get counts up, she was 
discharged home, to continue chemotherapy with her oncologist. I remember the two, the patient with her 
optimistic, loose, demeanor and the daughter with a serene but conscious look. At the time, the adjuvant 
trastuzumab trial was enrolling patients. One day, a data manager calls me saying there was a possible new 
patient that had undergone surgery and had Her2 amplified BC. To my surprise, this lady walks into the 
consultation room, her constant daughter following her. She had removed a ypT3 tumor with 8 positive 
nodes in her axilla and surprisingly exhibited renewed strength for her next journey. She greeted the idea of 
an adventure with a promising drug and was randomized in the trial to one of the therapeutic arms. I was 
amazed at how courageous this woman was, every step  of the way, accepting, almost with pride, each new 
therapeutic modality. She reached milestones and fought battles, in a concrete way. Nearly ten years have 
gone by, this woman contacts me occasionally, and she remains without evidence of breast cancer. I believe 
that if she had had this diagnosis in 1980, just 25 years before, she would have died. No demonstration of 
neoadjuvant chemotherapy for achieving resectability, no anthracyclines, no taxanes, no trastuzumab, 
different radiotherapy techniques and less powerful endocrine therapy.
There is a subtler reason to remember this story. While the content of medicine is constantly changing, its 
form, will remain astonishingly similar. It is about the form, not only about the content. We must master the 
past because history and science repeat and echo and we clearly walk in the footsteps of others. By looking 
back, we can see the way forward. Craig Jordan, the inventor of tamoxifen, when he delivered his Karnofsky 
memorial lecture in 2008, started by citing Haddow when he delivered his Karnosfsky lecture in 1970. 
Haddow showed that natural and synthetic estrogens had strong effect on some breast cancer patients and 
said the finding was of “major theoretical importance” but expressed disappointment that “so much of the 
underlying mechanism continues to elude us”. The tools that we will use to treat breast cancer in the future 
will doubtlessly alter so dramatically, in the next 25 years, that the landscape of breast cancer therapy might 
be unrecognizable, like the clinical course of the women that were treated in 1980. Future physicians will 
laugh at our primitive recipes of poisons to kill these magisterial cells. They will laugh at hospital admissions 
for ten days for profound neutropenia. But this womanʼs attitude, embodies our struggle against breast 
cancer, and this, will reverberate through history. To keep pace with this heterogenous disease we have to 
keep  inventing and reinventing strategies, learning and unlearning truths, living and reliving our experiences. 
We should be canny, relentless, obsessive, fierce, tireless, brilliant, adventurous and even mad, in our 
pursuit of creative research ideas, diagnostic and therapeutic elegance, cure and quality of life. We should 
devote all our energy to this mission, mobilizing and remobilizing our imagination, for, as we unfortunately 
witness every day, the five thousand year war on breast cancer has not yet been won.
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